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ABSTRACT 
A chemical synthesis of phosphocitrate (PC) was devised 
to facilitate investigation into its possible natural occurrence. 
Concomitantly, detection systems for characterising PC were 
developed utilizing thin layer chromatography, electrophoresis, 
isotachophoresis , and enzymatic and chemical PC assays. 
Synthesis of PC was effected by condensing 2-cyanoethyl 
phosphate (CEP) and triethyl citrate, followed by alkaline 
hydrolysis. CEP was considered to be the reagent-of-choice 
because of the ease of preparing [ 32 13 ]-CEP from [ 32 P1 -
inorganic phosphate enabling the production of [ 32 13 ]-PC. 
An ion-exchange chromatographic system was developed to 
provide ultimate purification of PC, and it was characterised 
by 'H, 13C and 31 P NM spectroscopy. 
PC was demonstrated to inhibit potently hydroxyapatite 
(HAP) formation being more powerful than ATP and 
pyrophosphate. PC was also found to inhibit strongly calcium 
oxalate formation, its presence modifying crystal morphology. 
The unique structure of PC led to the proposal of 
a structure-activity relationship for inhibitors. Secondary 
factors influencing inhibitor power were elucidated and two 
groups of inhibitors were recognised. Type I inhibitors, 
which included PC, appeared to be crystal growth inhibitors, 
whereas Type II inhibitors were proposed to act by a range 
of mechanisms. The demonstration of a synergistic interaction 
between Type , I and Type 11 inhibitors was used to support 
the claim that in physiological fluids, PC could act as a 
potentiating agent. 
Comparison of a purified fraction from tissue samples 
with authenticated PC showed that PC occurs in kidney and 
liver of the rat and rabbit whilst other studies indicated 
that small amounts of PC were present in rabbit bone and 
human urine. More detailed studies indicated that PC was 
present, at a 'level of ca. 1 nmol/mg mitochondrial protein, 
in mitochondria, a subcellular organelle known to concentrate 
calcium. 
Administration of [ 32 P1-PC demonstrated that PC Was 
stable in blood but rapidly hydrolysed in kidney. Further, 
PC was rapidly taken up by bone, consistent with its 
physicochemical properties. These results suggested that 
although PC itself might be useful in treating some disorders 
of calcium metabolism, for other disorders, such as 
urolithiasis, a more stable analogue may be desirable. The 
nature of such analogues was discussed. 
Further experimentation indicated PC was compart-
mentalised within mitochondria and preliminary , work 
demonstrated that it could be biosynthesized there under the 
impetus of calcium loading. Data supported the proposal that 
compartmentalisation protected PC from the extramitochondrial 
lytic activity. The role of PC as a mitochondrial agent 
stabilising calcium phosphate deposits as amorphous spherules 
rather than HAP needles was described, and the effect of 
this stabilisation on membrane integrity, enzyme activity and 
calcium mobilisation was also detailed along with specific 
roles for PC in particular tissues, 'especially bone. Avenues' 
for future research were presented' and possible roles of PC 
in the aetiology and therapy of some calcium metabolism 
disorders discussed. 
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CHAPTER 1 
TNT RODUCT ION 
1.1 	BACKGROUND  
Calcium is the major cationic constituent of most 
mineral deposits in biological systems. Deposition can occur 
as a result of the normal metabolism of organisms, for 
example in bones, teeth and shell material (Degens, 1976; 
Posner and Betts, 1975; Landis and Glimcher, 1978). In 
addition, pathological states can result in the formation 
of calcareous deposits (Fleisch et al., 1965; Catalina and 
Cifuentes, 1970) as in, for example, atherosclerosis, and 
stone formation in the urinary tract. In these mineralisations 
calcium may be present as a carbonate, a phosphate, or 
an oxalate, for example as the minerals calcite or aragonite, 
weddelite or whewellite, or amorphous calcium phosphate, 
brushite or hydroxyapatite, respectively. A combination of 
these salts may also occur ; for example dahillite is a mixture 
of calcium carbonate and hydroxyapatite found in bone 
(Degens, 1976). 
Over the last fifty years calcium has been shown 
to influence a wide variety of cellular functions (Table 1.1) 
which include': platelet aggregation, glucose transport, 
contraction of muscle myofibrils, discharge of neurotrans-
mitters and hormones, bioluminescence, and enzymatic activity 
(for example pyruvate dehydrogenase phosphatase, phospho-
fructokinase, fructose 1,6-diphosphatase and adenylate kinase). 
It is not surprising, therefore, to find calcium referred to 
as a "second messenger" (Rasmussen, 1977; Rasmussen and 
Goodman, 1977) due to its ability to affect many events in 
Table 1.1 	A representative sample of cellular functions regulated by calcium. * 
REFERENCES 
SECRETION OF:  
neurotransmitters  	 Fukuda and Kameyama (1979) 
hormones e.g. glucagon, adenohypophysasis hormone  	 Leclercq-Meyer et al. (1978): Moriarty (1978) 
proteins e.g. enzyme secretion by pancreas  	 Chandler (1978) 
agents for vasodilation and antivasodilation e.g. histamine from 
mast cells  	 Van Neutan and Wellens (1979) 
electrolytes and water e.g. in kidney epithelia  	 Greger et al. (1978): Suki (1979) 
CONTRACTILE MECHANISMS:  
muscle myofibrils  
	
MacLennan and Klip ( 1979 ) 
activities associated with microtubules and/or microfilaments e.g. 
cell division, flagellar motility  
	
Nishida (1978) 
MEMBRANE EVENTS:  
platelet aggregation  	 Massini et al. (1978) 
glucose transport  Hellman (1979) 
fluidity of membranes  	 Gordon et al. (1978) 
action potentials  Fukuda and Kameyama (1979) 
, OTHER FUNCTIONS:  
bioluminescence  	 Henry and Ninio (1978) 
photoreception  Clark and Duncan (1978) 
fertilisation  	 Lambert and Epel (1979) 
REGULATION OF SPECIFIC ENZYME SYSTEMS: 	 
pyruvate dehydrogenase phosphatase 
pyruvate dehydrogenase kinase 
fructose 1,6-diphosphatase 
lipases and phospholipases 
prostaglandin synthesis 
cyclic nucleotide phosphodiesterase 
Case (1980) 
*Based on data given by Case (1980) 
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a controlled manner. 
In order that calcium can control biological functions, 
intracellular and extracellular calcium levels must be closely 
regulated and today many normal calcium deposits, once 
thought to be inert, are regarded as in constant flux and•
intimately involved in calcium homeostasis (Neuman et al., 
1977; Heersche et al., 1978; Eilon and Raisz, 1978). Although 
ultimate control must involve the molecular mechanisms respon-
sible for deposition and re-absorption of mineral deposits, 
this level of control is only the last in a sequence of de-
creasing complexity involving (1) control at the organ level, 
(2) the exchange of intra- and extracellular calcium, and 
(3) fundamental molecular mechanisms of calcium deposition. 
1.1.1 CONTROL AT THE ORGAN LEVEL 
The highest level of control of calcium homeostasis 
involves organ function and the hormonally mediated inter-
action between them. The four major organs controlling 
calcium metabolism are the intestine - the absorption site 
(Ribovich and DeLuca, 1978; Marche et al., 1978; Morrissey 
et al., 1978), bone - the reservoir for calcium and phosphate 
(Thomasset et al., 1978; Dziak, 1978; Christakos and Norman, 
1978) , kidney - the site for excretion and reabsorption 
(McPartlin et al., 1978; Farrington et al., 1978; Bonjour 
et al., 1978), and the thyroid-parathyroid complex. This 
complex secretes hormones controlling calcium levels, princ-
ipally calcitonin and parathyroid hormone, in response to, 
among other factors, calcium concentration in the serum 
(Habener and Kronenberg, 1978). Calcitonin is a hypocalcemic 
factor inhibiting bone resorption, thus allowing its deposition 
4 
(Boris et 	al., 	1979; 	Messer 	et 	al., 	1973; 	Asch , 	1978; 
Ono et al., 1978) , whereas parathyroid hormone (PTH ) 
acts to stimulate bone resorption and to decrease renal 
calcium excretion (Thomas and Ramp, 1949; Broulik et al., 
1978; Habener and Kronenberg , 1978) . The third major 
hormone of calcium homeostasis is vitamin D acting via 
active metabolites. 
It is now known that the action of vitamin D is 
mediated, in part, by its metabolic transformation to 1,25- 
dihydroxy vitamin D and perhaps other active compounds 
for example 24,25-dihydroxy vitamin D (Ornoy et al., 
1978; Holick and Clark, 1978; DeLuca, 1979 ) . 
A 	primary 	site 	of 	metabolic 	control 	is 	the 
renal mitochondrial enzyme 25-hydroxy vitamin 
D-1 a-hydroxylase which is affected by such factors as serum 
calcium, PTH and serum phosphate levels (Norman and Ross, 
1979). Thus vitamin D .serves to increase intestinal absorption 
of calcium and facilitates PTH-stimulated bone resorption. 
Vitamin D, calcitonin and PTH are currently thought to be 
the major regulatory factors in calcium homeostasis (Arnaud, 
1978), although other factors can influence calcium and phos-
phate metabolism, including: vitamin . A (Kistler, 1978, 1979), 
vitamin C (Parker et al., 1979), growth hormone (Koskinen 
et al., 1977; Aloia et al., 1977), thyroid hormone (Maclntyre 
et al., 1978), sex hormones (Cruess and Hong, 1978), and 
perhaps vitamin K (Hauschka et al., 1978; Lian et al., 1978; 
Lian and Friedman, 1978). 
1.1.2 EXCHANGE OF INTRA- AND EXTRACELLULAR CALCIUM 
At the subcellular level mechanisms of calcium homeo- 
5 
stasis involve uptake and release of calcium by membranes 
[for example sarcoplasmic reticulum, mitochondria and Golgi 
(Herbst and Deamer, 1977; Yamazaki et al., 1979; Freedman 
et al., 1977, 1981)] and by calcium binding proteins such 
as calmodulin, vitamin D inducible calcium binding protein 
and parvalbumin (Means and Dedman, 1980; Laouari et al., 
1980; Morrissey et al., 1978; Maximov et al., 1978; Sowadski 
et al., 1978). In organelles, the calcium levels may rise 
to such an extent that calcareous deposits form there 
(Greenawalt et al., 1964; Appleton and Morris, 1979; 
Raeymaekers et al., 1981). 
At the cellular level mechanisms controlling calcium 
homeostasis include calcium entry across plasma membranes 
by, for example, passive entry, pinocytosis or ATP-energised 
uptake; and exit of the ion by mechanisms including ATP-
driven pumps, Na + -Ca++ exchange and exocytosis (Best and 
Ford, 1978; Brinley, 1978; Moore and Pastan, 1978; Kinne 
et al., 1977). Another facet of control at the cellular level 
is the specialised activities of differentiated cells, for 
example of osteoblasts and osteoclasts which control, in part, 
bone turnover (Vignery and Baron, 1978; Lewinson and Silber-
man, 1978; Heersche, 1978; Daniels, 1978; Teitelbaum and 
Kahn, 1980). 
1. 1 .3 FUNDAMENTAL MOLECULAR MECHANISMS OF CALCIUM 
DEPOSIT ION 
Although there are many mechanisms recognised as 
playing roles in controlling calcium homeostasis, perhaps 
the most important, and certainly the most basic, level of 
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control is the molecular mechanism(s) governing calcium salt 
deposition and dissolution. However, the exact mechanism( s) 
are still unknown and in order to gain information that 
might aid definition, three sites of calcification are - usually 
studied: (1) the bone site, (2) the urinary tract site, and 
(3) the intracellular site. 
1.2 	THE BONE SITE 
The exact mineral constitution of bone remains unknown. 
It is not a pure hydroxyapatite (Driesens et al., 1978; 
Driesens and Verbeeck, 1980; Driesens, 1980), but appears 
to be a carbonated hydroxyapatite (Posner, 1969; Tochon-
Darguy et al., 1980; Chickerur et al., 1980) or may even 
be a citrated hydroxyapatite (McCann, 1979; Meyer and 
Selinger, 1980). Recently a form of calcium phosphate amor-
phous to •X-ray diffraction has been recognised in bone 
(Wheeler and Lewis, 1977; Termine et al., 1967) , apparently 
decreasing with age (Termine and Posner, 1967). In vitro  
this amorphous form (ACP) is known to be the kinetic pre-
cursor of hydroxyapatite (Boskey and Posner, 1973; Meyer 
and Eanes, 1978a; Termine et al., 1970) and currently it 
is believed that ACP is also the first-formed phase in vivo  
(Landis and Glimcher, 1978; Posner and Betts, 1975; Posner, 
1973; Betts et al., 1975; Dougherty, 1978). 
In order to explain how calcium phosphate precipitates 
in a controlled fashion at the bone site, three models (Neuman 
and Neuman, 1958; Posner, 1969; Posner et al. , 1978) are 
usually advanced: 
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MODEL A: 	elevation of local calcium and phosphate levels 
to force precipitation from a supersaturated 
solution, 
MODEL B: 	creation of nucleating sites for calcification, 
or removal of 'substances blocking these sites, 
and 
MODEL C: 	removal of inhibitors of precipitation allowing 
mineralisation to proceed. 
1.2.1 MODEL A - ELEVATION OF LOCAL CALCIUM AND PHOSPHATE 
LEVELS 
Fluid aspirated from cartilage has been shown to contain 
insufficient calcium and phosphate for precipitation to occur 
spontaneously (Howell and Carlson, 1968), especially if 
A,CP, which is significantly more soluble than HAP (Meyer 
and Eanes, 1978a, b), is indeed the first-formed phase. 
Thus one model of calcification envisages elevation of calcium 
and/or phosphate levels as the impetus for precipitation. 
One method for elevating the concentration of phosphate 
suggested many years ago by Robison (1923) involves the 
hydrolysis of organic phosphoric esters at the bone site by 
alkaline phosphatase activity. The consequent elevation in r 
phosphate was proposed to initiate precipitation. Acceptanc'e 
of this model has been hampered by the ubiquity of alkaline 
phosphatases which does not therefore explain why calcific-
ation is normally limited to the bone site. Further, no phos-
phoric ester specific to the bone site has ever been found. 
In order to answer these criticisms, research has concentrated 
on the elucidation of any lytic activity at the bone site 
which might selectively cleave a particular phosphoric ester. 
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Pyrophosphate has been considered as a possible compound 
influencing calcification (Fleisch and Russell, 1970) and 
recently reports have described pyrophosphatase activity 
at the bone site (Korhonen et al., 1977; Arsenis and Huang., 
1977 ) , but it is still unclear whether this is due to a unique 
enzyme or is a facet of general phosphohydrolase activity 
(Posner, 1969). 
There is, however, another method by which calcium 
and phosphate levels can be locally elevated: concentration 
of the ions by vesicular bodies. Granules have been found 
in soft tissue mitochondria and have been identified by micro-
incineration and X-ray diffraction as ACP (Greenawalt et 
al., 1964). Furthermore, ACP granules have been observed 
in mitochondria prior to mineralisation 'in cartilage (Brighton 
and Hunt, 1978a, b; Lewinson and Silberman, 1978; Matthews 
et al., 1970 ) . Chondrocyte mitochondria are known to be 
capable of loading up to 300 times the calcium accepted by 
soft tissue mitochondria and are relatively insensitive to calc-
ium-uncoupling (Shapiro et .al., 1976; Shapiro and Lee, 1978; 
Lee and Shapiro, 1978) , high-lighting the capacity of mitocho-
ndria at the bone site to concentrate calcium. Lehninger(1970) 
has proposed that these "micropackets" of calcium phosphate 
are then passed out of the cell, by a process analogous to exo-
cytosis , for calcification. There is no direct evidence for this 
suggestion, but two recent avenues of research add , weight to 
the proposal. EM observation of the intestinal translocation of 
calcium indicates that mitochondria accumulate at the brush 
border, then take up calcium and move towards the basal lam-
allae (Weringer et al. , 1978 ) . If an analogous process occurs in 
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mineralising bone, then a controlled introduction of calcium 
phosphate to the calcification site, as envisaged by Lehninger, 
is possible. 
The second avenue of research implicating mitochondria 
in calcification has been obtained through EM observation 
of calcifying epiphyseal cartilage. The ACP deposits that 
accumulate in mitochondria disappear and simultaneously 
calcium phosphate deposits appear in small, vesicular bodies 
(Anderson and Hsu, '1978; Hsu et al., 1978; Wuthier et al., 
1977; Schraer and Gay, 1977; Boskey, 1979; Felix et al., 
1978; Ali et al., 1978; Dereszewski and Howell, .1978) unique 
to the mineralising front - the matrix vesicles. The exact 
source of the bodies is unknown, but since they can 
accumulate calcium and phosphate) and can initiate calcifi-
cation in vitro then, along with mitochondria, they are sites 
that can concentrate calcium in bone and may be intimately 
involved in controlling mineralisation. 
The local elevation of concentration in vesicular bodies 
leading to the precipitation of calcium phosphate appears 
well established, but .whether or not elevation of the calcium 
and phosphate levels in the extracellular fluid is responsible 
for initiating bone calcification remains unknown. Although 
accumulation and movement of the deposits from mitochondria 
to matrix vesicles is correlated with mineralisation in 
calcifying cartilage, its role as a causative factor has yet 
to be unambiguously demonstrated. 
1.2.2 MODEL B - NUCLEATION OF CALCIFICATION 
In another type of model proposed to explain calcific- 
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ation, the properties of some molecules to promote precipitation. 
is seen as the cause of bone formation. In these models, 
certain molecules nucleate bone mineral by mechanisms includ- 
• 
•ing calcium binding or the ability to promote epitaxial 
growth. In the latter regard, collagen has been often 
discussed since it has been shown to bind ions and induce 
the formation of hydroxyapatite needles in the hole zone 
of collagen fibrils (Berthet-Colominas et al., 1979; Althoff 
et al., 1978; Waddell, 1972). In vitro, collagen from a wide 
variety of sources has been shown to have the ability to 
nucleate hydroxyapatite (Rey et al. , 1977; Huckins, 1978; 
Quittner and Wadkins, 1978; Luben and Wadkins, 1971; 
Wadkins and Luben, 1978; Wiedner and Wilhelm, 1977). 
EM examination of mineralising bone indicates that hydroxy-
apatite does form on collagen fibrils in 	a regular fashion 
(Yamada, 1976; Lees, 1979). These data strongly suggest 
that collagen has a role in calcification. However, collagen 
is widespread in the body and it is difficult for this model 
to explain the specificity of calcification. Recent evidence 
(Hohling et al., 1980), however, has been used to argue 
that collagen from bone does possess some unique features 
associated with negatively charged amino acids acting as 
initiators of calcification. 
Phospholipids, either as proteolipids or as complexes 
with calcium and phosphate, have also been suggested as 
nucleators influencing calcification. A proteolipid that will 
promote precipitation in vitro (Ennever et al., 1978) has 
been isolated from bacteria which calcify (Boyan-Salyers 
et al., 1978). Recent work has suggested that an analogous 
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proteolipid is found in bone (Ennever et al., 1977; Wuthier 
and Gore, 1977). The complexes between acidic phospholipids, 
calcium and phosphate are well known for their ability to 
promote hydroxyapatite formation in vitro (Boskey and Posner, 
1977; Boskey, 1978). Acidic phospholipids that bind calcium 
have been isolated from bone (Vogel . et al., 1978; Wuthier 
and Gore, 1977) . It is important to note that whereas collagen 
is known to be elaborated before calcification ( Lees , 1979; 
Yamada, 1976 ) , a similar sequence with phospholipids is 
not yet defined. 
Another class of compounds proposed to nucleate hydro-
xyapatite are phosphoproteins (Lee et al., 1977; Keeley, 
1977). In fact, serine phosphate has been recognised in the 
protein present at certain calcified . sites, for example, the 
human aorta (Keeley, 1978). Recently, however, evidence 
has been presented (Termine and Conn, 1976; Termine et 
al., 1980) indicating that, in vitro at least, .phosphoproteins 
instead of nucleating hydroxyapatite inhibit its formation. 
• This anomalous type of behaviour has also been 
observed with another class of proteins suggested to be 
calcification nucleators; namely the y -carboxyglutamate 
( y -Gla ) containing proteins (Hauschka et al., 1975; King, 
1978; Price et al., 1976; Lian et al., 1978; Lian and 
Friedman, 1978) . A role in controlling calcification was 
suggested from the • observation that osteocalcin, a Y -Gla 
containing protein found in bone, was synthesised in chicken 
embryonic bone at the time of calcification (Hauschka and 
Reid, 1978a , b) . In fact, y-Gla containing proteins have 
been found in a wide variety of calcifications including 
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urinary stones, but a role as nucleator has been difficult 
to reconcile with the observation that in vitro it potently 
inhibits hydroxyapatite formation ( Price et al . , 1976 ) . The 
question also arises as to whether its appearance in calcif-
ications is merely a reflection of its calcium-binding ability. 
A regulatory role in calcium handling can be envisaged 
for phosphoproteins and y -Gla containing proteins because 
of their inhibitory nature. Only collagen and phospholipids 
(either as conjugates or complexes ) show clear potential 
hydroxyapatite nucleators and of these two, only collagen 
has been shown to be synthesised and laid down before 
calcification. 
Fleisch and Russell (1970 ) have suggested a modific-
ation to this basic model because of the difficulty in explain-
ing how collagen, which is ubiquitous, could nucleate 
calcification at specific sites and not at others. • In thiS 
model, pyrophosphate binds to nucleating sites on collagen 
and is specifically removed at the bone site, thus removing 
the barrier to hydroxyapatite formation. However, the applic-
ability of this model is limited by the fact that pyrophosphate 
itself is ubiquitous and, as yet, no specific enzyme has 
been unambiguously demonstrated at the bone site for the 
selective removal of pyrophosphate ( Posner , 1969) , although 
it is labile to the general phosphohydrolytic there and at 
other sites ( Fleisch and Russell, 1970 ) . 
1.2.3 MODEL C . - REMOVAL OF INHIBITORS OF CALCIFICATION 
Since the recognition that ACP may be the biological 
precursor of hydroxyapatite , many compounds have been shown 
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to inhibit 
inhibiting 
Inhibitors 
citrate, 
(Termine 
glycans 
(Hay et 
hydroxyapatite formation by stabilising ACP and 
the transformation of ACP into hydroxyapatite. 
include: ATP (Blumenthal et al., 1975,  1977), 
fructose 1,6-bisphosphate, 	magnesium, 	phosvitin 
and Conn, 1976; Termine et al., 1970), proteo- 
et al., 	1979), and poly-L-glutamate 
al. , 1979). In models of calcification involving 
(Blumenthal 
inhibitors, their selective removal at the bone site is proposed 
to initiate calcification. Inhibitors often used in such models 
are organic phosphoric esters so the factors suggested to 
remove them are the phosphohydrolytic activities present 
either extracellularly in forming bone, or in the matrix 
vesicles. 
Fleisch and Bisaz (1962) isolated a phosphate compound 
from urine which inhibited hydroxyapatite formation and 
recognised it as pyrophosphate. Since then work has establi-
shed it as not only a potent inhibitor of hydroxyapatite 
formation but as a compound occurring at the bone site 
(Perkins and Walker, 1958). Pyrophosphate, however, is 
highly labile in vivo (Jung et al., 1970) making it difficult 
to envisage how it could act specifically at the bone site. 
Nevertheless, because for example, nothing is definitely 
known on the possible occurrence of high concentrations of 
the inhibitors in a particular microenvironment, pyrophosphate 
has been often suggested as a controlling influence on 
calcification in vivo (Hausmann et al., 1970; Fleisch and 
Russell, 1970, 1972; Russell et al., 1970; Fleisch et 
al., 1970; Neuman et al., 1978). The recent recognition of 
matrix vesicles at the mineralising front leads to the 
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possibility that these bodies may contain an enzyme specially 
suited for the removal of pyrophosphate. As yet, however, 
despite the findings that these bodies are rich in phosphat-
ases (Fortuna et, al., 1978; Felix and Fleisch, 1976), no 
specific pyrophosphatase activity has been revealed. 
In an extension of this research motivated to take 
advantage of the physicochemical properties of pyrophosphate 
for therapy, its analogues - the diphosphonates, have been 
prepared. These compounds are stable to enzymatic hydrolysis 
(Strates et al., 1971) and have the ability to inhibit calcium 
salt precipitation (Fleisch et al., 1970; Russell et al., 1970) 
and dissolution (Robertson and Fleisch, 1970; Francis et 
al., 1969; Francis, 1969) by binding to the surface of the 
deposition (Meyer and Nancollas, 1973;.  Jung et al., 1973). 
Their use, however, in the treatment of calcium disorders 
such as Calcium lithiasis, Paget's disease and osteolytic•
sarcoma, has been limited by long-term effects due to dimini-
shed bone turnover (Francis et al., 1976; Miller and Jee, 
1977; Bone et al., 1979). Further, there is evidence that 
the analogues disrupt normal cellular metabolism (Komissar-
enko et al., 1977; Fast et al., 1977, 1978; Rowe and Hausmann, 
1976; Bisaz et al., 1975; Miller et al., 1977; Caniggia and 
Gennari, 1977; Michael et al., 1972; Palmoski and Brandt, 
1978; Ende, 1978). 
Another Phosphoric ester suggested to play a role 
analogous to pyrophosphate, is ATP (Leonard and Scullin, 
1969). Again its ubiquity has made such a model of calcific-
ation difficult to accept. Because pyrophosphate and ATP 
release phosphate when their inhibitory effect is abolished 
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by hydrolysis they could possibly act to elevate local 
phosphate concentrations; so if this model of calcification 
becomes tenable these types of inhibitors could be forseen 
to have a dual action. Unhydrolysed, they inhibit hydroxy-
apatite formation: hydrolysed, one of their cleavage products 
is a precursor of hydroxyapatite. 
Proteoglycans do not contain anionic phosphate groups 
that are often associated with inhibitory activity and in 
vitro show a different type of .inhibition (Blumenthal et al., 
1979) of the transformation of ACP into hydroxyapatite. 
Inhibitors usually delay the onset and sometimes the extent 
of the conversion process ; proteoglycans do not delay the 
onset but they • do decrease the rate of conversion and its 
extent. This occurs at high concentrations approximating 
to those found in cartilage. However, some workers consider 
proteoglycans to be extracellular matrices for deposition 
(Hohling et al., 1980; Reddi et al., 1978). Whatever the 
exact function of proteoglycans in the mineralising cartilage 
it must be shown that proteoglycans from uncalcified cartilage 
are different from those in calcified areas. In fact, some 
evidence has: been presented to this effect (Lohmander and 
Hjerpe, 1975), but the exact role of proteoglycans in mineral-
isation remains obscure. 
Clearly then there are many compounds which can 
regulate calcium phosphate formation through an inhibitory 
action. Models using inhibitors to explain bone formation, 
however, have been unable to convincingly demonstrate that 
their effect could be localised to the calcifying site. 
Research into the phosphohydrolytic activity • at the bone 
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site and more particularly in matrix vesicles may lead to 
an understanding of the role that inhibitors play in bone 
formation. 
1.3 	URINARY TRACT SITE 
Calculi found in the urinary tract are composed of 
various salts including calcium oxalate, calcium phosphate, 
uric acid, magnesium ammonium phosphate and/or cystine 
(King, 1971 ) . Most stones are predominantly calcium oxalate 
but a mixed composition is frequently found (Kennoki et al . , 
1978; Robertson et al., 197 8 ; Pellegrino and Biltz , 1978; 
Gonzalez-Diaz et al., 1979) . In addition to the crystalline 
matter, a matrix of protein or mucoprotein is always found 
( King , 1971; Resnick and Boyce. , 1978; Rao et al., 1978 ) . 
With regard to calcium lithiasis , Pak (1978) has noted 
that many broad aspects of their formation are analogous 
to the mechanisms suggested to explain bone deposition. 
Consequently, factors influencing lithiasis can be considered 
in the three main groups proposed for bone formation : 
MODEL A: calcium and phosphate levels - dependent on 
cellular and hormonal status, 
MODEL B: 	nucleation ( promotion) 	inorganic or organic 
substrates acting to promote the deposition 
of stone salts, and 
MODEL C: 	inhibitors - compounds which inhibit nucleation, 
growth and/or aggregation of calcium salts. 
1.3.1 MODEL A - ELEVATION OF LOCAL CALCIUM AND PHOSPHATE 
LEVELS 
Studies on the urine of stone formers indicates that 
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it is nearly always supersaturated with regard to stone 
components ( Fleisch , 1978; Robertson et al., 1971) . However, 
non-stone formers quite often excrete urine that is also super-
saturated (Gill et al., 1974; Finlayson , 1978) . Therefore, 
there tends to be disagreement as to whether the urine of 
stone formers is more supersaturated than that of normal 
individuals. Pak and Holt (1976 ) , for example, found that 
the activity product ratios of brushite and calcium oxalate 
were elevated in stone-forming groups due mainly • to a• high 
renal excretion of calcium. However, Crassw eller et al., 
(1978 ) found that Whilst calcium phosphate supersaturation 
was greater in stone-formers, levels of saturation of urine 
with calcium oxalate were identical in stone-formers and 
normal individuals. Consequently, Finlayson (1978 ) has 
suggested that stone formation . may arise from a difference 
in boundary conditions ( that is conditions resulting in meta-
stability of urine ) , or the stochastic nature of the process, 
urinary inhibition or some other process. Robertson et al. 
(1978 ) have attempted to isolate the factors predisposing 
an individual to form stones and have found that apart from 
factors influencing saturation of urine, other elements includ-
ing inhibitors •and promoters also influence lithiasis . Factors 
requiring consideration include : ( 1 ) calcium, ( 2 ) oxalate, 
(3 ) pH, (4) acid mucopolysaccharide , and (5) uric acid. 
More recently Hautmann et al. (1980 ) investigated the concent-
rations of calcium and oxalate in the cortex, medulla and 
-7  renal papillae. Whereas the ion product Was 6 x 10 	M2  in 
the cortex, medulla and urine ( approximately the formation 
product of calcium oxalate ) , in renal papillae it was 1 x 
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10 -4 M 2 . Strictly activities should have been used to allow 
for the effect of chelation. Nevertheless, the high relative 
concentration of calcium and oxalate in ' renal papillae ( x1000 ) 
does raise the question as to why lithiasis does not proceed 
in normal individuals and highlights the role that inhibitors 
must play to prevent stone formation in the urinary tract. 
1.3.2 MODEL B - NUCLEATION OF STONES 
The organic matrix of stones is well known ( Rao et 
al., 1978; Delatte et al., 1976; Boyce and King, 1959 ) and 
its role as an etiologic factor has been discussed. However, 
despite the fact proteins, which can promote crystallisation 
( Boyce et al., 1954) , are raised in concentration in the urine 
of stone-formers, the role of promoters has been largely 
ignored until recently ( Delatte et al. , 1976), presumably 
because inclusion of organic matrices into stones could be 
a secondary effect. Calcium binding or irritation of the 
urinary tract could account for their presence.. 
After the recognition of a new amino acid, y -c ar box y-
glutamate ( Hauschka et al., 1975,  1978 ) , came the discovery 
of y -Gla containing proteins in many calcifications including 
bone and calcium stones ( Hauschka and Reid, 1978a ) . These 
proteins strongly bind calcium and were proposed to act, 
• therefore, as a centre for subsequent crystal growth (Lian 
and Friedman, 1978 ) . In vitro, however, y -Gla containing 
proteins strongly inhibit the formation of hydroxyapatite 
( Hauschka and Reid, 1978b) so the role of these calcium 
binding proteins in the promotion of calcium lithiasis is 
undefined. 
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Recently data has been published which re-establishes 
the importance of a nucleating agent in the etiology of stone 
formation. Hallson and Rose (1979) concluded from studies 
on the effect of ultrafiltered urine on precipitation that human 
urine contains macromolecules which promote both the 
formation of calcium oxalate and calcium phosphate crystals. 
Notably the ultrafiltrate generally failed to develop crystals, 
whereas addition of the retained uromucoid promoted 
precipitation. 
'The role of organic. components in nucleating precipit-
ation of calcium salts remains controversial but the . phenomen-
on of epitaxis, in which crystals of one salt induces the 
growth of another type of salt, has become established and 
is currently the focus of much attention. Lonsdale (1968) 
has tabulated the dimensions of the common stone-forming 
compounds in their usual habits and has shown that the 
geometrical fit between the respective lattice-works is very 
close in a large number of cases. This was suggested to 
account for the common observation that stones are of mixed 
composition. Since then, in vitro studies have established 
that brushite will nucleate calcium oxalate (Pak and Holt ,1976), 
and that monosodium urate monohydrate nucleates calcium 
phosphate and calcium oxalate (Pak et al., 1976; Coe et 
al., 1975; Pak and Arnold, 1975). This latter finding emphas-
izes the role that excessive urate excretion, one of the risk 
factors given by Robertson et al., (1978), could play in 
calcium lithiasis. Further evidence for the role of urate 
comes from the observation that lowering the hyperuricosuria 
that often accompanies calcium urolithiasis reduces the 
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formation of calcium stones (Coe, 1978) . 
Nucleation of calcium salt precipitation by organic 
components, although possible in vitro, remains as with bone 
formation, of unclear significance in vivo. Epitaxial 
induction by stone components, however, is not only well 
established in vitro but explains several observations 
including the mixed composition of stones and the role of 
urate excretion in calcium lithiasis. 
• 1.3.3 MODEL C - INHIBITORS OF STONE FORMATION 
The supersaturation generally found in urine and 
the presence of nucleators leads to the question as to why 
stones • do not form more, often. Consequently one line of 
research has centred on compounds present in urine that 
act to inhibit the deposition of stone salts. 
Inhibitors can act to retard crystal growth after 
nucleation and/or to inhibit the aggregation of crystals. 
In addition, when calcium phosphate deposition is involved, 
comkunds can act to stabilise ACP formation, thus inhibiting 
the crystallisation of hydroxyapatite. 
Inhibitors that have been found in urine and tested 
in vitro include citrate, .pyrophosphate (Meyer and Smith, 
1975a , b) , magnesium ( Fleisch and Bisaz , 1964 ) , acidic poly-
peptides ( Nakagawa et al., 1978 ) , ribonucleotides ( Ito and 
Coe, 1977 ) , and glycosaminoglycans (Sallis and Lumley, 1979 ) . 
Trace metals (: Cu -r+ , zn 11 , Ill  Sn I and Al ) found in urine 
are not considered to be of major importance as inhibitors 
(Meyer and Angino, 1977 ) . Although it has been claimed 
( Sutor et al., 1978,  1979a, b; Sutor and Percival, 1978 ) 
that an artificial urine possesses an equal inhibitory action 
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to urine samples, this is not a generally accepted view. 
For example, Bisaz et al. (1978) have attributed 77% of the 
inhibitory potential of urine to citrate, pyrophosphate and 
magnesium, concluding That inhibitors of an as yet unknown 
nature may be present. Rose (1975) noted that an artificial 
urine composed of 12 solutes did not have the full inhibitory 
effect, of normal urine. However, it should be noted that 
the quantitation of inhibitory activity in urine is a controver-
sial subject. It is a relatively simple task to test a compound 
for inhibitory activity but it, has proved difficult to devise 
systems that allow quantitation, and enable the activity 
product for calcium and phosphate in urine samples to be 
• measured and related to that sample's tendency for stone 
salt formation (Fleisch, 1978; Finlayson, 1978). 
There is some evidence that normal individuals excrete 
a urine that contains more inhibitory units than stone-formers 
urine (Singla et al., 1978; Howard, 1976), but there is no 
consensus as to which inhibitory agent may be depleted in 
stone-formers urine. Pyrophosphate and peptides have been 
tested ,(Lewis et al., 1966; Russell and Hodgkinson, 1966; 
King and Boyce, 1962; Boyce and King, 1963; Boyce et 
al., 1962) but no unambiguous results have emerged. Since 
stone-formers have been found to excrete larger crystals 
than normal individuals in response to an augmented oxalate 
supply (Robertson and Peacock, 1972; Robertson et al., 1971), 
some research has focussed on the urinary glycosaminoglycans, 
potent crystal growth inhibitors, as a risk factor in the 
etiology of stone disease (Robertson et al., 1978). 
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Urine contains substances inhibiting stone salt precip-
itation and subsequent crystal growth and aggregation, but 
the exact contribution of each inhibitor to calcium phosphate 
and calcium oxalate formation remains uncertain as does 
the role of inhibitors in stone disease. Indeed, not all the 
inhibitors in urine may have been recognised yet. 
1.4 	INTRACELLULAR SITE  
Calcium is distributed unequally within the cell but 
attempts to elucidate its occurrence in the cellular compart-
ments have been hampered by the damage caused on disrupt-
ion of the cell. Nevertheless, evidence has accumulated 
indicating that mitochondria act as a "sink" for intracellular 
calcium ( Bygrave , 1978; Fiskum and Lehninger,  , 1980 ) . 
Mitochondria from various sources are now known to take 
up calcium in a process dependent on respiration and linked 
to H + -efflux ( Yamazaki et al., 1979; Revis and Marusic , 
1979; Panfili et. al. , 1976; Blondin et al., • 1977; Te'w,  , 1977; 
Harris, 1978) . Further, in response to external conditions 
calcium will be released from mitochondria (Shapiro and 
Lee, 1978; Hamilton and Holdsworth , 1970; Luthra and Olson, 
1976 ) . During the loading of calcium into mitochondria the 
appearance of granules in the matrix has been noted and 
these are now known to be deposits of ACP (Greenawalt 
et al., 1964; Ostrowski et al., 1975; Becker et al., 1974 ) . 
Notably, hydroxyapatite , the more insoluble phase, is not 
deposited and consequently the soluble calcium levels in 
the mitochondria must be higher than if hydroxyapatite had 
formed. This must affect the metabolic state of the mitochondria, 
since calcium levels modulate this ( Denton et al., 19 80) . 
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Apart. from this effect, the organelle can more readily mobilise 
calcium if ACP is precipitated since the amorphous phase 
is more labile than hydroxyapatite (Termine and Eanes, 1972). 
The foregoing observations indicate that in the deposit-
ion of mitochondrial calcium phosphate, calcium loading is 
a crucial factor. Unlike bone and stone formation, the elev-
ation of calcium levels can be accepted as a causative factor. 
However, in common with these other two calcifying systems, 
the role of inhibitors is a promising area. Since only ACP 
forms in mitochondria the question arises as to the nature 
of the factors responsible for this. In this regard, ATP and 
magnesium have recently been suggested to play a role 
(Blumenthal et al., 1977), but in general the phenomenon 
of intramitochondrial calcification is not well understood. 
For example, the question of' nucleation in mitochondrial 
calcification has not been examined. 
1.5 	CONCLUSIONS AND OUTLINE OF RESEARCH PROGRAMME 
The above discussion on the possible mechanisms of 
calcification at the various sites indicates that of the three 
general models A,, B and C (elevation of calcium and phos-
phate levels, nucleation, and inhibition) , the most acceptable 
model and the one most clearly demonstrated to influence 
all calcifying systems is inhibition. Calcium and phosphate 
levels, whilst implicated in mitochondrial calcification, are 
of unknown significance in bone mineralisation and in the 
etiology of urinary and renal stones. Similarly, the role 
of nucleation is unclear. However, although the exact role 
and complete. chemical identity of inhibitors is not known, 
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observations clearly indicate that they influence calcification 
to some degree. At the bone site, for example, ACP has been 
detected so inhibitors must act to stabilise this form. 
Similarly, ACP has been demonstrated to be deposited in 
mitochondria and must be stabilised by inhibitors. In urine, 
which is usually supersaturated with respect to stone salts, 
the role that inhibitors must play is again emphasised. Many 
inhibitors have already been identified at calcifying sites 
such as ATP, citrate, pyrophosphate, glycosaminoglycans 
and magnesium, but none of these provide a fully acceptable 
model of calcification. In order to explain, in detail, calcif-
ication and especially the role that inhibitors play in this 
process, much work has been done to recognise new inhibitors 
of calcification. 
The identification of any new inhibitor that might 
enable a more detailed explanation of calcification to be 
deduced has necessitated research in this area usually to 
involve purification of samples from calcifying sites, recogni-
tion of inhibitory activity in particular fractions, and identi-
fication of the inhibitory agent(s) in that fraction. In this 
way it has been shown that, for example, a group of 
salivary proteins, including statherin, potently inhibit 
calcium phosphate (Hay et al., 1979; Schlesinger and Hay, 
1977; Wong and Bennick, 1980). Similarly, protein inhibitors 
from urine have also been found (Nakagawa et al., 1978) , 
and there is a continuous search for new and more potent 
inhibitors. 
Perhaps the most promising of recent developments 
started, from the work of Howard et al. (1967) who isolated 
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a potent inhibitor, in an impure form, from urine and 
suggested it was peptidic. Later work (Barker et al., 1970 ) 
found that it was stable in 6N HC1 at 110 ° C for at least 
72hr suggesting the compound was not of peptidic nature. 
Smith et al. (1973 ) substantiated this claim . and found that 
the inhibitor had a molecular weight of less than 1000 and 
was anionic and stable to enzymatic digestion including 
trypsin , intestinal alkaline phsophatase and crude papain . 
In a similar type of study Thomas (1971 ) purified 
urine from stone formers and healthy individuals by ion 
exchange chromatography. Two inhibitory peaks were detected, 
the first containing organic phosphates and pyrophosphate . 
The second peak contained citrate and other inhibitors resist-
ant to hydrolysis. It was suggested that the second peak 
was decreased in patients with idiopathic renal lithiasis 
but the nature of the compounds in this peak remained 
unknown. 
In continued investigation into the nature of the 
compound( s ) , Howard (1976 ) reported that acidification of 
a solution of phosphate, citrate and calcium followed by 
neutralisation led to a great increase in inhibitory potential 
of the mixture. "Factor X" formed by this in vitro - reaction 
was postulated to be present in 
identity of "factor X" and indeed 
was obscured by the fact that the 
used to isolate it from urine also 
formation. Howard ( 1976 ) tentatively 
ion-exchange procedure 
caused its artefactual 
postulated that "factor 
biological samples but the 
its very existence in nature 
X" which contained phosphate and citrate, might well be 
a new compound "phosphocitrate". Using an impure, chemically 
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synthesised preparation of phosphocitrate, inhibitory ability 
towards calcium phosphate formation was demonstrated. The 
impurity of the sample, however, meant that the chemical 
nature of "factor X" could not be unambiguously assigned. 
Further, complications arose when earlier work by Meyer 
et al. (1959) on the synthesis and lability of phosphocitrate • 
was considered. In this isolated publication, which did not 
lead to any subsequent reports, phosphocitrate was demonstra-
ted to be completely hydrolysed within 4hr in 0.1N HC1 at 
100 ° C. Clearly this lability data did not agree with the 
lability of the inhibitor previously described (Howard et 
al., 1967; Howard, 1976; Barker et al., 1970). Thus, 
although research suggested a new inhibitor, was present 
in urine, its exact identity and indeed its very existence 
was still speculative, partly due to artefactual formation 
during its purification. 
The role of "phosphocitrate" was unclear mainly 
because no authenticated phosphocitrate had been tested for 
anticalcifying activity, nor had any been used for comparison 
with "factor X". Indeed, Sutor et al. (1979a) had even 
questioned Howard's assertion that acidification and neutral-
isation of a solution of phosphate and citrate could produce 
phosphocitrate. Lehninger (1977) reported in a review on 
the possible role of mitochondria in calcification that, 
although phosphocitrate was a potentially important new 
inhibitor, unambiguous identification awaited use of a high—
yield organic synthesis for the purpose. It was suggested, 
however, that "factor X" was also present in mitochondria 
acting to stabilise the "micropackets" of calcium phosphate 
27 
that formed as the amorphous phase. As a cautionary note 
it was added that the inhibition shown by the biological 
fraction could be due to an impurity migrating with the 
postulated phosphocitrate. 
In view of the preceeding comments,. work described 
in this thesis represents an attempt to seek confirmation 
of earlier proposals on the identity of the inhibitor and 
to extend work into aspects of its physiological role( s) and 
general biochemistry. Initially an attempt was made to 
develop an alternative synthesis of phosphocitrate and to 
characterise it for use as a standard and general biological 
probe. As a consequence, the availability of this reference 
compound was forseen as enabling the development of analytic-
al systems for the investigation into the possible • natural 
occurrence of phosphocitrate. For phosphocitr ate to be of 
value as an inhibitor of calcification it should affect the 
crystallisation of both calcium phosphate and calcium oxalate. 
This thesis reports on such studies and will consider the 
broader question of why certain compounds are more potent 
inhibitors than others. 
Finally, the possibility of the natural occurrence 
of phosphocitrate raises questions as to its lability in vivo 
at calcifying sites, its biosynthesis and subcellular distrib-
ution.•These aspects will be discussed with reference to 
physiological role( s) that these data may support. In 
addition,, the potential of • synthetic phosphocitrate for use 
as a therapeutic agent in controlling some disorders of 
calcium metabolism will be considered with reference to 
information on its lability in vivo. 
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CHAPTER 2 
SYNTHESIS 	AND 	CHARACTERISATION OF PHOSPHOCITRATE 
2.1 	INTRODUCTION  
Any investigation into the possible natural occurrence 
of phosphocitrate (PC) or of its physicochemical properties 
first requires that a pure compound be available as a refer-
ence material. As a further consideration, isotopically labelled 
PC would be of potential value in elucidating the metabolism 
of PC in biological systems. 
For these criteria to be met, two approaches to the 
synthesis of PC were therefore indicated: either a high-yield 
synthesis enabling [ 14 C1-citrate to be used for labelling, or 
a method allowing the use of [ 32 13 ]-phosphoric acid which, 
in comparison to other radiochemical materials, is relatively 
inexpensive to purchase and can be Obtained in high specific 
activity. 
The only previous • synthesis of PC reported was that 
described by Meyer et al. (1959) which unfortunately cannot 
•satisfy the above criteria. The method was of low yield and 
the phosphorylating reagent was dibenzyl chlorophosphate 
which is difficult to label with phosphorus-32. Further, the 
synthesis, as described, required special equipment: a 
molecular still. The low yield may have been due partly 
the tertiary sterically-hindered hydroxyl group of the 
starting chemical, triethyl citrate, which would effectively 
_block reaction with the phosphorylating reagent. Since the 
attempt by Meyer et al. (1959), an increased range of more 
powerful phosphorylating reagents has become available 
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(Slotin , .1977; Zhdanov and Zhenadarova , 1975 ) and of these 
two o-phenylene chlorophosphate and cyanoethyl phosphate 
appeared to meet the criteria expressed. 
o-Phenylene 	chlorophosphate 	(o-PCP ) 	is considered 
now to be one of the most potent phosphorylating reagents 
available ; it reacts rapidly even with tertiary or sterically-
hindered hydroxyl groups (Khwaja et al., 1970; K hwaja 
and Reese, 1971 ) , and was therefore selected for evaluation. 
Although it is not easy to label o-PCP with phosphorus-32, 
since the reagent must be synthesized from relatively expens-
ive [ 32 13 1-PC1 by a lengthy method, nevertheless the possib-
ility of a high-yield might enable [ 14 labelling . The basis 
of the synthetic pathway ( Figure 2.1) involves three steps: 
(1 ) coupling of o-PCP with an alcohol ( ROH ) ; ( 2 ) cleavage 
of the heterocyclic ring by the addition of water; and (3 ) 
removal of the protecting group by either reductive cleavage 
or oxidation. 
Another phosphorylating reagent, 2-cyanoethyl phosphate 
(CEP ) , has been used to prepare [ 32 13 1-labelled nucleotides 
( Tener 1961 ) and since the method employs [ 32 P 1-phosphoric 
acid, it is now frequently used for this purpose ( Slotin , 
1977; Hecht et al., 1973 ) . Figure 2.2 outlines the steps 
involved in this synthesis which requires prior activation 
of the pyridinium salt of CEP with dicyclohexylcarbodi-imide 
( DCC) giving an adduct that will react with an alcohol. 
Alkaline hydrolysis of the protecting group gives the phos-
phoric ester, and the • aqueous conditions also decompose 
unreacted DCC. The simple Preparation of [ 32  P 1-CEP from 
[ 32 pp 	indicated it was another reagent worth evaluating. 
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pyridine/R.T . 
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Figure 2. 1 Synthesis of phosphoric esters using o-phenylene 
chlorophosphate 
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Figure 2.2 Synthesis of phosphoric esters using 2-cyanoethyl 
phosphate 
activated adduct 
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Although synthesis of PC might be achieved by either 
of these routes, separation of products and ultimate purific-
ation of PC presents additional problems. The initial synthesis 
of PC described by Meyer et al. (1959) used an ion-exchange 
chromatographic system for purification of the product. The 
use of formate as the buffer anion obviously led to poor 
separation and further, the calcium salt of PC had to be 
prepared after chromatography in order to separate it from 
the buffer eluant. One of the objects of preparing PC was 
to test it for its anti-calcifying ability - as evaluated by 
the prevention of calcium phosphate or calcium oxalate precip-
itation so it was desirable to be left with a salt 
uncontaminated with divalent metal ions, which could possibly 
interfere with the calcification systems. 
As another consideration, 	investigation by Howard 
(1976) has suggested that acidic conditions may lead to 
artefactual production of PC in a low yield. Although this 
is not a consideration in the isolation of chemically-synthe-
sized PC it does imply, that for any other subsequent attempt 
to quantitatively isolate PC from biological sources, an ion-
exchange system operating at neutral pH is desirable to 
eliminate, if possible, artefact formation. 
The high binding capacity of ion-exchange resins 
compared with cellulose or silica based systems suggested 
it was reasonable to use the former type of chromatography, 
but desirable to try a more strongly binding anion for eluting 
citrate and PC with the aim of effecting a better separation 
of these anions. Consequently, various ion-exchange systems 
were investigated during attempts to prepare PC. 
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2.2 	'MATERIALS  
TriethylCitrate and hydracrylonitrile were purchased 
from Fluka Chemical Co., Buchs, Switzerland and o-phenylene 
chlorophosphate was a product of Aldrich Chemical Co., 
Milwaukee, Wisconsin. All other chemicals were reagent grade 
and obtained from usual commercial sources. 
Before use, tetrahydrofuran was dehydrated by passage 
through a basic alumina column (Woelm, Eschwege, Germany) 
and stored over molecular sieve 4A. Pyridine was refluxed 
over KOH pellets and recovered by distillation. The resins 
AG 1-X8 (100-200 mesh) , chloride form, and AG 50-W-X8 (200- 
400 mesh) , hydrogen form, were products of Bio-Rad Labora-
tories, Richmond, California. The resins were cycled before 
use with appropriate solutions (Bio-Rad Laboratories, 1976 ) 
and the AG 1-X8 resin coverted to either the nitrate or bicarb-
onate form. 
Wheat germ acid phosphatase (E.C. 3.1.3.2; 0.4U/mg 
protein) was from the Sigma Chem. Co., Sydney, Australia, 
and alkaline phosphatase ( E.C. 3.1.3.1; 400U/0.17m1; calf 
intestine, Grade I) was a product of Boehringer-Mannheim, 
Melbourne, Australia. 
2.3 	METHODS  
2.3.1 CHEMICAL ANALYSES 
2.3.1. 1 Citrate  
Citrate was determined by degradation to pentabromo-
acetone as described by Taylor (1953). Accordingly 5m1 of 
27N H 2 SO 4 
was added to 5m1 of the test solution and after 
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mixing, 5m1 of an oxidising-brominating mixture containing 
19.84g KBr, 5.44g KBrO 3 and 12.00g NH 4V03 in 1 litre was 
added. 
The tubes were allowed to stand for 30 minutes ; then 
2m1 of freshly prepared ferrous sulphate solution ( 22.0% 
FeS0 4 .7H 20 in 1N H 2SO4) 
was added to decompose unreacted 
bromine. The tubes were mixed and left for 10 minutes. Six 
ml of light petroleum spirit (60-80 °C b.p. ) was added and 
each tube was mixed vigorously for. 1 min before the green, 
aqueous layer Was carefully removed by vacuum aspiration. 
Sufficient anhydrous sodium sulphate was then added to 
completely absorb any aqueous phase remaining, and the 
organic phase was poured into clean, chilled test tubes. 
A 5m1 portion was pipetted into a test tube containing 3m1 
of freshly prepared 2% Na 2 S and each tube shaken for 
min . The top, organic layer was removed and the yellow, 
aqueous phase colorimetrically determined at 450nm within 
10-20 min. Standards of 0-200 pg citrate were included 
routinely. 
2.3.1.2 Phosphate  
Inorganic phosphate (P ) was estimated by the Fiske- ]. 
SubbaRow — method ( Fiske and I (- SubbaRow 1925, 1929) . One 
ml of 5N H 2 SO 4 
and lml of 2.5% ammonium molybdate was 
added to 8m1 of sample. After mixing 100p1 of a reducing 
solution (2.5% of mixture comprising lg 1-amino-2-naphthol 
sulphonic acid, 6g Na 2 S 0 3 , 6g Na 2 SO 5 ) was added, the 
tubes mixed and allowed to stand for 15-30 min . Colour devel-
opment was measured at 620nm and standards of 0-2 mcl 
KH 2PO 4 were included routinely. 
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2.3.1.3 Phosphocitrate  
Based on the published data of Meyer et al. (1959) 
regarding the lability of PC and subsequently confirmed 
here, PC was analysed for citrate or P1  a 4h hydro-
lysis at 100 ° C either at a neutral PH or in the presence 
of 0.1N Li 2 SO 4 . 
2.3.2 HIGH-VOLTAGE PAPER ELECTROPHORESIS 
Khwaja et al. (1970) have reported a buffer for use 
in high-voltage electrophoresis in conjunction with their 
synthetic work using o-PCP. The buffer used was 0.05M tri- 
- 	 . 
,ethanolarrane bicarbonate (pH 7.5). High-voltage electrophoresis _ 
was run on 3MM Whatman paper for 11-2h before the paper 
was ' removed and air-dried prior to staining procedures. 
2.3.3 STAINING TECHNIQUES 
2.3.3.1 Citrate 
Citrate was visualised by either the method of Higgins 
and von Brand (1966) or using dimethylaminobenzaldehyde 
(DMAB). 
(a) The method described by Higgins and von Brand (1966) 
involves spraying the dried electrophoretogram with a solution 
of aniline/ribose (1.0m1 aniline in 97m1 of methanol was 
added 'to lg of ribose dissolved in 3m1 of water) and heating 
at 120 °C for 5 min. Krebs cycle acids gave brown spots on 
a light background. 
(b) A dimethylaminobenzaldehyde (DMAB) reagent (Zweig 
and Sherma, 1972) (1g DMAB in l'Oml acetic anhydride and 
90m1 acetone) was sprayed onto the dried electrophoretogram. 
Heating at 100 ° C for ca. 5 min revealed citrate as a red 
spot on a light yellow background. 
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2.3.3.2 Phosphate  
Phosphate and its esters were visualised by a number 
of different methods all involving the initial reaction between 
P 1 . and ammonium molybdate but differing in the manner 
of reducing the complex to give a coloured spot. 
(a) Quinine sulphate (0.05g) in 100m1 water was mixed 
with 0.5g ammonium molybdate in 400m1 water followed by 
the addition of 4m1 conc. HNO 3 	After spraying the dried 
electrophoretogram, P 1  . and phosphoric esters were observed •  
as dark spots on a light, fluorescent background under UV 
light (Dawson et al., 1969 ) . 
(b) Ammonium molybdate ( 5g ) dissolved in a mixture of 
90m1 acetone and 5m1 each of conc. HCI and HC10
4 was sprayed 
onto the dried paper before heating at 80 C for 3 min (Dawson 
et al., 1969 ) . Phosphate was seen as a yellow spot and sub-
sequent irradiation with UV light visualised phosphoric esters 
as blue spots. 
(c) The electrophoretogram was sprayed with a reagent 
comprising 5% ammonium molybdate in 90m1 of acetone, 5m1 
of conc. HC1 and 5m1 of conc. HC10 	before heating at 
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80 °C for 3 min. A further spray with 0.5% benzidene in dilute 
acetic acid (90:10 I-1 2 0/glacial acetic acid v/v) followed by 
drying and exposure to ammonia fumes revealed P i and its 
esters as blue spots (Zweig and Sherma, 1972) . 
2.3.3.3 Phosphocitrate  
It was not possible to visualise PC using either 
citrate or P . 1  sprays. However, as demonstrated here, PC 
is labile to the action of phosphatases. Thus it was possible 
to stain PC after electrophoresis and subsequent hydrolysis 
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with acid phosphatase using methods for citrate• or phosphate. 
Accordingly, dried electrophoretograms were treated as 
described by Fletcher and Malpress (1953 ) , giving an initial 
spray with a solution of 5% CaC1 2 6H 2 0 in 80% Et0H. After 
air drying, the paper was sprayed with a buffer comprising 
15mg acid phosphatase in 1.0m1 of 0.1M sodium acetate buffer 
(pH 4.8 ) . The paper was enclosed between two plates to retain 
moisture and incubated at 37 °C for lh. Phosphate was then 
visualised using one of the sprays detailed above. 
2.4 	RESULTS 
2.4.1 SYNTHESIS OF PHOSPHOCITRATE 
2.4.1.1 Synthesis using o-phenylene chlorophosphate  
The initial steps were based on the work of Khwaja 
et al. (1970 ) . A flask equipped with a pressure equalising 
dropping funnel and silica gel drying tube was charged 
with 1.37g triethyl citrate ( TEC) and 0.9m1 of anhydrous 
pyridine in • 2m1 of tetrahydrofuran ( THF ) . A sample of o-
PCP (0.98g) dissolved in 3m1 of THF was added dropwise 
over 15min to the cooled, mechanically stirred solution during 
which time a white precipitate of pyridinium hydrochloride 
formed. The • precipitate was separated by filtration and 0.25m1 
of water was added to the filtrate. After standing for 10 
min , excess pyridine and water was evaporated off by rotary 
vacuum evaporation. Electrophoretic analysis indicated that 
three phosphate-containing components were present in the 
reaction mixture ( Figure 2.3 ) , although two of these were 
only minor components on the basis of the intensity of stain-
ing. A comparison with electrophoretograms of P 1 and o-hydro- 
ED 
P/HP 
RM 
• [0] . RM 
Figure 2.5 
P/HP 
RM 
hyd. 
[0] RM 
High-voltage 	electrophoretogram 	of 	partly 
hydrolysed oxidised reaction mixture. 
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Figure 2.3 High-voltage electrophoretogram of the reaction- 
mixture after coupling o-PCP with TEC. 
HP 
RM 
Figure 2.4 High-voltage 	electrophoretogram 	of oxidised 
reaction mixture 
x origin 
intense spot 
I 	1 faint spot 
inorganic phosphate 
HP 	o-hydroxyphenyl phosphate 
RM reaction mixture 
[0] RM 	reaction mixture after 
oxidation 
hyd. 	oxidised reaction mixture 
[0] RM 	after brief alkaline. 
hydrolysis 
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xyphenyl phosphate ( formed by the synthetic reaction after 
omitting TEC) indicated that these were the two major compon-
ents of the reaction mixture. The presence of the slowest 
migrating material (Compound A) , which was the major comp-
onent, was taken as evidence for the successful production 
of the desired condensation product. 
The next step involved the removal of the protecting 
group. Oxidation was chosen since reductive cleavage requires 
platinum oxide which is an expensive reagent. Oxidation, 
however, by any of the three methods listed by Khwaja et 
al. (1970) led to the formation of darkly coloured solutions 
with gummy material often deposited. Despite these difficulties 
electrophoretic analysis ( Figure 2.4) indicated that only 
two phosphate-containing components were present: P i and 
presumably phospho-triethyl citrate (Compound B ) . The major 
compound migrated in front of the protected condensation 
product (Compound A) , perhaps reflecting an increase in 
charge and a decrease in molecular size. This interpretation 
was substantiated by analysis of the oxidised reaction mixture 
after subsequent exposure to alkaline conditions since P . 
and four phosphoric esters were detected ( Figure 2.5) ; the 
esters perhaps correspond to phosphocitrate and its mono-, 
di- and tri-ethyl esters. 
Meyer et al. (1959) had originally described a mild 
method for the removal of the ester groups of triethyl citrate 
involving the precipitation of calcium phosphocitrate. Conseq-
uently a two-fold excess of both 0.1M NaOH and CaC1 . 2 
6H 2 0 was added to phospho-triethyl citrate and the mixture 
left to stir overnight. The calcium salt that formed was dark 
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coloured and after decalcification with Dowex 	50W-X8 
(H + form) the solution that was obtained was still dark 
coloured. The dye appeared to impair electrophoretic analysis 
since definitive resolution was not achieved. If this solution 
was loaded onto an AG 1-X8 column in either the nitrate,. 
bicarbonate or formic form a dark band formed. As shown 
in Figure 2.6, chromatography on an AG 1-X8 nitrate column 
using batch elution with NaNO
3 
 solutions allowed resolution 
of P and citrate. However, attempts made to separate'compon-
ents of a decalcified solution were unsuccessful as shown 
in Figure 2.7; separation of components was not obtained. 
In an effort to determine the cause of this difficulty, 
{ 32 pl .... p i was added to the coloured, decalcified solution. 
After column chromatography, <60% of the radioactivity was 
recovered. Thus the dye appeared to interfere not only with 
resolution but also with the recovery of compounds. Khwaja 
et al. (1970) decolourised their solutions with activated char-
coal. However, use of this approach led to adsorption of 
the product ( Figure 2.8). 
Quinone material in plant extracts has been success-
fully removed using Florisil, Fuller's Earth or Celite 
(Ter.minck and Avrameas, 1976; Fafunso and Byers, 1977; 
Sadler and Shaw, 1978; Newbury and Possingham, 1977; 
Hagerman and Butler, 1978). However, it has been reported 
that whilst Florisil efficiently removes UV impurities leaving 
citrate unbound, phosphorylated sugars and nucleotides are 
not quantitatively recovered. In any, event, none of these 
adsorbents sufficiently removed the dye from the decalcified 
solution (Table 2.1) . 
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Figure .2.6 Resolution of P 1 	citrate using an AG 1- 
X8 (NO -) ion-exchange system 3 	• 
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Figure 2.7 Attempt to separate components of the decalcified 
solution using an AG 1-X8 ( NO 3 ) ion-exchange 
system. 
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Figure 2.8 Loss of phosphoric ester product after treatment 
with activated charcoal. 
BEFORE 	 AFTER 
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Table 2.1 Decolouration of a quinone solution by various 
adsorbents. 
ADSORBENT* 	 % DECOLOURATION 
Norit A 
(activated carbon) 
	 931=6 
• Fuller' s Earth 
Florisil 
(60-100 mesh) • 
Celite 545 
• *500g adsorbent added to 5m1 of a 0.1% solution of the 
quinone. The solution was previously adjusted to a pH of 
10, then neutralised. 
+ Values given are means - 1S.D. 
+ Solution darkened by treatment 
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These difficulties, combined with the fact that the 
alternative method to remove the ,protecting group involved 
the use of platinum oxide, led to the more intense investiga-
tion of the use of 2-cyanoethyl phosphate (CEP) in the prep-
aration of phosphocitrate. This 'reagent appeared to be 
particularly useful due to its easy preparation from 
[ 32 p which might enable ready [ 32 P] -labelling of phospho-
citrate. 
2.4.1.2 Synthesis using 2-cyanoethyl phosphate  
2.4.1.2.1 	Preparation of crude phosphocitrate 
The barium salt of 2-cyanoethyl phosphate was 
prepared from phosphorus oxychloride and 3-hydroxy propio-
nitrile ( hyd r acry lo nitrile ) as outlined by• Tener (1961 ) . 
Twenty-six grams of the compound was treated with AG 50W-
X8 ( H ; 200m1 resin bed volume ) to remove the barium and 
the eluant concentrated by rotary evaporation. 
The resulting oil was dissolved in 500m1 of anhydrous 
pyridine before the addition of a two-fold excess of triethyl 
citrate ( TEC) ( 44.0g ) . The mixture was evaporated at 30 °C 
in vacuo to an oil, pyridine ( 800m1) was then added and • 
the solution again evaporated. The process was repeated 
twice more before the final addition of 400m1 of pyridine 
and 98g of dicyclohexylcarbodi-imide ( DCC) . The reaction 
flask was stoppered and allowed to stand at room temperature 
for 6 days with occasional stirring. At the end of this period, 
pyridine was evaporated off, 500m1 of water added to decom-
pose unreacted DCC, and the mixture stirred for lh. The 
water was evaporated off, a further 500m1 of water added 
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and the mixture stirred, and filtered. The residue was then 
stirred • with a further 100m1 of water to ensure complete 
recovery of the coupled product from the solid. The combined 
filtrate and washings were evaporated to give a golden brown 
oil. 
The use . of a two-fold excess of TEC results, after 
hydrolysis, in a high proportion of citrate in the mixture 
which will bind to ion-exchange resins necessitating use 
of adequate amounts of resin to bind the anions. Clearly 
if citrate could be removed, a smaller quantity of resin 
could be used, increasing the efficiency of the ion-exchange 
purification. 
TEC is uncharged so it does not bind to AG 1-X8 resin 
indicating that if the unhydrolysed mixture was poured down 
a column of AG 1-X8, TEC might pass unhindered through 
the column whereas anionic species such as CEP • and the 
coupled product (TEC-CEP) might bind and be recoverable 
by elution with the appropriate buffer. The advantage of 
purific.ation at this stage of the synthesis is that since non-
binding TEC is present rather than citrate, sufficient resin 
bind only CEP and CEP-TEC need be used to afford 
resolution of the reaction components. 
In a preliminary experiment, 200mg of the oil was 
dissolved in about 2m1 of 50% Et0H adjusted to a pH of 7, 
and the solution was applied to a 1.5 x 5cm (AG 1-X8 
(HCO -) column. The column was washed successively with 3 
50m1 each of 50% Et0H, water and 1.0M NaHCO 3 . The eluant 
was collected in 5m1 fractions which were subsequently hydro- 
lysed either in mild alkaline conditions to convert TEC to 
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citrate, or at 100 °C for 4h in 0.1N H2504 for phosphate anal-
ysis. The results of such a column purification are given 
in Figure 2.9 , indicating that unreacted TEC does indeed 
continue to wash through the column in 50% Et0H. No phos-
phate containing compounds were detected at this point, but 
were detected after elution with 0.1M NaHCO
3 
suggesting 
that a separation of TEC from the desired coupled product 
was possible. 
Consequently the pilot method was scaled up ; the 
total amount of oil obtained after coupling (ca. 60g) was 
dissolved in a minimum of 50% Et0H (ca. 75m1) , adjusted 
to a pH of 7.0 and applied to a 3.0 x 40cm column of AG 
• 1-X8 ( FICO - ) 	Unreacted TEC was removed with 70m1 of 50% 3 
Etat ( pH 7) at a flow rate of 1-2m1/min. In preliminary 
experiments, 0.27M NaHCO 3 was found to elute citrate and 
CEP, therefore a more concentrated buffer ( 0.45M) was used 
to ensure efficient elution of all material bound to the AG 
1-X8 column. Buffer ( 2-2.5 L of 0.45M NaHCO
3 
) was passed 
through the column and the eluant subsequently decarbonated 
with AG 50W-X8 (H + form) . After filtration, the filtrate was 
evaporated to dryness either by lyophilisation or by rotary 
evaporation at 300 C in vacuo. This procedure resulted in 
19.2g of a golden oil (30-35% yield) . 
Tener (1961 ) has reported that, unlike free CEP, bound 
CEP is quite labile and that the cyanoethyl group can be 
readily hydrolysed in mild alkali at 50 °C in 2 min giving 
the required phosphoric ester. Consequently, the coupled 
product isolated by ion-exchance chromatography was treated 
in a similar way with the exception that calcium was 
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300 
H 0 	0.1M NaHCO 50% Et0H 
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Figure 2.9 Separation of TEC from the coupled intermediate 
using an AG 1-X8 (HCO -3 ) column. 
Eluant volume (ml) 
free P. 
hydrolysable P i 
*Expressed as 	p mol of citrate released after alkaline 
hydrolysis. 
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included in the hydrolysis mixture in order to precipitate 
phosphocitrate as • it formed. This latter approach was based 
on the work of Meyer et al. (1959 ) . Accordingly, 5.4g of 
the coupled product was stirred with 1000m1 of 0.1N NaOH 
and 7.0g of Cacl 2 at 50o C for 5-10 min before pouring into 
a chilled beaker. The beaker and its contents were cooled 
to 4 ° C and left overnight. After adjusting to a pH of 8.5 
the mixture was lyophilised, 100-150m1 of water added, and 
the mixture left at 4 ° C for 1-2h. The solid was collected 
by centrifugation ( 800-1000g ) , washed with absolute Et0H , 
acetone and ether respectively, giving 4.5g of a white solid. 
2.4.1.2.2 Ion-exchange chromatographic purification of 
phosphocitrate 
In order to improve the ion-exchange separation 
of citrate and phosphocitrate over the previously described 
system, which used a gradient of HC1 (Meyer et al., 1959), 
and to permit separation at pH 7, the use of an AG 1-X8 . 
( NO -) system was investigated. Nitrate - a strongly binding 3 	• 
anion - was foreseen as eluting citrate and PC more readily, 
and thereby enabling better resolution of these anions. 
In order to apply this system to the purification of 
phosphocitrate , 500mg of the impure salt was dissolved in 
10m1 water with the aid of 5m1 of AG 50W-X8 ( H + form ) . The 
mixture was applied to a 1.5 x 5cm column of AG 50W-X8 
and the eluant collected and adjusted to a pH of 5-7 before 
loading into a 1.5 x 10cm column of AG 1-X8 ( NO - ) at a 3 
flow rate of 1-2m1 min' . . As shown in Figure 2.10, the batch- 
wise elution of phosphate, citrate and CEP and subsequent 
application of a linear gradient of NaNO 3 (0.1M to 0.2M) 
0 
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Figure 2.10 Purification of PC from citrate, CEP and 
P. 	using AG 1-X8 (NO -3 ) chromatography. 
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eluted a product which, when hydrolysed, contained P i and 
citrate in a 1 :1 molar 
Although the separation 
complete, it was found 
ratio - presumably phosphocitrate. 
of citrate and P. 	from 	PC was 
1 - 
that the isolation of PC from the 
buffer was difficult due to the need to form an insoluble 
salt. Since Ca (NO 3 ) 2 is soluble in Et0H the calcium salt 
of PC was precipitated after adding 2 volumes of Et0H to 
the relevant tubes These conditions, however, also led to 
the precipitation of NaNO 3 . Instead of persisting with this 
method which would ultimately have yielded a calcium salt 
contaminated with NIaNO•
3' 
 an alternative method was sought 
because the sodium salt is more useful for routine work. 
Another anion with almost the same binding affinity 
as nitrate is bicarbonate which has the further characteristic 
of decomposing in acid to give carbon dioxide. Consequently 
if sodium bicarbonate buffers are used then the addition 
of the resin AG 50W-X8 ( H ) would not only bind sodium 
ions but, by the subsequent release of protons into solution, 
decompose bicarbonate. The pH during this process falls 
to 4-5 so if this procedure was performed at 4 ° C PC hydro-
lysis should be minimal. 
An important requirement for any chromatographic 
system is that it operates at neutral pH. In this respect 
0.5M Na HCO 
3 stock solution gassed • with CO 2 for 10-15 min 
became acidified to a pH of 7-7.2. This process did not 
significantly affect the bicarbonate .content of the stock 
solution as indicated by conductimetric measurements on 
solutions of various HCO - concentrations, before and after 
3 
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bubbling with CO 2 ( Figure 2.11 ) . In order to determine the 
concentration of bicarbonate needed for batch-wise resolution, 
preliminary itrate 
and CEP from an AG 1-X8 ( HCO 
3 
) column and established 
that 0.27M NaHCO
3 was the minimum concentration required 
to batch-elute these anions. Treatment of 300mg of the impure 
salt with Dowex 50W -X8 ( H + form ) gave a Ca ++ -free solution 
which. was adjusted to a pH of 7 and loaded onto a 1.5 x 
10cm column of AG 1-X8 ( HCO ) resin at a flow rate of 1- 3 
2m1/min . Batch-wise elution with 0.27M NaHCO - 	removed 
3 
P. , citrate and CEP, and PC was eluted using 0.45M 
NaHCO 3 . 
Scaling up this procedure involved passing 4.5g of 
the dissolved impure salt through a column of AG 50W-X8 
( 40m1 resin bed volume) and adjusting the eluant to a pH 
of 7 before loading onto a 3 x 15cm column of AG 1-X8 
(HCO ) . Phosphate, citrate and CEP were eluted with 2-2.5L 3 
of 0.27M NaHCO
3' and PC was then recovered by elution with 
0.45M NaHCO 3 , collected in 300 fractions of 10m1 volume 
( Figure 2.12 ) . The presence of PC was detected by analysis 
of P . and citrate before and after hydrolysis. Contents of 
tubes containing PC were pooled, treated with AG 50W-X8 
(14 + ) in the cold, the pH of the filtrate adjusted to 7 with 
diluted NaOH , and the solution lyophilised to give a white 
powder. •The powder was dissolved in a small amount of water 
(20-50m1) and decarbonated again to ensure complete removal 
of • excess salt. Lyophilisation gave sodium phosphocitrate 
which was stored in a desiccator at -20 ° C. Analysis revealed 
the sample contained <1% inorganic phosphate and after 3 
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Figure 2.11 Conductivity of NaHCO 3 solutions before and 
after gassing with CO 2 . 
no treatment (pH ca 8) 
0----e after treatment (pH - ca. 7) 
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Figure 2.12 Purification of PC on an AG 1-X8 (HCO -3 ) resin 
column using sodium bicarbonate buffers. 
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months there was no evidence of decomposition. Determination 
of the total phosphate content of the solid enabled calculation 
of the molecular weight of the salt. This was found to be 
445gmo1 corresponding to a molecular formula of Na 5 
. P C . 
ca. 4H, ) 0. 
L 
2.4.2 SYNTHESIS OF [ 3 4]-LABELLED PHOSPHOCITRATE 
Barium [ 32 13 ]-cyanoethyl phosphate is available from 
the Radiochemical Centre, Buckinghamshire, Amersham, England; 
but in this instance labelled reagent was prepared from 
120mg of [ 32 15 ]-phosphoric acid as described _ by Tener (1961 ) . 
Barium was removed by treatment with AG 50W-X8 ( pyridinium 
form; 7m1 resin bed volume ) and the eluant, after the 
addition of 5m1 of pyridine, was evaporated to dryness 
in vacuo at 30 °C. A large excess of TEC was added ( 200mg ) 
together with 10m1 of pyridine. The solution was evaporated 
to an oil, a further 10m1 of pyridine added, and the solution 
again evaporated. This procedure was repeated twice before 
the addition of 5.0m1 of pyridine and 800mg of DCC. The 
flask was set aside for 3 days before evaporation and the 
addition of 5m1 of water to decompose surplus di-imide. The 
mixture was stirred for lh , evaporated, and another 5m1 
of H 2 0 added. Following filtration the residue was washed 
and the combined filtrate and washings evaporated to give 
a golden oil. 
The oil obtained was treated with 140m1 of 0 . 1M NaOH 
and 600mg of CaC1 2 at 50 °C for 7 min before the suspension 
was rapidly cooled and allowed to stand at 4 ° C overnight. 
Fifteen mg of unlabelled PC was added, the mixture adjusted 
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to a pH of 8.5, lyophilised, the residue taken up in 10m1 
of water, centrifuged, and the precipitate washed as before. 
After treatment with AG 50W-X8 (8m1 resin bed volume), the 
material was loaded onto a 1.5 x 10cm column of AG 1-X8 
(HCO 
3
). This column was treated in parallel with another 
column loaded only with unlabelled PC and both columns 
were then washed, each with. 400m1 0.27M NaHCO
3' 
A volume 
(1L) of both 0.27M and 0.5M NaHCO 3 buffer were used to 
provide a linear gradient to both columns simultaneously 
and 300 fractions of 4m1 volume were collected. Either the 
radioactivity of the tube contents was determined, or P. 
was analysed after hydrolysis: Relevant tube contents were 
pooled and decarbonated as before to give sodium phospho-
citrate of specific activity 200 i.iC i /m mol. 
2:4.3 CHARACTERISATION OF PC 
2.4.3.1 Spectroscopic  
NMR spectra were recorded at the National NMR Centre, 
Canberra, Australia ( 'H NMR at 270M Hz, 13 C NMR at 67.889M 
H z) or at Oxford University, U.K. ( 31 P NMR at 7kM Hz). 
2.4.3.1.1 
	1 H NMR spectroscopy 
1 H NMR spectra of both citrate and phospho-
citrate were recorded for comparative purposes, at a pH 
of 7.3 and ambient temperature. The spectra are shown in 
Figure 2.13 and both display a characteristic AB type spectra 
(Dyer, 1965). The lack of any other peaks in the spectrum 
of PC attests to the purity of PC. .However, if the area up-
field of the PC peaks (representing the area where citrate 
protons resonate) is amplified, peaks due to citrate can 
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Figure 2.13 	1 H NMR spectra of: (a) citrate, and (b) 
phosphocitrate. 
2 
HB 
FIA—C—CO; 
RO—C—CO; 
I-1 4—G —CO; 
HB 
HOD 
3 
a: 
b: R 
58 
be recognised ( Figure 2.13 ) ; this indicates that the level 
of citrate present in the sample is <1%. 
	
2.4.3.1.2 	13 C NMR spectroscopy 
The 13 C NMR spectra of citrate and PC were 
determined with sample conditions 25 ° C and pH 7.1. Coupling 
of the 31 P nucleus to the 13 C nucleus can be seen to give 
rise to characteristic splitting patterns in the spectra of 
phosphocitrate ( Figure 2.14 ) . The lack of any other peaks 
apart from the 13C-PC resonances again attests to the purity 
of synthetic PC. 
2.4.3.1.3 
	31 P NMR spectroscopy 
31 P NMR spectroscopy at 7kM Hz indicated that, 
relative to 88% H 3 PO 4 ' 
PC resonates at 2.1 , 1.1 and 0.2 
ppm at p1-I's of 5, 7 and 8.5 respectively. Notably the peaks 
were singlets. If the reference was changed to methylene 
diphosphonate then the absence of P. is demonstrable; this 
is shown in Figure 2.15. 
The pH-dependence of the PC 31P-resonance is shown 
in Figure 2.16 , over the pH range 2.5 to 11, and is compared 
with a variety of other organic phosphates ( Ogawa et al., 
1978 ) . Due to the number of dissociating groups in PC and 
the lack of detail in the pH-dependence curve, the pK ' s 
could not be - determined. 
2.4.3.2 Lability 
2.4.3.2.1 	Chemical lability 
The lability of a 1mg/m1 solution of PC was 
determined over a wide range of conditions, as illiistrated 
a 
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wilyAvit.v NeAvi 
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Figure 2.14 	13 C NM R spectra of: ( a ) phosphocitrate, and 
( b ) citrate. 
0-2C Ca H / Ca l-f cco; I b 
OR 
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Figure 2.15 
 31
P NMR spectrum of phosphocitrate*. 
MDP = methylene diphosphonate 
PC = phosphocitrate 
*Determined at pH 7, ambient temperature. 
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Figure 2.16 pH-dependent chemical shift behaviour of PC 
compared with other phosphoric esters* 
-5 	0 
	+5 	+10 	+15 
Chemical shift relative to H3PO4 (ppm) 
F6P 	fructose 6-phosphate 
PC phosphocitrate 
CF 	 creatine phosphate 
y-ATP 	y-P in ATP 
a-ATP 	a-P in ATP 
* 
PC data has been superimposed on data obtained for other 
phosphoric esters as determined by Ogawa eL al. (1978). 
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in Figure 2.17. Notably PC appeared to be more labile to 
heat than any particular pH; PC decomposed within 4h at 
100 C whether conditions were acid or alkaline. In contrast, 
at 0 °C solutions were stable indefinitely. At room temperature, 
PC solutions showed intermediate stability, decomposition 
occurring slowly over a period of days. 
2.4.3.2.2 	Enzymatic lability 
To determine whether PC was degraded by phos-
phatase activity, the release of citrate was monitored during 
an incubation with either acid or alkaline phosphatase . Using 
0.71 U of acid phosphatase, 0.093 umol PC was incubated at 
37 ° C and a pH of 4.8: using 4.4 U of alkaline phosphatase, 
0.35 urnol PC was incubated at 37 °C and a PH of 10. 4 . The 
results are given in Figure 2.18 and indicate PC is completely 
hydrolysed within 15 min with either phosphatase. From the 
rates of hydrolysis under these standard conditions, it was 
estimated that the enzymatic lysis of PC was 3% or 2% that 
of p-nitrophenyl phosphate with acid or alkaline phosphatase 
respectively. 
2.5 	DISCUSSION  
The data presented here indicate that PC can be pre-
pared from CEP and TEC. This method offers several advant-
ages over that using dibenzyl chlorophosphate since the yield 
is higher, specialised equipment is not necessary and, most 
importantly, the CEP method can be readily applied to the 
synthesis of [ 32  13 1-PC. Using o-phenylene chlorophosphate, 
the initial yield was found to be superior to that using 
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Figure 2.17 Stability of PC under various conditions. 
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Figure 2.18 The degradation of PC by either acid or 
alkaline phosphatase activity. 
alkaline phosphataSe 
acid phosphatase 
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CEP, reflecting its phosphorylating power. However, oxidation 
apparently liberates o-benzoquinone (Khwaja et al., 1970) , 
a reactive species which not only forms polymeric material 
but disrupts the binding and resolution of ion-exchange 
columns. The alternative is to catalytically hydrogenate the 
group using platinum oxide, an expensive procedure. Even 
if this is done, it is synthetically difficult to introduce 
a label into PC since either [ 32  13 1-PC1 5 
must be used to 
synthesize the phosphorylating reagent, or [ 14 C]-citrate 
to prepare the triethyl ester for PC synthesis. Consequently, 
despite its lower yield, the ease and relative cost of prepar-
ing [ 32 13 ]-CEP from [ 32 13 ]-P i makes it the reagent of choice 
for the synthesis of [32 13 1-PC. 
Proof that the compound prepared by the CEP method 
is indeed PC, in which the phosphate group is esterified 
to the tertiary hydroxyl group rather than one of the 
carboxylic acid moieties citryl phosphate rests on the 
following observations: 
1. The use of triethyl citrate ( >99% purity) ensures 
that it is only the tertiary hydroxyl that is phosphorylated 
rather than any of the "blocked" carboxyl groups. 
2. Acyl phosphates are significantly more unstable 
than phosphoric esters. In fact, citryl 1-phosphate has been 
prepared (Gulyi et al., 1963,  1965; Walsh and Spector, 1968,   
1969; Walsh, 1970) and has been found to be highly labile: 
it can only be stored for 2 days in a desiccator in vacuo 
and at 20° C will completely decompose in lh in an aqueous 
solution at pH 8.5-9. In contrast, the data presented here 
indicate that PC can be stored, desiccated, for at least 6 
months at -20 C with no discernible change. Further, no 
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significant changes occur when PC is kept in alkaline solution 
at room temperature for many hours. 
3. 	Spectroscopic evidence unambiguously character- 
ised PC. As shown in Figure 2.19 , the methylene protons 
of both citrate and PC are never equivalent in any conform-
ation so that the unequal protons interact causing splitting 
and giving rise to the typical AB pattern. Particularly 
1 characteristic in the H NMR spectrum of PC is the downfield 
shift of the AB pattern relative •to citrate due to the presence 
of the electron withdrawing phosphate group which deshields 
the H A and H B protons. Only citryl 3-phosphate in which 
phosphate is esterified to the central carboxyl group could 
give rise to the AB pattern since 1 or 6 substitution (citryl 
1-phosphate) would result in an ABXY system ( Figure 2.20 ) . 
The 1H NMR spectra of citrate and PC allow various 
characterising parameters to be calculated (Dyer, 1965 ) , 
including the chemical shifts ( ) for the hypothetical non-
interacating HA  and H B , the differences in chemical shifts 
between H A and H B ( AB ) , and the HA-HB 
coupling constants 
These data are given in Table 2.2 
Spectroscopic proof that citryl 3-phosphate had not 
been prepared is given by analysis of the 13 C NMR spectra, 
although other considerations, for example lability, also 
rule out the possibility. The peaks in the 13C NMR spectrum 
of citrate are assigned according to the published data of 
Johnson and Jankowski (1972 ) . The signal from the methylene 
carbons (C a 
) is enhanced due to the nuclear Overhauser 
effect. Significantly, all the Peaks are singlets. In the 
13 C NMR spectrum of PC, 31 P-  31 C coupling is expected since 
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Figure 2.19 Non-equivalence of the methylene protons in 
citric acid and phosphocitric acid 
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Figure 2.20 Expected ABXY system for the 1 H NMR spectrum 
of citryl 1—phosphate 
HA 
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Table 2.2 1 H NMR chemical shift ( a ) data, coupling constants J 	) and differences in chemical shift 
   
between protons A and B ( aAB ) for citrate and PC*. 
CITRATE 	 PHOSPHOCITRATE 
Peak 	a (ppm) 	Peaks + a -AB(Hz) 	GAB(Hz) 	Peak 	a (ppm) 	Peaks+ a 	I) -AB Hz 	a AB (Hz) 
1 
2 
3 
4 
2.00 
1.94 
1.86 
1.80 
1.96 
1.96 
1.83 
1.83 
16 34 1 
2 
3 
4 
2.45 
2.39 
2.17 
2.12 
2.42 
2.42 
2.15 
2.15 
15.5 72 
*Determined at pH 7.3, ambient temperature. 
Value calculated for uninteracting H A and liB. 
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phosphorus-31 has a nuclear spin. Indeed, as shown in 
Figure 2.14, the central carboxyl carbon (C d) and the central 
113 
carbon (C b) 
are split into doublets from which 31P-Li C coupling 
constants ( J 	) CP 	
are calculable. These are given in Table 
2.3, together with peak positions for citrate and PC. 
Another characteristic feature of the 13C NMR spectrum 
of PC is the nature of the chemical shifts relative to citrate. 
In fact it is these that indicate where citrate is phosphoryl-
ated. Attachment of a phosphate group is known to cause 
a 5 -carbon downfield shift and a y -carbon upfield shift 
(Mantsch and Smith, 1972) , the latter being dependent on 
the stereoche- mistry of the molecule. Thus the y -methylene 
carbons (C a ) are not significantly affected, whereas there 
is a shift ( y, = -3.2Hz) with the other y -carbon (C d) . The 
5-carbon (C b ) is shifted downfield as expected (B p = 6.1Hz ) 
The B -downfield and y -upfield shifts -are consistent only 
with the phosphate being esterified to the tertiary hydroxyl 
group. If phosphate were esterified to the peripheral carboxyl 
group - citryl 1-phosphate - a different pattern of shifted 
peaks would result. Further, with citryl 3-phosphate which 
is phosphorylated at the central carboxyl group, the shifts 
would be the reverse of those observed. 
Although the 31P NMR spectrum does not add to the 
structure proof given above, comparison with a range of 
other organic phosphates ( Figure 2.16) indicates that the 
3/ PC resonance is characteristic. The change in the 	P- 
resonance with pH ( Figure 2.16) does not enable the pKs ' s 
for phosphocitrate to be determined, presumably because 
the dissociations occur over a relatively small pH range. 
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Table 2.3 
	13C NMR chemical shift ( a ) data for citrate and 
PC and 31P- 13C coupling constants (J cp ) for 
PC* 
CARBON 	CITRATE 	 PHOSPHOCITRATE 
ATOM 	a (ppm) 	a (PPM) 	J cp (Hz) 
C a 	 -20.70 
	 -20.98 
	3
J CP < -1-2 ' 5 
8.61 	 14.74 
	2 
JCP 7 ' 4 
	
112.71 	 111.68 
	4 Jcp <±3.0 
115.35 
	
112.12 
	3
JCP 7 ' 4 
*Determined at pH 7.1, 25 °C. 
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In order that pure material was available for spectro-
scopic analysis and for reference purposes, ion-exchange 
procedures had to be developed due to certain faults assoc-
iated with the previously reported systems. Thus the ion-
exchange method reported here using sodium bicarbonate 
buffers offers several advantages: 
1. Separation is complete giving pure PC uncontam- 
inated with citrate or P. enabling its direct use, without 
further purification, in calcifying systems. 
2. The neutral operating conditions circumvent 
the possibility of artefact formation thus allowing the potent-
ial use of this system in biological investigations where 
quantification is a paramount consideration. 
3. The use of sodium bicarbonate allows the isolat- 
ion of sodium PC quite readily since decarbonation is effected 
simply by the addition of an acidic ion-exchanger. 
Resins exchanged with other anions, for example nitrate, 
necessitate the ultimate isolation of PC as an insoluble salt. 
However, the nitrate based system does afford slightly better 
resolution and therefore could be of use to separate [ 32 13 ]- 
compounds when recovery of compounds from eluants is not 
required. For most purposes it would appear that the use 
of the sodium bicarbonate system to produce a. soluble form 
of PC is most advantageous because of the good resolution 
obtained and ease of decarbonation to facilitate the isolation 
of sodium PC. 
The availability of PC led to a study of its chemical 
lability. This study essentially agrees with earlier work 
by Meyer et al. (1959) but extends knowledge of the 
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lability of PC under certain conditions. Previous work has 
led to the grouping of phosphoric esters into three classes, 
depending on their lability, and include: (i) "free phosphate", 
compounds such as acetyl phosphate that hydrolyse very 
rapidly under acidic conditions, ( ii) acid labile phosphate, 
compounds that hydrolyse after 15 min boiling in 1N 
H 2 50 4 such as nucleotide polyphosphates, and ( iii) "residual" 
phosphate withstanding such treatment, including glucose 
6-phosphate and adenosine 5-phosphate (Lindberg and Ernster, 
1956). In this context PC is partially acid labile since it 
is <10% hydrolysed after 15 min at 100 ° C in 1N H 7 SO / . In 
contrast, solutions kept at 0 0  C whether acidic or alkaline 
appear to be indefinitely stable. 
The enzymatic lability of PC has also been studied 
and in this regard PC has been found to be cleaved by both 
acid and alkaline phosphatases. This important observation 
suggests that a coupled enzymatic assay for PC may be poss-
ible involving initial cleavage of PC into citrate and P : 
by the action of phosphatases. Once cleaved citrate may 
be determined by published enzymatic assay techniques. 
A further prediction to arise from the observation 
on the enzymatic lability of PC, is that in vivo PC may 
have a degree of lability. 
2.6 	SUMMARY  
1. A synthesis and purification of PC has been 
described. 
2. Of the phosphorylating reagents investigated, 
CEP appeared to be the most useful. o-Phenylene chlorophos-
phate was not suitable since oxidation gave rise to products 
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which hindered chromatographic techniques. 
3. AG 1-X8 ( HCO -) columns were superior for the 3 
isolation of PC because of resolving power and t, ease ,of decarb-
onation of buffers. 
4. 1H, ' 3C and 31 P NMR provided structural proof 
of PC and further indicated that the synthetic method gives 
high purity PC. 
5. PC hydrolysed in 3h at 1000 C but was stable 
indefinitely at 0 0C over a wide range in pH. 
6. PC was labile to acid and alkaline phosphatases.• 
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CHAPTER 3 
FURTHER DEVELOPMENT OF SEPARATION AND 
ANALYTICAL SYSTEMS FOR PHOSPHOCITRATE 
3.1 	INTRODUCTION  
In the preceding chapter, a chemical_ synthesis of 
phosphocitrate (PC) was described and the product character-
ised by physical and other methods. With the availability 
of PC as a reference material it was now possible to explore 
the development of systems for the potential purification 
and analysis of PC from natural sources. 
Although 	sensitive 	tests 	exist 	for 	detecting 	and 
determining P i (Brunette et al., 1978; Anner and .Moosmayer, 
1975; Penney, 1976; Lindberg and Ernster, 1956; Lanzetta 
et al.,1979) and indeed have proven satisfactory for analysing 
hydrolysed PC, selective PC analysis would be facilitated 
by the additional analysis of citrate. In fact, citrate is 
known to undergo a unique degradation, .under well-defined 
conditions, to give pentabromoacetone (PRA). This reaction 
is the basis of selective assays resulting in varying degrees 
of sensitivity (Taylor, 1953; Ettinger et al., 1952); PRA 
gives a colour reaction with sodium sulphide (Taylor, 1923) 
or thiourea (Ettinger et al., 1952). A special modification 
developed by Jones (1967) has employed the Fujiwara reaction 
of halogenated hydrocarbons (Leibman and Hindman, 1964) 
to give a very sensitive chemical assay for citrate in the 
range 0-10 v g. The major disadvantage of this method is the 
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requirement to use benzidine as a chromophore since it is 
a known carcinogen, and therefore undesirable for routine 
analysis. Consequently, attempts were made to find a suitable 
substitute for benzidine. 
The strongly acidic conditions necessary for the 
chemical determination of citrate together with the temperature 
of reaction (ca. 50 o C) indicated that PC would be hydrolysed 
during the assay. The chemical method then, is limited to 
the determination of total citrate since hydrolysis of PC leads 
to a background colour reaction. In contrast, Passonneau 
and Brown (1974) have developed a coupled enzyme assay 
system operating under mild conditions. With this technique 
citrate is cleaved to acetyl CoA and oxaloacetate (OAA) using 
citrate lyase (EC 4.1.3.6); then the OAA is reduced to malate 
by malate dehydrogenase (EC 1.1.1.37). The latter reaction 
invol ■/es the oxidation of NADH to NAD+ which can be monitored 
by fluorimetric (Passonneau and Brown, 1974; Lowry et al., 
1961) or UV (O'Neill and Sakamoto, 1969; Costello and O'Neill, 
1969) techniques. In the preceding chapter PC was shown 
to be cleaved by phosphatase activity; thus, providing PC 
is not degraded in any way by citrate lyase, then the 
possibility arises that alkaline phosphatase added to the 
standard coupled enzyme assay for citrate would afford a 
technique for analysing free citrate and PC. These aspects 
are reported in this chapter. 
In biological samples it might be desirable to effect 
a preliminary separation of citrate from PC to enable PC 
determination. The ion-exchange system described in the 
preceding chapter was, in part, developed for this purpose 
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and also to enable the simple isolation of material from 
eluting buffers. Furthermore, since Howard (1976) has claimed 
that acidic conditions during column chromatography lead 
to artefact formation, the chromatographic method was 
developed to operate at a pH of 7. However, Howard did 
not directly isolate or quantitate PC to reach his conclusions. 
Consequently, this chapter describes a more rigorous invest-
igation of the suggestion that acidification and neutralisation 
of a solution of citrate and phosphate can cause PC 
production. Clearly, in biological studies, where quantitation 
of PC is vital, it is important to know what level of 
artefactual PC production is present - if it occurs at all 
- and to elucidate the conditions responsible for such a 
reaction so that they may be avoided if at all possible. 
Although chromatographic resolution of biological 
material on •ion-exchange resins, together with chemical and 
enzymatic analysis of products is of value in identifying 
PC in nature, it is advantageous to have other techniques 
to confirm results obtained. In order, then, to facilitate 
comparison with synthetic PC, other methods were investigated 
including thin-layer chromatography (TLC), high-voltage 
electrophoresis, isotachophoresis, high-pressure liquid 
chromatography , (HPLC) and gas-liquid partition chromato-
graphy (GLC). 
Because of the wide range of techniques investigated 
and the extent of the data accumulated, some pertinent to 
the subsequent development of an analytical or separation 
technique, this chapter is organised so that individual 
techniques 	and 	their 	associated 	results 	are 	described 
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separately. Highlights and conclusions gained from these 
techniques are then incorporated into a general discussion. 
3.2 	METHODS AND RESULTS 
3.2.1 ANALYTICAL TECHNIQUES 
3.2.1.1 Citrate and PC  
3.2.1.1.1 	Chemical 
Citrate was determined by conversion to the 
pentabromoacetone (PBA) derivative and followed by the 
Fujiwara reaction, as reported by Jones (1967). PBA was 
prepared as described earlier (Section 2.3.1.1) and 4m1 
aliquots of the organic phase were pipetted into tubes contain-
ing 2.5m1 of a mixture of pyridine, water and tetramethyl 
ammonium hydroxide (60:20:0.8, v/v). The tubes were held 
in a water bath (ca. 50 °C) while a stream of N 2  gas was - 
_ directed into the tubes to evaporate the organic phase. The 
tubes were stoppered and then immersed in a boiling water 
bath for 3 min before cooling for 10 min in an ice bath. 
The colour reaction was initiated by the addition of 0.5m1 
of a  solution of 1.5% recrystallised benzidine in 28% formic 
acid. The tubes were left standing for 1-3h at room 
temperature in the dark before measuring the absorbance 
at 530nm. Citrate standards (0-10 pg) were included routinely. 
The method was not specific for free citrate, as PC 
itself was found to give a colour reaction (ca. 30%) in the 
PBA-citrate assay. Thus this method can measure reliably 
only total citrate. At 100°C in 0.1N H 2 SO4 PC is hydrolysed 
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completely after 4h. Accurately weighed samples of PC 
subjected to these hydrolysis conditions were found to contain 
the theoretical amount of citrate after chemical citrate 
analysis. 
In order to find a replacement for benzidine, a range 
of aromatic amines was tested as chromophores in the citrate 
assay. After colour development UV spectra for each reagent 
were read against the appropriate blanks and the absorbance 
values determined over a range of wavelengths. The results 
are given in Figure 3.1. None of the reagents gave the 
intense colour observable with benzidine although aniline 
and 4,4 ' -methylenedianiline (MDA) gave strongly absorbing 
brown coloured solutions. Notably the commercial analogue 
of benzidine - 3,3' , 5,5 ' -tetramethylbenzidine - did not give 
a strong colour reaction. MDA was selected as a benzidi ne 
substitute since aniline requires distillation before use, 
whereas 	MDA 	can 	be 	used 	without 	recrystallisation. 
A comparison of benzidine and MDA as chromophores 
is given in Figure 3.2. Benzidine causes the development 
of an intense colour reaction but above 10 lig citrate the 
colour is so intense that Beer's Law does not appear to be 
obeyed. MDA, in contrast, since it does not give such a 
strong colour reaction, gives a linear absorbancy with regard 
to the amount of citrate present over a larger range 
(0-25 . 
These observations allow for the development of a 
flexible chemical citrate assay. Above a certain level of 
citrate, a pink colour develops in the pyridine phase during 
the assay. In this instance if benzidi ne was added the 
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Figure 3.1 Spectra of various chromophores after colour 
reaction in the citrate assay. 
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Figure 3. 2 Comparison of benzidine and 4 , 4'-methylene 
dianiline as chromophores in the citrate assay. 
[citrate] ( pg) 
benzidine (A 530 ) 
I------a MDA (A510 ) 
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absorbance would be too high for spectrophotometry. However, 
the addition of MDA would allow for accurate analysis. Thus 
the development of a pink colour in the pyridine phase acts 
as a convenient guide to the selection of the appropriate 
chromophore; benzidi ne is added only if no colour forms 
in the pyridine phase. 
3.2.1.1.2 	Enzymatic 
Citrate was determined by measuring the NADH 
consumed using the coupled enzyme assay described by 
Passonneau and Brown (1974 ) . PC was found not to be degraded 
by citrate lyase : PC did not cause an oxidation of NADH. 
Consequently, PC could be analysed after a pre-incubation 
w ith d 
citrate. It was found that 10p1 of alkaline phosphatase (calf 
intestine, Grade 1, 400U/0.17ml) added to ca. 50g PC caused 
100% hydrolysis after 15 minutes at 37 ° C and pH 10.4. 
Accordingly, total citrate was determined by pipetting 
1.0m1 of 10mM glycine-KOH buffer ( pH 10.4) , up to lml of 
sample, and 10 ill alkaline phosphatase into a 3m1 cuvette 
(1 x lcm light path ) and incubating at 37 ° C for 10-20 min . 
After this period, 1.0m1 of 100mM Tris-HC1 buffer ( pH 7.0 ) , 
10 pl malate dehydrogenase (850U/m1) , 0.2ml of NADH (8mg 
NADH in 10m1 of 0.1M carbonate buffer, pH 10.6) were added. 
After thorough mixing, the absorbancy at 345nm was measured 
before the addition of 10 p 1 citrate lyase reagent [ 2mg of 
the solid (2.2U/mg protein ) in lml of 50mM triethanolamine 
buffer, pH 7.4, containing 0.03mM ZnC1 2 and 0.5M 
(NH 4  ) SO 4 
 1. Within 10 min the absorbance decreased to a 
2  
steady value. 
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Free citrate was measured by the omission of alkaline 
phosphatase from the mixture. The difference between total 
and free citrate gave an estimate of PC concentration. 
By adjusting the amount of NADH added initially the 
method conveniently may be changed to a fluorimetric assay 
allowing 0-2 p g of citrate to be determined. Figure 3.3 gives 
the . standard curves for citrate using the fluorimetric and 
UV techniques. 
3.2.1.2 Phosphate and PC  
Phosphate was determined by the Fiske-SubbaRow 
method ( Fiske and SubbaRow,  , 1925, 1929 ) as described in 
the preceding chapter (Section 2.3.1.2). Preliminary studies 
indicated that 4h in 0.1N H2SO4 at 100° C was sufficient to 
cause complete hydrolysis of PC to its components. 
3.2.2 SEPARATION TECHNIQUES 
3.2.2.1 Ion-exchange chromatography  
Whereas batch elution was sufficient to resolve PC 
from contaminants in the synthetic procedure , greater resolution 
and accuracy appeared necessary for biological applications. 
Accordingly, gradient elution was investigated under precise 
conditions where material was loaded onto a 10 x 1.5cm resin 
column at a flow rate of lml min -1 at room temperature. 
PC (50 pg ) and citrate (500 pg) were dissolved in water, the 
PH adjusted to between 7 and 8 and the solution loaded onto 
an AG 1-X8 ( HCO) column. A batch elution with 600m1 of 
3 
0.27M NaHCO 3 
 was made before a linear gradient was applied 
to the column. Five hundred ml each of 0.27M and 0.50M 
Na HCO 	was used to provide the gradient. As shown in 
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Figure 3.3 Standard curves for citrate using either fluorimetric 
or UV detection 
[citrate] (n mon 
• UV : standard curve for [citrate] 
o---o fluorescence : standard curve for 
[citrate] 
Figure 3.4, under these well-defined conditions, PC eluted 
characteristically after 300rn1 of gradient had been passed 
through the column. After the passage of a further 120m1, 
PC was completely removed from the column and there was 
no difficulty in reproducing this pattern. PC was detected 
by analysing either chemically or enzymatically for citrate 
released after hydrolysis. 
In order to ascertain whether the acidification followed 
by P i neutralisation of a solution of P i and citrate led 
to PC production, 100mg each of citrate and P i (as Na 2 HPO4 ) 
were dissolved in 20m1 water and the pH adjusted to 1. After 
15 min the pH was adjusted to 7, and the solution subjected 
to the exact chromatographic procedure described above. 
There was no evidence that PC or indeed any other citrate 
esters were formed. This result might be challenged . on the 
basis that insufficient material was present for analysis, 
but when the tubes corresponding to the position PC eluted 
(i.e. 300-420m1) were pooled, decarbonated, and concentrated 
by freeze-drying, again there was no evidence that PC was 
present. 
The use of triethylamine bicarbonate was investigated 
with a view to eliminating the decarbonation step involving 
the addition of AG 50W-X8 (H ) since direct lyophilisation 
will remove the triethylamine salt. However, when small 
amounts of PC (50 pg) were added to 50-100ml of triethylamine 
bicarbonate buffers, quantitative recovery was not obtained 
(<60%). This was in contrast to the full recovery demonstrable 
with sodium bicarbonate buffers. Presumably the amino group 
of triethylamine reacted with an acidic group on PC under 
400m1 
0.27M 
NaHCO
3 
.••••• .••• 
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Figure 3.4 Typical elution profile of citrate and PC from 
an AG 1-X8 (HCO ) column under standard 
operating conditions. 
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these dehydrating conditions to give a compound that did 
not react in the coupled enzyme citrate assay. 
3.2.2.2 Thin-Layer Chromatography (TLC)  
Glass plates were coated to a thickness of 0.25mm 
with cellulose (MN300HR from Machery-Nagel, Duren, Germany) . 
After sample application, plates were developed in one of 
the experimental solvents before air-drying and staining 
with a relevant stain for citrate or P ( Section 2.3.3 ) . 
Various solvent systems were tested for their ability 
to resolve P and PC. Some systems failed to give ' tight ' 
spots, and of those that did ( see Table 3.1) an isobutyric 
acid/5.5% NH 3 
/Me0H solvent (60:40:100, v/v) gave the best 
separation of PC from P. and citrate; the RF 's were 0, 20, 
0.42 and 0.44 respectively. Table 3.2 gives the R F s of a 
wide range of organic phosphates in this TLC system. Clearly 
if a phosphate stain is used, not all of the compounds can 
be resolved from one another. A citrate stain, however, will 
stain hydrolysed PC - pre-treated with an acid phosphatase 
solution - enabling PC to be distinguished from other 
phosphoric esters. 
For routine analysis, mixtures were resolved using 
the isobutyric acid solvent and PC was detected by staining 
for citrate or P . after hydrolysis with acid phosphatase. 
3.2.2.3 High-voltage paper electrophoresis  
High-voltage 	paper electrophoresis was performed 
essentially as described by Khwaja et al., (1970) as detailed 
earlier ( Section 2.3.2) . After electrophoresis, the paper was 
dried and spots visualised using the staining techniques 
Table 3.1 . RF values obtained for the separation of P i , citrate and PC by TLC using a range 
of solvent systems. 
R F 
SOLVENT 	 COMMENTS 
CITRATE P. PC 
Et0H 
Et0H/H 2 '0/formate 	(100:20:2 v/v) 
ca. 	0.7 ca. 	0.6 
0.85 0.61 
PrOH */H 20/formate 	(100:20:2 v/v) 
0.62 0.44 0 
Et0H/H 20/triethylamine 
(100:20:2 	v/v) . 0.84 0 0 
Eucalyptol/PrOH*/formate/H 2 0 
(50:50:20:10 	v/v) 
lsobutyric acid/5.5% NH /Me0H 
0.44 0.19 0.10 
(60:40:100 v/v) 0.42 0.44 0.20 
tight spot for citrate 
tight spots, but resol-
ution of PC and Pi poor 
tight spots and resol-
ution of PC from P. 
and citrate good 
spots are streaked 
spots are streaked 
spots are streaked 
PrOH = propanol 
89 
Table 3.2 R 's of phosphoric esters using an isobutyric 
acid/5.5% NH 3 /Me0H solvent system (60:40:100 
v/v) 
COMPOUND 
	
R F 
P. 
1. 
	 0.44 
ribose 5-P 
	
0.34 
AMP 
	
0.32 
ADPG 
	
0.28 
glucose 1-P 
	
0.26 
fructose 1, 6-P a 	 0.26 
glucose 1, 6-P a 	 0.23 
PC 
	
0.20 
ADP 	 0.13 
ATP 	 0.05 
90 
outlined before (Section 2.3.3). Figure 3.5 illustrates the 
electrophoretic resolution of P i , citrate and PC. Although 
separation of PC from citrate is poor in this system, there 
is an absolute resolution of PC and P. indicating that this 
method has particular application to the separation of 
[ 32 13 1-labelled compounds. This conclusion was confirmed 
by electrophoresis of a range of phosphoric esters; PC was 
resolved from compounds which included nucleotides, fructose 
1,6-diphosphate and phosphoglycerate. Relative mobilities 
are given in Table 3.3 
3.2.2.4 Analytical isotachophoresis  
Analytical 	isotachophoresis 	is 	a 	relatively 	new 
technique which will separate, for example, mixtures of 
inorganic anions (Bocek et al., 1977, 1978a), and metabolites 
such as Krebs cycle intermediates (Bocek et al. , 1976, 1978b; 
Sjodin et al., 1975) without the need to form derivatives 
before separation. In capillary-type analytical isotacho-
phoresis, samples are introduced between two electrolytes, 
termed leading and trailing buffers, for sub -sequent electro-
phoresis in the capillary tube. The samples ions are arranged 
in order of their _mobilities into discrete zones and can be 
detected by UV, thermal or conductimetric techniques (Arlinger 
and Lundin, 1975; Brown and Hinckley, 1974; Delmotte, 1979; 
Everaerts et al., 1975, 1976). 
The instrument used for isotachophoresis was made 
in these laboratories and is described schematically in 
Figure 3.6. This machine had facilities for both UV and 
conductimetric analysis as shown. A range of buffers was 
investigated and all buffers were 
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Figure 3.5 High-voltage paper electrophoresis of 1  citrate 
and PC. 
• x origin 
= inorganic phosphate 
CIT = citrate 
PC =phosphocitrate 
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Table 3.3 Mobilities 	of 	phosphoric 	esters 	relative 	to 
P 1 	conditions of high-voltage electrophoresis 
COMPOUND 	 RELATIVE MOBILITY 
P. 	 1 
3-phosphoglycerate 	 1 
fructose, 1,6-P 2 	 0.90 
PC 	 0.72 
glucose 6-P 	 0.65 
pyrophosphate 	 0.55 
AMP 	 0.45 
ADP 	 0.45 
ATP 	 0.43 
HIGI4 51't AGE 
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Figure 3.6 Schematic diagram of instrument used for 
  
analytical isotachophorersis. 
1 = trailing buffer 
2 = injection port 
3 = capillary tube 
4 = UV detector 
5 = conductimetric electrode 
6 = leading buffer 
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thoroughly degassed before use. Samples were pre-treated 
with AG 50W-X8 (H+ ) to remove divalent cations which appeared 
to cause solubility problems. After freeze-drying the sample 
was dissolved in a minimum amount of liquid and 2-30 pl 
injected. The migration current was set initially at 200mA 
and reduced to 50mA for the major period of the run and 
for recording purposes. The running time was between 25 
and 50 min, depending on the length and internal diameter 
of the capillary tube. 
Table 3.4 summarises results on the resolution of 
P , citrate and PC over a wide pH range. The systems 
providing the best resolution of these components operated 
at a pH of 4.7. Two buffer systems could be used to give 
this pH. One used 10mM HCl/aniline [0.2% hydroxypropylmethyl 
cellulose (HPMC)] as the leading electrolyte and 5mM glutamic 
acid (0.2% HPMC) as the terminator. An alternative system 
used 6-aminocaproic acid (0.2% HPMC) as the leading electro-
lyte, and 5mM pivalic acid as the terminator. With this latter 
_system, PC, citrate, P i and pivalic acid migrate in that 
order and give characteristic step heights of 25, 40, 50 and 
75mm respectively, as shown in Figure 3.7. If aniline is 
used, oxidation products are formed and the traces are often 
unstable. 
Analytical isotachophoresis will resolve and quantitate 
microgram amounts of PC in mixtures, but the technique 
does not completely separate samples with a high salt 
concentration. This disadvantage can be partially alleviated 
by using AG 1-X8 (HCO 3- ) ion-exchange column chromatography, 
and subsequent decarbonation with AG 50W-X8 (H + ) to give 
-Table 3.4  Resolution of PC, P. and citrate by analytical isotachophoresis at different pHs. 
STEP STEP TIME+ 	STEP 	 STEP 	
STEP + STEP TIME 	 TIME . 	TIME 	 TIME HEIGHT TIME HE 1GHT 	HEIGHT (mi n) . HEIGHT HEIGHT 
HEIGHT 
(mi n) 	 (mi n) (mi n) (min) (mi n) (mm) 	 (mm) (mm) 	 (mm) 	 (mm) 	 (mm) 
PC 	 22 	18 	26 	24 	30 	25 	25 	17 	24 	20 	22 * 	26 * 
P 	 27 	31 	40 	44 	45 	40 	40 	21 	36 	30 	47 	72* 
Citrate 	36 	55 	52 	94 	60 	52 	50 	25 	54 	52 	22* 	26* 
Terminator 	84 	68 	73 	109 	95 	70 	75 	30 	88 	63 	65 	80 
Leading* 	glycine HC1 	13 -alanine HC1 	aniline HC1 	6-aminocaproic 	f3 - a la nine HC1 histidine HC1 
terminating 	acetate ac etate glutamate 
	acid HCL 	g lut amate 	glut ornate 
pivalic acid 
pH 
	
3.5 	 4.5 
	 4.7 	 4.7 
	 4.8 	 6.0 
leading = leading electrolyte (10mM ) , terminating = trailing electrolyte ( 5mM) , all solutions with 0.2% hydroxypropyl 
methyl cellulose. 
times vary with salt concentration, concentrations of migrating ions and length of capillary tube. 
* co-migration of PC and citrate. 
t.0 
u-1 
P. 
citrate 
CO
N
D
U
C
TI
V
IT
Y
 (
c
h
ar
t  
re
co
rd
er
  u
n
it
s  
50 
96 
Figure 3.7 Isotachophoretic separation of P i ' citrate and 
PC. 
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pivalic acid 
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desalted, cation-free samples. 
3.2.2.5 High Pressure Liquid Chromatography (HPLC)  
High pressure or high performance liquid chromato-
graphy ( HPLC) involves passage of substances to be resolved 
through a microparticulate separating column at pressures 
normally greater than atmospheric, enabling efficient 
resolution to be obtained (Scott, 1978; Tomlinson et al., 
1978; Santi et al., 1975; Eksborg et al., 1973; Hearn and 
Hancock, 1979) . Components once separated are commonly 
detected by UV, fluorimetric or refractometric techniques, 
the first two being the most sensitive. Unfortunately in the 
present application the separation of P citrate and PC 
UV and fluorimetric detection systems are of little use 
since these ions contain no UV-absorbing or fluorescent 
moieties. Although, at 210nm carbonyl moieties absorb to 
a small degree, 10 lig of citrate, for example, is the threshold 
for detection (Palmer and List, 1973; Turkelson and Richards, 
1978). One method to increase sensitivity is to tag anions 
with a UV-absorbing counter-ion as in the ion-pairing 
straight phase chromatographic system developed by 
Lagerstrom (Lagerstrom, 1975; Eksborg et al., 1973) . However, 
this particular method has not been extended to such hydro-
philic molecules as the polyacids citrate, P i and PC. Indeed 
P is used as an inert ion in the system indicating the 
difficulty that would be involved in applying this method 
to the present requirements. 
Another method facilitating UV-labelling is to attach 
phenacyl moieties to acidic groups using the crown ether 
97 
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method. 	 Not 	only 	does 	this 	method 
permit UV detection, but it has also enabled derivatised 
samples to be resolved by reversed phase HPLC. This method 
has been applied to dicarboxylic acids (Grushka et al., 
1975), but not to tricarboxylic acids. Whether phosphate 
or phosphoric acid moieties would be derivatised is as yet 
unknown. As a final consideration, the extended periods 
of heating required for derivatisation suggests it cannot 
be applied to PC analysis because of the lability of PC at 
higher temperatures. 
From experiences with the conventional ion-exchange 
systems, preliminary investigation centred on the possibility 
of using an anionic column to enable the HPLC separation 
of P citrate and PC. Furthermore, since NO 3 had given 
the best resolution with conventional techniques, this was 
used as the eluting ion with HPLC. Waters Associates equip-
ment was used consisting of two Model 6000A Chromatographic 
Solvent pumps, a Model 440 Absorbance Detector, a Differential 
Refractometer Electronics Unit and a Model 660 Solvent 
Programmer. Samples (10-50 pl) were loaded onto an anionic 
AX column before gradient elution. All buffers were filtered 
and degassed before use. Using a programmed sequence of 
flow rates, together with a gradient pump facility (linear 
from 0 to 0.2M NaNO3 ), an attempt was made to resolve anions. 
Unfortunately components could not be detected by UV due 
to the high background from NO 3 buffer; the minimum 
sensitivity of diffractometry was > 50 pg citrate. In fact, the 
use of gradients. rendered diffractometry difficult so that 
fractions had to be collected, hydrolysed, and then analysed 
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for phosphate and citrate. The result from such an experiment 
is shown in Figure 3.8 indicating that HPLC will resolve 
the mixture of anions - P PC and citrate. However, the 
difficulty of detection makes this method of little advantage 
over conventional ion-exchange and adds the disadvantage 
that only small amounts can be resolved at any one time. 
3.2.2.6 Gas-Liquid Partition Chromatography (GLC)  
GLC 	requires 	the 	derivatisation of non-volatile 
components so that separation can be effected. Quantitative 
trimethylsilylation of citrate has been described by Dalgliesh 
et al. (1966). Accordingly, lmg of cation-free sample was 
dissolved in a minimum of pyridine (50-100 p 1) and 200 )11 
of a mixture of hexamethyldisilaze (HMDS) and trimethyl 
chlorosilane (TMS) ( from Pierce Chemical Co., Rockford, 
U.S.A. ) added. After 30 min 2-10 p1 aliquots were injected 
into a Varian Aerograph 1520 machine fitted with I 12% DC-
QF 1 on Gas Chrom Q column and an F. I.D. detector. The 
injector temperature was 180 ° C, column temperature 180 ° C 
and the detector temperature 200 ° C. The gas flow  
was set at ca. 10m1 min 	before calibration. Under these 
conditions the retention times of pyrophosphate, P 1 	citrate 
and TEC were found to be 2, 8-9, 40-48 and 50-60 min 
respectively. 
When PC, treated with HMDS/TMS/pyridine mixture, 
was .injected into the column, only citrate and P 1 . were 
detected ( Figure 3.9). When pyridine was omitted, no peaks 
were observed with PC. A reason for this apparent decompos-
ition of PC might be the use of the free acid of PC rather 
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Figure 3.8 Separation of P , citrate and PC by HPLC using 
an anionic (AX) column. 
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than the more stable sodium salt. 
In • an attempt to avoid these problems, various other 
methods for irimethylsilization were investigated. A milder 
method developed specifically for the derivatisation of 
phosphoric esters ( Hashizume and Sasaki, 1966) requires 
dissolving the sample in dimethylsulphoxide (DMSO) , addition 
of cyclohexane to extract the derivatised sample, and addition 
of the trimethylsilylating reagent. When PC was subjected 
to this procedure, a yellow colour appeared in the DMSO 
phase. This was not observed when other test phosphoric 
esters were derivatised; whereas these compounds gave single 
peaks after GLC, no PC peak was detectable. 
No PC peak was detectable using other 
reagents (Pierce Chemical Co., Rockford, U. S. A. ) including 
N-trimethylsilyldiethylamine , N-trimethylsilylimidazole and 
N ,0-bis ( trimethylsilyl)acetamide 
These data suggest that PC is unstable to trimethyl-
silylation . 	Consequently, 	other 	applicable 	derivatisation 
procedures were sought (Nicholson, 1978a, b; Cram, 
1978 ) . The most promising appeared to be methylation since 
this involved the introduction of a relatively small group 
into a sterically crowded array of acidic groups. Methylation 
can be effected by •either a thionyl chloride/Me0H mixture 
or by using diazomethane , for example. The former will give 
complete esterification of polyacids only if heated at 60 ° C 
for 20-30 min , conditions that will hydrolyse PC. The reactivity 
and difficulty of handling diazomethane led to the avoidance 
of this method, but the more recent work by Tew et al. (1980 ) 
indicates that complete derivatisation of PC was not possible 
under the conditions used. 
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3.3 	DISCUSSION  
A number of techniques,both analytical and preparative, 
have been investigated for purifying and quantitating PC 
exploiting various characteristics of the PC molecule. The 
data presented here indicate that the AG 1-X8 (HCO - ) ion- 3 
exchange chromatographic system developed affords definitive 
separation of PC from citrate and that PC elutes at a charact-
eristic volume upon linear gradient elution. Quantitative 
recovery is possible using sodium as the cation but with 
triethylamine this is not possible, presumably because 
coupling with PC occurs under the dehydrating conditions 
of lyophilisation, rendering citrate undetectable using enzymic 
assay. 
The development of this system enabled a rigorous 
examination of the claim by Howard (1976) that acidification 
and neutralisation of a sample of P i and citrate leads to 
PC production. In his study the compound was not isolated 
or characterised. Rather, the indirect evidence of a rise 
in the anti-calcifying potential of the mixture was taken 
as an indication of the production of a new calcification 
inhibitor. The increase in molar strength due to acidification 
and neutralisation is known not to significantly affect inhibit-
ion (Termine and Posner, 1970; Termine et al., 1970); thus 
the new compound was proposed to be PC. 
Sutor et al., (1979a), however, have questioned whether 
PC can be formed in this way, claiming that chemical 
arguments cannot substantiate such an artefactual formation. 
This claim, however, is not valid as known organic reactions 
104 
would in fact support such a method of PC production (Figure 
3.10) . For example, the S N 1 and El reactions of t-butyl 
alcohol in aqueous sulphuric acid give t-butyl sulphate and 
t-butylene respectively. An reaction of P citrate 
can thus be foreseen to give PC by a closely analogous 
process. Furthermore, S N 1 reactions are favoured by solvents 
with a high dielectric constant, for example, water, allowing 
stabilisation of ions formed; and tertiary alcohols inductively 
stabilise intermediate carbanions ( Roberts and Caserio , 1965 ) . 
Consequently the reaction of citrate, a tertiary alcohol, in 
dilute aqueous phosphoric acid is optimally suited to produce 
PC contrary to the theoretical predictions of Sutor et al. 
(1979a) . As a further indication of the likelihood of the 
artefactual formation of PC, the El reaction of citrate to 
give aconitate in acid is well known ( Howard, 1976; Roberts 
and Caserio, 1965) . 
Nevertheless, in the present study no evidence could 
be found supporting the idea that acidification and neutral-
isation of P . and citrate leads to PC production. Instead 
of relying on indirect evidence, samples from ion-exchange 
chromatographic columns were pooled, decarbonated, and 
freeze-dried before direct enzymatic and chemical analysis 
for PC. The amounts of P and citrate used in these experi-
ments were in excess over the levels calculated to be present•
in biological samples of less than 100g , indicating that tissue 
samples. can be subjected to , TCA extraction followed by KOH 
treatment without spurious PC production. The question of 
the inclusion of PC into the K104 deposit remains unanswered 
Figure 3.10 Possible SN 1 and El reactions of citric acid 
to give phosphocitric acid and aconitic acid 
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at this stage, but could be readily investigated using 
[ 
 
P]-PC (see Section 6.3.1) . 
PC, once separated, can be determined by either the 
chemical or enzymatic techniques developed here . An alternative 
chromophore to the commonly used benzidine is suggested 
to be 4,4 ' -methylene dianiline (MDA) which is less toxic 
and although not giving the same intense colour reaction 
as benzidine, it does allow estimation of a wider range of 
citrate concentrations. These observations have allowed a 
versatile citrate assay to be developed: benzidine is used 
to detect low citrate concentrations (0-8pg ) and MDA to detect 
a wider range of citrate levels (0-20 . 
• 	 A limitation of the chemical citrate assay is the 
partial reaction that occurs with PC itself. Consequently, 
only total citrate can be measured accurately by this method 
so that complete separation of citrate - and PC by column 
chromatography, is obligatory. As an alternative the coupled 
enzyme system described here is more flexible. PC is not 
cleaved by citrate lyase but since it is s labile to both 
alkaline and acid phosphatase, measurement of free citrate 
and PC is possible. Microgram and submicrogram quantities 
can be determined using fluo rimetric techniques, provided 
background fluorescence is minimal. 
A list of' the techniques useful for characterising PC 
is given in Table 3.5. HPLC and GLC are not listed because 
of difficulties involved in the application of these techniques. 
The trimethylsilylating methods necessary for GLC appear 
to lead to the decomposition of PC. Furthermore, even milder 
techniques such as methylation are not effective in fully- 
Table 3.5 	Techniques for identifying phosphocitrate. 
SYSTEM 
	
DETAILS 	 COMMENTS 
Ion-exchange chromatography 
Thin layer chromatography 
Enzymatic 
Chemical 
AG 1-X8 ( HCO
3
- )
' 
pH 7.2-7.4 
coupled assay with phosphata se, 
citrate lyase and malate 
dehydrogena se - UV or fluorimetric 
batch or gradient elution with 
definitive separation of P i , citrate 
and PC 
distance from origin (cm): PC (23), 
P 	(32), citrate (25) 
PC sensitivity: 0.2-100pg 
High-voltage paper electrophoresis 	 3MM: 0.05M triethanolamine-HCO3 
pH 7.5, 2000v/2hr 
Cellulose: isobutyric/5.5% NH 3 ! 	RF values: PC (0.2) , P1 (0.44) , 
Me0H (60:40:100 v/v ) 	 citrate (0.42) 
P BA derivative with benzidine 	PC sensitivity: 0.5-5pg 
lsotachophoresis 	 aminocaproic acid/pivalic 	 step height (mm): PC (25), citrate 
acid system 	 (40), Pi (50), pivalic acid (75): 
PC sensitivity: nmoles 
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derivatising PC (Tew et al., 1980). With HPLC, present 
detection techniques make unreacted PC difficult to detect. 
The HPLC anionic column separation developed here is 
therefore limited, requiring the collection of fractions and 
subsequent analysis of tube contents to identify separated 
components. The use of ion-pair reversed phase HPLC could 
not be used to improve detection since if. a UV absorbing 
counter ion was used the background UV absorption would 
be too high for the detection of resolved components. The 
only techniques that could, in theory at least, improve 
sensitiVity are phenacyl derivatisation of PC, or straight-
phase ion-paired chromatography. The former, however, 
requires derivatisation conditions that would hydrolyse PC 
and the latter technique is presently only of use with 
relatively hydrophobic molecules, certainly not with such 
hydrophilic entities as PC, and citrate. 
One technique that does not require UV absorption 
for sensitivity in detection, and in fact works optimally 
for highly charged anions, is isotachophoresis. As an 
analytical technique this method has great applicability 
since nanomole amounts of PC are detectable and PC, further-
more, is characterised by a unique step height reflecting 
the particular conductivity of the migrating anionic zone. 
The width of the zone is proportional to the amount of 
material present enabling quantitation. 
Isotachophoresis is ideal for pure solutions; but 
technology has not yet been perfected to quantitate compounds 
in the presence of high salt concentrations. Thus the caproic 
acid/pivalic acid system described here offers the possibility 
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of at least confirming the presence of PC in biological 
samples, if indeed it is present. 
Another useful technique is TLC which ,by using specific 
phosphate and citrate stains, will separate PC from citrate 
and P and allow for its visualisation after cleavage with 
acid phosphatase. The limitation of TLC is that only small 
volumes of samples can be applied, a limitation which is 
not quite as restrictive with high-voltage paper electro-
phoresis. This latter technique permits good separation of 
PC and P 1  . using a triethylamine-bicarbonate buffer, although 
separation between citrate and PC is not definitive. However, 
alteration of running conditions or even second dimension 
electrophoresis may resolve PC and citrate; but at present, 
staining for phosphate will selectively stain PC and not 
citrate. Electrophoresis separates PC from a variety of other 
Pe. - sters and these data suggest that this method is probably 
best suited to experiments where it is necessary to monitor 
[ 32 
 
P]-labelled components. 
If a compound gives a positive reaction for PC in 
more than one system then its identity as PC is more assured 
than a positive reaction in just one system, since each system 
has some limitations. Consequently, the techniques developed 
here allow not only the separation and determination of the 
citrate content of a "PC fraction", but, by comparison with 
authentic PC, the more confident assertion that the compound 
is indeed PC. 
3.4 	SUMMARY 
1. 	Total citrate in PC can be determined by using 
the chemical P BA-citrate assay ; however, PC was found to 
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be hydrolysed under the conditions, so free citrate cannot 
be accurately measured. 
2. 4 , 4 ' -methylenedianiline was found to be a 
substitute for benzid me and the use of both reagents has 
allowed the development of a flexible citrate assay. 
3. Free citrate and PC can be measured by a 
coupled enzyme system using alkaline phosphatase to cleave 
PC. Submicrogram amounts of PC can be determined. 
4. An ion-exchange chromatographic system was 
developed that eluted PC from a column at a characteristic 
volume. 
5. Acidification and neutralisation of citrate and 
P . was not found to lead to PC production. 
6. A TLC system was found that separated PC 
from P 	and citrate; the R F 's  were 0.20, 0.42 and 0.44 
respectively. 
7. High-voltage paper electrophoresis at pH 7.4 
was demonstrated to resolve a wide range of phosphoric esters: 
Separation of PC and citrate was poor. 
8. A variety of systems for analytical isotacho- 
phoresis were investigated. Using an aminocaproic acid/ 
pivalic acid system, best separation and detection of PC, 
P and citrate was obtained. 
9. HP LC with , an anionic ion-exchange column 
(NO 	separated PC P 	and citrate but detection thresholds 
were too high for this technique to be of great use. 
10. Under a wide range of derivatisation conditions, 
GLC could not detect PC. 
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CHAPTER 4  
ANTI-CALCIFYING POTENTIAL OF PHOSPHOCITRATE  
4.1 	INTRODUCTION  
The 	availability • of 	highly-purified 	PC 	enables 
investigation of its ability to inhibit both calcium phosphate 
and calcium oxalate precipitation. These experiments are 
particularly important since Lehninger (1977) has cautioned 
that the powerful activity shown by biological fractions might 
not be due to PC but to some other factor(s) present. Further, 
whereas Howard (1976) has claimed "factor X" - presumably 
PC - inhibits HAP formation, Tew and Mahle (1977) have 
• reported that the "purified factor" only inhibits if citrate 
is present. Work in this chapter is aimed 	at clarifying 
• these conflicting reports and at elucidating the inhibitory 
characteristics of PC which might indicate whether PC should 
be considered as a new biological factor influencing biological 
calcification systems. 
Calcium phosphate deposition can occur in association 
with the formation of renal stones, mitochondrial granules 
and the hydroxyapatite (HAP) of bone (Posner, 1973; Bygrave, 
1978; Fleisch, 1978). Amorphous calcium phosphate . (ACP) 
is recognised as the precursor of HAP both in vitro (Meyer 
and Eanes, 1978a, b) and in vivo (Dougherty, 1978; Posner 
and Betts, 1975). Test systems have been established based 
on the fact that when ACP hydrolyses •after a specific time 
to the more basic phase (HAP), the acidity that develops 
in solution can be neutralised by controlled base titrimetry. 
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This type of system has been used to determine whether 
particular compounds can inhibit HAP formation and as a 
result compounds such as ATP, pyrophosphate, phosvitin 
and citrate have been established as inhibitors. The structur-
al variety of compounds known to inhibit has led to little 
progress in understanding how the structure of a molecule 
affects its ability to inhibit. 
Limited studies by Robertson and Fleisch (1970) have 
led to the suggestion that compounds possessing an H 203 P-
X-P03 H 2 structure (X may be C, NI or 0) will inhibit. The 
findings that fructose 1,6-bisphosphate and glycerol 2,3- 
bisphosphate also inhibited has caused Termine and Conn 
(1976) to broaden this initial concept proposing that "if 
inhibitor P-O-P bonds are not present, low molecular weight 
metabolites containing two ester phosphates (but not mono-
phosphate or carboxylic acid .groups) also inhibit". Clearly 
PC does not comply with this structural criterion. If then 
PC does show inhibitory properties then a re-appraisal of 
the structural factors influencing • inhibitory ability is 
warranted. 
Another important calcium salt in man is calcium 
oxalate. Whereas calcium phosphate is quantitatively more 
important, calcium oxalate is a major component of renal 
and urinary stones (King, 1971). If PC is to play a role 
in the prevention of lithiasis it should inhibit not only 
calcium phosphate deposition but also calcium oxalate 
crystallisation - a phenomenon as yet unstudied. The effect 
of PC on calcium oxalate precipitation was investigated using 
two experimental systems. One system involved the growth 
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of calcium oxalate on glass fibres; the other involved seeding 
a metastable solution of calcium oxalate. The use of two 
systems then has enabled a more extensive investigation 
of the inhibitory, activity of PC. 
Comparison of the inhibitory ability of PC with a 
range of well-known inhibitors was also undertaken. These 
inhibitors included ATP, EHDP, pyrophosphate, citrate and 
chondroitin sulphate C. These were tested in the calcium 
oxalate and/or calcium phosphate test systems, allowing the 
ability of PC to inhibit the deposition of either of the calcium 
salts to be compared.- 
The addition of a single compound to calcification 
systems allows any inhibitory ability to be revealed; but 
such an effect cannot be an accurate reflection of the way 
the compound acts in vivo, where many cellular and chemical 
interactions may influence inhibition. Synergism and other 
interactions have been investigated with calcium phosphate 
precipitation but there is no evidence from calcium oxalate 
studies. For example, Blumenthal et al. (1977) have shown 
that Mg 1"F  has a synergistic effect with ATP on the inhibition 
of HAP formation. From preliminary work using impure PC, 
Howard (1976) has postulated that perhaps citrate and PC 
formed another synergistic couple. An attempt has been made 
to study these effects in both calcium phosphate and calcium 
oxalate systems, because of the important implications of 
such interactions to the physiological situation. In addition, 
the adsorption of PC onto HAP and calcium oxalate was also 
investigated, since inhibition is usually considered to involve 
adsorption onto active growth sites. 
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4.2 	MATERIALS  
Phosphocitrate was prepared as described earlier 
(Section 2.4.1.2) and imidodiphosphate (PNP ) as described 
by Yount (1974). Ethane 1-hydroxy diphosphonate ( EHDP ) 
was a gift from Proctor and Gamble, Cincinatti, U.S.A. 
Adenosine phosphates were products of Calbiochem, Sydney, 
N. S. W . 	Hydroxyapatite was from Bio-Rad Laboratories, 
Richmond, California, U.S.A. 	Water was decarbonated and 
distilled before use. All •other chemicals were reagent grade 
and obtained from commercial sources. 
4.3 	METHODS 
4.3.1 CALCIUM PHOSPHATE PRECIPITATION 
The transformation of ACP into HAP was followed 
titrimetrically essentially as described by Meyer and Eanes 
(1978a). Using a 1L flask, 0.5m1 portions of 0.50M CaC1 2 
and 0.50M NaH 2 PO 4 were added to 600m1 of gtirred, high-
purity decarbonated water and equilibrated in a water bath 
at 25 °C. Sufficient 2M NaOH was then added over 60s to adjust 
the pH to 7.4. The mixture was maintained at this pH 
throughout the course of the reaction by using a pH-stat 
( Radiometer , Copenhagen, Denmark ) and CO 2 was excluded 
from the system by bubbling N 2 . 
4-3.2 CALCIUM OXALATE PRECIPITATION 
• 4-3.2.1 Glass fibre system 
Calcium oxalate crystals were grown on glass fibres 
essentially as described by Sutor (1969 ) and modified by 
Sallis and Lumley (1979 ) . Glass threads (20 x 0.2mm) were 
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fixed with adhesive tape to a short glass rod — 10 per rod. 
Cups of 25ml capacity were placed between two glass troughs 
enclosed in a chromatographic tank. The troughs were filled 
either with 0.1M CaCl 2 (pH 6.4) or 0.1M sodium oxalate (pH 
6.4) . The cups were filled with 19m1 of 0.2M sodium acetate 
buffer (pH 6.1) and lml of the test solution. Wicks (6mm 
x 11cm) were cut from Whatman no. 1 paper and placed two 
per cup so that one led to the calcium solution, the other 
to the oxalate solution. The experimental apparatus is 
illustrated in Figure 4.1. 
At specified times wicks were removed, the glass rods 
taken out and either examined under a light microscope or 
analysed for calcium, essentially by the method of Kepner 
and Hercules (1963) . For calcium analysis the glass fibres 
were left overnight in 4m1. of 2N HC1 before 10-20 pl was 
removed from solution and added to a calcein solution 
(0.7mg/100m1 0.8N KOH) in test tubes washed in 1N HNO
3 • 
After 10-20 min samples were read in a fluorimeter ( excitation 
360nm, primary filter Schott UG11 ; emission >410nm, secondary 
filter Wratten 2A) and compared _ with standards of 0-12mg% 
made from anhydrous CaCO 3 . 
4.3.2.2 Metastable solution method  
Seed crystals were added to a metastable solution 
of calcium oxalate as described by Meyer and Smith (1975a) . 
The seed crystals were prepared by adding dropwise over 
2h solutions of 100m1 of 0.4M CaCl 2 and 100m1 of 0.4M 
potassium oxalate to 300m1 of distilled water kept at 70 °C. 
After this addition, the seed crystals were maintained at 
70 °C for a further 5h then allowed to cool overnight to room 
116 
Figure 4.1 Apparatus used to measure growth rate of 
calcium oxalate crystals on glass fibres*. 
*The equipment used was essentially that described by Sallis 
and Lumley (1979). 
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temperature. The solid was collected by centrifugation and 
repeatedly washed with distilled water until the supernatant 
gave a negative test for chloride (addition of conc. AgNO 3 
to the supernatant). The solid was thoroughly dried then 
suspended in water (18mg/m1). Sufficient stock solution for 
subsequent experiments was retained and incubated for at 
least 10 days at 37 °C to mature the seed crystals. 
In order to perform the assay, 0.5ml of 50mM CaCl2 
and 0.5m1 of 50mM potassium •oxalate were added to 49m1 of 
0.15M NaC1 at 37 0  C and stirred mechanically. 1.0m1 of the 
test solution was added and the pH adjusted to 6.0. Then 
0.4m1 of the seed crystals suspension was added, the pH 
checked and a sample immediately taken and filtered through 
a Millipore filter (0.45 i m). Samples (2.0m1) were removed 
at 0, 5, 10, 15, 30, 45, 60 and 75 min, and filtered through 
a Millipore membrane (0.45Pm)• 
Calcium in the _ filtrates was determined by Atomic 
Absorption Spectroscopy. Lanthanum solution (0.4m1 of 50,000 
ppm), 5N HC10 4 (0.2m1) and water (0.7m1) were added to 
samples (0.7m1) and thoroughly mixed. Concentrations were 
determined on a scale calibrated between 2 and 8pg Ca/ 
ml. 
4.3.3 ADSORPTION OF PC ONTO HAP AND CALCIUM OXALATE 
250mg of either calcium oxalate or HAP was added 
to 193='-10 p g citrate (present as PC) in 3m1 of 0.15M NaC1 
at 37° C and pH 7.4. After brief stirring, the solid was spun 
down and the supernatant analysed for free and total citrate. 
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4.4 	RESULTS 
4-4.1 CALCIUM PHOSPHATE CRYSTALLISATION 
4-4.1.1 Comparison of the anti-calcifying ability of PC 
Figure 4.2 details the amount of base added in order 
to maintain a constant pH in suspensions of calcium phosphate 
formed in the presence or absence of test compounds. The 
break in the rate of base addition corresponds to the ACP 
to HAP transition (Boskey and Posner, 1973) and a compound 
inhibits if it delays the onset of this transition (1 ). 
Clearly, as shown in the figure, . although ATP and EHDP 
are both inhibitors, 50 M of EHDP is more effective than 
40 pM ATP. The relative potency of compounds can be better 
assessed if a comparison is made of the effect of inhibitors 
over a given concentration range on I . Thus Figure 4.3 
compares PC with some selected inhibitors and indicates that 
their potency is in the order: PC >> EHDP > ATP >> citrate. 
Nct only does PC inhibit, but it is the most potent inhibitor 
of the compounds tested. Notably EGTA, a chelator with a 
high affinity for calcium affinity, did not inhibit even at 
0.5mM. 
4.4.1.2 Interaction of PC, citrate and Mg ++ ; and PC with  
an artificial urine  
Under physiological conditions it is unrealistic to 
envisage one inhibitor acting in isolation. In order to gain 
some information on how PC might act in vivo, the inter- 
actions between Mg 	citrate and PC were examined. These 
experiments at least indicate whether interactions are possible, 
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Figure 4.2 Inhibitory effect of ATP and EHDP on the 
transition of ACP into HAP. 
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Figure 4.3 Effect of inhibitor concentration on the onset 
of the transition ( I t ) of ACP into HAP. 
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although the physiological state is not closely modelled. 
Results from these experiments are given in Table 4.1. Tests 
were conducted at 200  C to emphasise interactions, since at 
37 ° C induction times are decreased. PC with either citrate 
or Mg++ acts synergistically, but in contrast Mg ++ and citrate 
do not inhibit to the extent expected on the basis of an 
additive effect on inhibition. The three inhibitors act together 
synergistically but not to the extent expected, considering 
the action of Mg ++ and PC; and PC and citrate. 
These preliminary results indicated that PC could 
perhaps interact with ions present in physiological fluids. 
Consequently the action of PC in the presence or absence 
of an artificial urine was investigated. The synthetic urine 
used was that described by Miller et al. ( 1977) and its 
constituents are given in Table 4.2. PC (20M) gives an 
increase in the induction time of 25min and 5m1 of synthetic 
urine gives an increase in the induction time of 6min. Together 
an increase in I t of 56min results, corresponding to a 180% 
increase 	over 	an 	additive 	effect 	cu 	inhibition. 
4.4.2 CALCIUM OXALATE PRECIPITATION 
4.4.2.1 Glass fibre system 
Table 4.3 gives the abilities of pyrophosphate, PC 
and chondroitin sulphate C [MW ca. 60,000 (Yamagata et 
al., 1968; Schiller et al., 1961) ] to decrease the deposition 
of calcium oxalate onto glass fibres. Data indicate that 
chondroitin sulphate C is a more potent inhibitor than PC 
on a molar basis; weight-for-weight PC is much more effective. 
In the absence of added inhibitors, crystals on the 
glass fibres were hexagonal deposits characteristic of the 
A t (min) t Alt(exP.)
t 
	SYNERGISM xp.)I 
DIFFERENCE 
COMBINATION* 
2+ Table 4.1. Inhibitory ability resulting from interactions of Mg 	, PC and citrate on HAP 
formation. 
PC 
Mg  
citrate 
15 
12 
7 
PC + Mg 2+ 
PC + cit. 
2+ Mg 	+ cit. 
49 	 27 	 +22 	 YES 
59 	 22 	 +37 	 YES 
16 	 19 	 -3 	 NO 
+ PC + Mc 2 + cit. 	 50 	 34 	 +16 	 YES 
*Amounts used were: 3.0mg PC, 28mg MgC1 2 .2H2 0 and 28mg trisodium citrate dihydrate. 
t 	s were determined at pH 7.4, 20 o C, as described in the text. 
t (expected) was calculated on the basis of an additive effect of inhibitors on HAP formation. 
Table 4.2. Composition of an artificial urine. 
SUBSTANCE 	 AMOUNT (g/l) 
Na 2 SO 4 	 3.33 
KH 4 Cl 3.18 
KCI 	 8.31 
MgS0 4 .7H 20 	 2.00 
Na 2 HPO 4 	 0.58 
NaH 2 PO 4 . H 20 	 4.12 
NaC1 	 9.25 
Na 3 citrate .2H 20 	 0.80 
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Taken from Miller et al. (1977) . 
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Table 4.3. The ability of PC, pyrophosphate and chondroitin 
sulphate C to inhibit calcium oxalate crystal 
formation on glass fibres. 
COMPOUND 	[INHIBITOR] (mM) 	 % INHIBITION* 
Pyrophosphate 	 1.1 	 484 
PC 
	
0.33 	 66 1-3 
Chondroitin 
sulphate C 	 0.10 	 55±7 
*3 trials; mean ±1 S.D. 
Table 4.4. Adsorption of PC onto calcium oxalate and HAP. 
ADSORBENT p[ PC 	( g) * [PC]final(  pg)* %ADSORPTION TYPE (250mg) 	initial 
HAP 
	 193±10 	 1.1±0.2 
	
99 
Calcium oxalate 	1931'10 	 1051'4 
	
46 
*4 trials; mean ±1 S.D. 
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dihydrate. Pyrophosphate presence altered the crystal habit 
to dodecahedrons of the dihydrate. In the presence of PC 
or chondroitin sulphate C, crystals were predominantly of 
the oval, biscuit and dumb-bell habits characteristic of the 
monohydrate, although some dodecahedral prisms were also 
observed. 
4.4.2.2 Metastable solution method 
4.4.2.2.1 	Comparison of PC with pyrophosphate 
In order to confirm results from the glass fibre 
system suggesting PC was more potent than pyrophosphate 
as an inhibitor of calcium oxalate precipitation, comparative 
experiments were undertaken using the metastable solution 
method. Figure 4.4 shows the rate of depletion of calcium 
from solution upon seeding a metastable solution with calcium 
oxalate - crystals with or without 27 1iM inhibitor. The ion- 
iring correction outlined by Meyer and Smith (1975a, b) 
is not necessary in these cases due to the small amount 
of inhibitor added. Clearly, PC inhibits more than pyro-
phosphate (PP . ) in this system. For quantitation, the data 
were treated as described by Meyer and Smith (1975b); Figure 
4.5 indicates that 27pM PP inhibits 50% and 271.1M PC, 82%, 
substantiating the results obtained with the glass fibre system. 
4.4.2.2.2 	Interactions of PC, Mg ++ and citrate 
In order to investigate whether synergism 
between inhibitors occurs in the precipitation of calcium 
oxalate,. experiments similar to those conducted in the 
calcium phosphate system were undertaken. However, with 
the calcium oxalate system, if sufficient ions were added 
1 	I  
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Figure 4.4 Effect of inhibitors on the rate of depletion 
of calcium from a seeded metastable solution 
of calcium oxalate. 
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Figure 4.5 Quantitation of the inhibitor potency of PC and 
pyrophosphate. 
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into the seeding assay, which interact with Ca ++ or oxalate, 
relatively elaborate computation must be carried out to correct 
for ion-pairing. If two ions are added the computation is 
complicated. For example, if Mg and citrate are added, then 
the following interactions must be considered: citrate with 
Mg g  and Ca ++ , and oxalate with Mg 	and  Ca ++ . Further, 
allowance must be made for differing affinities of ion-pairing. 
These difficulties can be avoided by adding small amounts 
of Ma ++ and citrate sufficient to warrant computational 
correction. Under these conditions no synergism with PC was 
observable as shown in Figure 4.6. 
4.4.3 ADSORPTION OF PC ONTO CALCIUM OXALATE AND HAP 
Adsorption of inhibitors onto calcium salt surfaces 
has been considered to be the likely mechanism of inhibition. 
Active growth sites are blocked decreasing possibilities for 
future crystal growth and nucleation. Investigation of the 
possible adsorption of PC onto calcium oxalate and HAP was 
therefore undertaken. Table 4.4 gives the amounts of PC 
left in solution after the addition of either calcium oxalate 
or HAP: 250mg of HAP adsorbed > 99% of the initial PC in 
solution, whereas 250mg of calcium oxalate absorbed 46%. 
In both cases the remaining solution contained <4% free 
citrate. These findings conform to the idea that inhibitors 
act by being adsorbed onto active growth sites. 
4.5 	DISCUSSION  
The data presented here indicate PC is a potent 
inhibitor of both calcium phosphate and calcium oxalate 
crystallisation and does not require the presence of citrate 
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2+ Figure 4.6 The effect of adding Mg 	, citrate or PC alone 
or in combination on the rate of depletion of 
calcium from a seeded metastable solution of 
calcium oxalate 
10 	20 	30 
Time (min) 
	 PC + Mg 2+ 
A----• -- —A PC (20pM) 
0— – – – --0 PC + citrate 
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for inhibition, contrary to the report of Tew and Mahle (1977). 
In fact, PC is significantly more powerful as an inhibitor 
of HAP formation than EHDP and ATP, the latter two compounds 
being recognised as two of the most potent inhibitors (Fleisch, 
1978). The finding of this remarkable inhibitory ability of 
PC indicates it could play a role as an inhibitor in biological 
systems and therefore gives some support to the suggestion 
that PC may be the factor responsible for the potent inhibit-
ion shown by various biological fractions (Howard, 1976; 
Lehninger, 1977). However, before the inhibitory effect of 
these fractions is attributed to PC, careful purification is 
required to demonstrate that PC is present and is the effective 
factor. 
PC inhibits HAP formation although it does not contain 
"two ester phosphates" which have been suggested to be 
structural prerequisites for inhibition; this indicates a re-
appraisal of the structural factors that affect inhibition 
is necessary. The testing of a wide range of compounds for 
inhibitory ability that will enable elucidation of the structure-
ability relationship of inhibitors is indicated. 
As to the mechanism(s) by which PC inhibits HAP 
formation, inhibition cannot simply be due to Ca++ chelation 
as Sutor and Percival (1978) have suggested, since EGTA 
does not significantly affect the transformation process. The 
strong adsorption of PC onto HAP indicates that binding to 
active growth sites is the likely mechanism consistent with 
proposals by Meyer and Nancollas (1973), and Meyer et al. 
(1974) on the action of other phosphoric ester inhibitors. 
phosphate surfaces 
Mg ++ and citrate 
( Krane and Glimcher, 1962). 
combined causes a decrease 
In contrast, 
in expected 
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The mechanism of action of a single ion is readily explicable 
but the underlying mechanism(s) ) responsible for the synergist-
ic interactions between ions are more difficult to discern. 
It appears likely that the reason Mg ++ and PC interact syner-
gistically is analogous to that proposed for the synergism 
++ between Mg ++ and ATP: chelation of Mg 	an d PC protects 
PC from transformation that is known to occur on calcium 
inhibition, perhaps due to a reduction in concentration of 
their active species by chelation . The basis for the synergism 
between citrate and PC is not obvious from the results 
presented here, but a likely explanation is that inhibitors 
bind to different sites on calcium phosphate surfaces so that 
they efficiently cover the surfaces, blocking growth and 
seeding. When all three inhibitors - Mg ++ , citrate, PC - 
are present, synergism is still apparent, although less than 
that expected on the basis of the Mg ++ /PC and PC/citrate 
couples. Presumably this is due to the Mg 	inter- 
action which decreases the amount of free Mg 	citrate 
available for synergism with PC. Synergism was also observed 
between PC and an artificial urine suggesting that in vivo 
PC could act as a potentiating agent, a small, concentration 
serving to greatly increase the anti-calcifying ability of 
a particular biological fluid. It should be noted, however, 
that although such physico-chemical phenomena are prominent 
in well-defined in vitro calcifying systems, it may not be 
valid to suggest that therefore this occurs physiologically. 
Tew et al. (1978 ) have suggested that mitochondria 
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contain PC on the basis that mitochondrial extracts inhibit 
the transformation of ACP into HAP. However, since many 
compounds inhibit this fraction (Termine and Conn, 1976; 
Termine and Posner, 1970), this result is equivocable and 
direct proof, involving isolation and characterisation of the 
active ingredient, is required. 
PC is a potent inhibitor not only of HAP formation 
but also of calcium oxalate formation. In fact, weight-for-
weight PC is the most potent of the inhibitors tested which 
included chondroitin sulphate C, accepted to be one of the 
most potent inhibitors of calcium oxalate formation. However, 
on a molar basis, chondroitin sulphate C is more powerful 
than PC. 
PC affects the morphology of calcium oxalate crystals 
which grow on glass fibres suspended in a solution of 
Ca ++ and oxalate. Without inhibitors, deposits were hexagonal 
deposits characteristic of the dihydrate (weddelite), whereas 
in the presence of PC or chondroitin sulphate C crystals 
were predominantly of the oval, biscuit or dumb-bell habits, 
characterising the deposit as the monohydrate (whewellite). 
These observations concur with previous reports (Sutor, 1969; 
Welshman and McGeown, 1972) indicating inhibitors alter 
crystal habit. 
The potent ability of PC as an inhibitor of calcium 
oxalate precipitation was confirmed with • an assay which 
used calcium oxalate seed crystals to initiate deposition 
from a metastable Ca ++ and oxalate solution. In contrast 
to the synergism between PC, citrate and Mg ++ observed 
in the inhibition of HAP formation,no synergism was detectable 
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with calcium oxalate precipitation. 
The mechanism by which PC inhibits calcium oxalate 
precipitation is likely to be adsorption of PC onto growth 
sites as indicated by the ability of calcium oxalate to •adsorb 
PC. Once blocked, these sites can no longer nucleate further 
growth, so a decrease in the number of active sites inhibits 
crystal growth. 
PC then has been demonstrated to be a potent inhibitor 
of both calcium phosphate and calcium oxalate formation. 
Indeed, with regard to calcium phosphate precipitation, the 
synergistic interaction between PC and other ions, as 
demonstrated here, suggests that PC could act as a potentiat-
ing agent, amplifying the inhibitory potential of a group 
of inhibitors. The physico-chemical characteristics indicate• 
that if PC is found naturally then it could be a new inhibitor 
for consideration in the control of biological calcification. 
This work emphasises the need to define unambiguously the 
biological occurrence of PC with a view to clarifying its 
sites of action and therefore possible biological roles. 
4.6 	SUMMARY  
1. PC was found to be a potent inhibitor of HAP 
formation; it was demonstrated to be more powerful than 
ATP, EHDP and pyrophosphate. 
2. PC interacts synergistically with citrate and 
Mg ++ to inhibit HAP but not calcium oxalate formation. 
3. PC potentiates the ability of an artificial urine 
to inhibit HAP formation. 
4. PC potently inhibits calcium oxalate formation. 
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5. Using a glass fibre nucleating system, PC was 
found to modify the crystal morphology, and to be more potent 
- on a weight-for-weight basis 	than pyrophosphate or 
chondroitin sulphate C. 
6. Using a method involving the seeding of a 
metastable solution of calcium and oxalate, PC was found 
to be a more potent inhibitor than pyrophosphate. No 
synergism between Mg ++ 	citrate and pyrophosphate was 
found. 
7. PC was adsorbed onto calcium oxalate and HAP.. 
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CHAPTER 5 
STRUCTURE-ACTIVITY 	RELATIONSHIP 	OF 	INHIBITORS 	OF 
HYDROXYAPAT ITE PRECIPITATION 
5.1 	INTRODUCTION  
Termine and Conn (1976) have suggested that low 
molecular weight compounds will inhibit the transformation 
of amorphous calcium phosphate (ACP) into hydroxyapatite 
(HAP) if they possess at least two ester phosphates. However, 
the demonstration that PC potently inhibits indicates that 
this criterion requires re-appraisal since PC is a monophos-
phate. In order to define the structural factors influencing 
inhibitor .power, a selection of compounds was tested for 
inhibitory activity and this chapter reports on the results 
of the study. Two of the compounds examined were carboxylic 
monophosphates, phosphonoacetate and phosphonoformate, 
which, along with PC, do not conform to the structural 
criteria proposed by Termine and Conn (1976). 
The development of a structure-activity relationship . 
of 	inhibitors 	of 	HAP 	formation 	could 	be 	of 	use 	in 	several 
areas, 	having the potential to 	aid: 
1. the 	identification 	of 	biological 	compounds 	which 	on 
structural 	considerations 	are 	predicted 	to 	inhibit, 
but are 	as yet unrecognised; 
2. the 	understanding of 	the 	nature of 	the 	binding 	sites 
and 	the 	mechanism 
surfaces, 	and 
of 	binding to 	calcium 	phosphate 
3. the 	prediction 	of structures 	of inhibitors 	that 	might 
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be worth synthesizing for use in the therapy of some 
Ca + + metabolic diseases. [These compounds should 
inhibit HAP precipitation, so the Ca"metabolic diseases 
that could be treated include Paget's disease, urolith-
iasis and osteolytic sarcoma.] 
Although the structure of inhibitors may yield some 
information on the nature of the binding sites, further data 
on the mechanism(s) of inhibition was sought by monitoring 
the transformation of ACP into HAP not only by the usual 
base titrimetric technique but by other methods. These methods 
involved measurement of calcium ion activity and of laser 
light scattering. During the course of this study it became 
evident that data obtained from light scattering measurements 
added a further dimension to the prsent study since it was 
possible to separate the inhibitors into two distinct groups. 
Observation by transmission electron microscopy (TEM),together 
with other data on the conversion process,confirm this division 
and have enabled consideration of the mechanism(s) of inhib-
ition responsible for the grouping of the inhibitors. 
A synergistic interaction between Mg ++ and PC, and 
between citrate and PC on the inhibition of HAP formation 
were noted in the preceding chapter. To clarify the mechan-
ism(s) of such interactions, and also to examine whether 
other interactions of this nature might occur in vivo, the 
activity of pairs of inhibitors was •studied with particular 
reference to the two groups separated by the light scattering 
data. 
The findings presented here and the results and 
proposals of other workers which directly or indirectly 
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substantiate the conclusions reached, are discussed in terms 
of the structure-activity relationship of inhibitors and the 
secondary factors influencing inhibitor power. 
5.2 	METHODS 
5.2.1 MONITORING OF THE CONVERSION PROCESS 
Monitoring of the conversion process was achieved 
by measuring three parameters: 
a. Base titration  
The base titrimetric method was essentially that 
described by Meyer and Eanes (1978a),outlined in the preced-
ing chapter (4.3.1). 
b. Calcium-ion activity 
A calcium-ion selective electrode (Type F2112Ca) and 
a reference electrode (Type 90-01) from Radiometer,Copenhagen, 
Denmark, were immersed in the stirred suspension. The system 
was calibrated with Ca + + -NFTA buffers from 5 x - 10 -5 to 5 
x 10 ++ -3 mM Ca enabling direct determination of ion activity 
without computation. 
c. Turbidity  
A laser light beam (laser model KED-1, 633nm from 
Laser Electronics, Queensland, Australia) was directed through 
the suspensions to impinge on a cadmium sulphide light 
dependent resistor (ORP 12) with a peak spectral response 
of 610nm (Radiospares Components, Subiaco, Western Australia). 
Signals from both the detector and calcium-ion selective elect-
rode were fed through a voltage amplifier and outputs were 
coupled to a two-pen 10mV potentiometric recorder. The turbid-
imetric system was calibrated with suitable filters. Variation 
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in background light intensity,which initially led to instability 
in the traces, was eliminated by masking the sides of the 
water bath with black plastic. The use of laser light for 
turbidity measurements eliminates problems with UV light 
requiring monitoring in stirred cuvettes (Termine and Eanes, 
1972) , whereby turbidity and base titration could not be 
simultaneously monitored as the mixture required strong 
buffering with Tris. 
Figure 5.1 illustrates the method used to calculate 
data. An upward deflection of the pen represents increasing 
turbidity associated with a change of ACP into HAP. Tangents 
were drawn to the flattest part of the traces representing 
the pre- and post-transformation period as shown by the 
dotted lines. The differences between these two values was 
designated AA 633 . Data from base titrimetric and calcium-
ion activity measurements were calculated in an identical 
fashion. 
The precise time at which the conversion process starts 
(i.e. the induction time: I ) was determined as described 
by Meyer and .Eanes (1978a) and, as illustrated in Figure 
5.1 , it is the point of intersection of the tangents to the 
flattest portion of the pre-transition period and the steepest 
part of the transformation period. The value for I t could 
be calculated from any of the three parameters monitored 
since they changed simultaneously. 
5.2.2 TRANSMISSION ELECTRON MICROSCOPY (TEM) 
Prior to and during the transformation process, aliquots 
of the reaction mixture were removed for TEM analysis. Drop-
lets were placed on formvar-coated grids and excess liquid 
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Figure 5.1 Change in turbidity with time and the method 
of calculating the induction time (I t ) 
*AA633 is the change in turbidity associated with the conversion 
process. 
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removed after 30s by touching the edges with filter paper 
( Eanes et al., 1976). Following air-drying the specimens 
were examined in an Hitachi H300 electron microscope at 
75kV. In some instances samples removed after the transition 
were filtered (Millipore membrane, 0.45 p m) and the solid 
embedded in Epon before sectioning ( Francis, 1969). 
5.3 	RESULTS  
In the preceding chapter it was noted that a plot 
of I against inhibitor concentration indicated that as 
inhibitors PC >> ATP > EHDP > citrate. Notably, although citric 
acid was a very weak- inhibitor, the incorporation of a phos-
phate group into the molecule in PC produced powerful inhib-
ition. Figure 5.2 shows the inhibitory ability of PNP , 
PP . and phosphonoformate; they all inhibit indicating that 
multiple carboxyl groups, whilst enhancing inhibitory ability, 
are not the minimum requirement for potent inhibition. Any 
compound with a phosphate group - and an acidic group, either 
a carboxylic or phosphate group , for example phosphonoformate, 
will potently inhibit. 
To determine the effect of inhibitor power of the 
proximity of relevant groups, the potency of phosphonoformate, 
2-phosphoglycerate and 3:phosphoglycerate were compared 
as shown in Figure 5.3. Data show that the shorter the bond-
ing between phosphate and carboxylic groups, the more power-
ful the inhibitor is since PF > 2-PG > 3-PG. In other experi-
ments compounds such as o-phosphoserine and o-phosphothreon-
ine which were tested to investigate the effect of amino group 
substitution, failed to inhibit over the same concentration 
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Figure 5.2 Inhibitory ability of imidodiphosphate (PNP), 
pyrophosphate (PP i ) or phosphonoformate (PF) 
over a concentration range. 
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Figure 5.3 Effect of increasing concentrations of phosphono-
formate ( PF ) , 3-phosphoglycerate (3-PG) and 
2-phosphog lycerate ( 2-PG) on I t . 
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range. Similarly, no inhibition occurred with fructose 1- 
phosphate, EGTA, E-nitrophenyl phosphate and the carboxylic 
acids: formic, succinic, malic and oxalic acids. 
The effect of substituting sterically bulky groups 
onto an inhibitor, and the influence of the number of active 
groups present,was examined using ATP, ADP, tripolyphosphate 
and PP . . The results are shown in Figure 5.4 indicating 
that inhibitor power increases with the number of active 
groups, in this instance phosphate groups. The sterically 
bulky adenosine moiety decreases inhibitor potency since 
ATP is not as powerful as Aripolyphosphate nor ATP as 
PP. . To evaluate the possibility that the bond angle between 
the active groups modulates inhibitor power, phosphoenol 
pyruvate was compared with phosphonoacetate at particular 
concentrations. At 50 pM phosphonoacetate inhibited but no • 
effect was seen with phosphoenol pyruvate - even at 300pM. 
In order to further investigate the effect of an inhib-
itor on the precipitation of ACP and its subsequent trans-
formation into HAP, the magnitude of base uptake, calcium-
ion depletion and turbidity change ( AA 633 ) associated with 
the transition was compared over a range of inhibitor concent-
rations. It is evident from the base uptake curves alone 
that inhibitors affect the conversion process in either of 
two ways. As shown in the preceding chapter (see Figure 
4.3, Section 4.4.1.1), ATP does not alter the amount of base 
consumed during the transformation, whereas EHDP causes 
a decrease in base consumption. It is data from the effect 
of inhibitor. concentration on AA633 however, that more defini-
tively separate inhibitors into two classes which are referred 
25 	50 
[ Inhibitor] ( pM) 
75 	100 
144 
Figure 5.4 Effectiveness of ATP. ADP, tripolyphosphate 
(PPP i ) and pyrophosphate (PP i ) as inhibitors 
of HAP formation: influence of the number 
of P . groups on inhibitory power and modification 
by the presence of adenosine 
A--A. PPP. 
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to here as Type I and Type II inhibitors. Typical results 
are shown in Figure 5.5 for a Type I inhibitor ( EHDP ) and 
indicate that the magnitude of the turbidity change 
( AA 633 ) reaches a maximum at a particular concentration 
( for example, with EHDP it is 40 pM) . At higher concentrations 
AA  633 rapidly decreases concomitant with a rapid reduction 
in base uptake and calcium-ion depletion from solution. Figure 
5.6 gives typical results for a Type II inhibitor (ATP) 
indicating that in contrast to Type I inhibitors they do not 
affect A A 633 the amount of base uptake nor calcium-ion ' 
depletion. A range of inhibitors has been tested in this fashion 
and, when data are plotted for each inhibitor, graphs take 
either of the two forms shown in Figures 5.5 and 5.6 , thus 
enabling umambiguous grouping of the compounds. 
Selected data from such groups are tabulated in Tables 
5.1 and 5.2. For Type I inhibitors the concentration eliciting 
the maximum AA 633  is given in Table 5.1 , together with _a 
higher and lower concentration for contrast. The effect of 
these concentrations on the amount of base uptake, Ca ++ - 
ion depletion and I is also given. With Type II inhibitors, 
representative concentrations over a broad range are tabulated 
in Table 5.2 which gives their effect to delay the onset of 
the transformation ( i.e. the induction time, I t ). Type I 
inhibitors then, include ( in order of potency) : PC, EHDP , 
tripolyphosphate , imidodiphosphate and PP i . Type II inhibitors 
include: ATP, ADP, phosphonoformate , 2-phosphoglycerate, 
3-phosphoglycerate, Mg +4- and citrate. 
The morphology of the calcium phosphate particles 
formed in the presence or absence of inhibitors from either 
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Figure 5.5 Effect of EHDP concentration on the transformation 
of ACP into HAP. 
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Figure 5.6 Effect of ATP concentration on the transformation 
of ACP into HAP. 
• 	turbidity change at A 633 
	• amount of base uptake 
amount of calcium-ion depletion 
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Table 5.1 Effect of increasing concentration of Type I inhibitors on the 
parameters defining the ACP to HAP transformation. 
INHIBITOR 
	
[INHIBITOR] ( pM) e A633 eCa++ (mM) OH (mM) 	I t (min) 
None 	 0.44 	1.3 	0.75 	17 
PC 	 10 	0.60 	1.3 	0.74 	22 
25 	0.96 	1.2 	0.70 	35 
40 	0.45 	0.3 	0.35 	65 
EHDP 	 15 	0.50 	1.3 	0.75 	22 
40 	0.80 	1.0 	0.70 	32 
55 	0.37 	0.3 	0.25 	53 
Tripolyphosphate 	 15 	0.60 	1.3 	0.75 	19 
45 	0.98 	1.2 	0.72 	33 
70 	0.48 	0.4 	0.25 	58 
lmidodiphosphate 	 15 	0.70 	1.3 	0.75 	19 
45 	1.00 	1.0 	0.65 	30 
70 	0.32 	0.3 	0.20 	54 
Pyrophosphate 	 15 	0.60 	1.3 	0.75 	18 
55 	0.96_ 	1.0 	0.65 	35 
80 	0.45 	0.3 	0.25 	60 
The parameters defining the transformation (AA633'  ACa ++ ,A0H) were measured. 
as described in the text. 
Table 5.2 	Effect of increasing concentration of Type II inhibitors on I t . 
INHIBITOR 
CONCENTRATION ( pM) 
15 30 50 100 150 200 300 
ATP 20 22 35 > lh >lh >lh > lh 
ADP 18 20 30 >48 >lh >lh > lh 
Phosphonoformate 17 20 28 45 >lh >lh > lh 
2-phosphoglycerate 17 18 22 .30 41 52 > lh 
3-phosphoglycerate 17 17 18 21 27 33 49 
Mg2+ 17 17 18 21 25 29 36 
Citra-te 17 17 18 19 21 23 27 
Data shown represent time of induction (I t ) at selected concentrations and, unless otherwise shown, the time 
given as expressed in minutes. 
The parameters defining the transition (A A 633,A  Ca
++, AOH) did not change from the control values listed in 
Table 5.1. 
>lh indicates no transformation was detected over the time period monitored. 
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group was compared. Samples were taken for TEM analysis 
before; during and after the transformation, and Plate 5.1 
shows the typical appearance of spherical particles before 
the transition and of needle-like particles after the 
transition. 
The initial spontaneous precipitation of ACP due to 
the addition of base appeared unaltered by the presence 
of inhibitors, an observation also supported by light scatter-
ing and calcium-ion activity measurements. Subsequently, 
as described by Eanes et al. (1976), the spheres increased 
in diameter, although addition of an inhibitor caused a 
decreased rate of growth of the ACP spheres. Just prior to 
the transformation all particles were of similar appearance, 
but during the transition a change in morphology becomes 
evident with the spheres of ACP appearing indistinct and 
needle-like deposits appearing - again . a phenomenon previous-
ly noted (Eanes et al., 1976). After the transition, needles 
of HAP usually appear except when high concentrations of 
Type 1 inhibitors are present. Furthermore, the turbidity 
of the suspensions then remained essentially constant over 
the time monitored (30-60 min) suggesting the time course 
of the Ostwald ripening process (Despotovic et al., 1975; 
Nancollas and Mohan, 1970) was too long for detection in 
these experiments. 
As shown in Chapter 4,synergism between Mg ++, citrate 
and PC exists for the inhibition of HAP formation. Whereas 
the interactions between mg ++ and citrate, and PC and 
Mg ++ could be rationalised as due to chelation, it was 
noted that the interaction between PC and citrate could not 
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Plate 5.1 Typical transmission electron micrographs (TEMs) 
of calcium phosphate deposits. 
A : before conversion (x200,000) 
B : after conversion (x400,000) 
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be so well understood. However, the results in this chapter 
indicate that PC and citrate are of different inhibitor types 
(as defined here) and act by different mechanisms. This 
partially substantiates the claim made in the preceding 
chapter that they bind to different sites to efficiently block 
active growth sites. To examine whether this observation 
was an example of a general phenomenon, pairs of inhibitors 
(either from the same group or one from each) were tested 
and the results are given in Table 5.3. When pairs of inhib-
itors were from the same group no synergism was observable: 
the effect on I was purely additive. Notably however, when 
one inhibitor was Type I and the other Type II, synergism 
was apparent. 
5.4 	DISCUSSION  
The finding that PC (a polycarboxylic monophosphate) 
inhibits HAP formation requires a re-appraisal of the suggest-
ion that at least two ester phosphates need to be present. 
The observation that phosphonoformate and phosphonoacetate 
- carboxylic monophosphates 
- 
potently inhibit, whereas 
carboxylic acids do not, suggest that for potent inhibition 
the minimum structural requirement is a phosphate group 
and an acidic group, either a carboxylic or preferably an 
additional phosphate group. This latter consideration arises 
from the fact that, for example, pyrophosphate is a more 
potent inhibitor than phosphonoformate. 
There are situations nevertheless, where this rule 
needs qualification: polycarboxylic, phosphate-free molecules 
will inhibit (Hay et al., 1979), but the minimum number 
Table 5.3 	Effect of compounds on the 	inhibition 	of 	hydroxyapatite 	formation 	when 	added in pairs. 
COMBINATION* INHIBITOR 
TYPE A 1 t (min) 1- 
	t, It (exp. ) 	DIFFERENCE 	(min) [t, It -Alt (exp.)] 	
SYNERGISM 
PC 1 20 
PNP 1 33 
3-PG 11 9 
Cit. 11 32 
PA 11 16 
PC + 3-PG 1 	+ 	11 41 	 29 	 +12 YES 
PC + PNP 1 	+ 	1 54 54 . 0 NO 
Cit. 	+ PNP 11 	+ 	1 100 	 49 	 +51 YES 
PA + PNP 11 	+ 	1 81 64 +17 YES 
PA + Cit. 11 	+ 	11 48 	 48 	 0 NO 
3-PG + Cit. 11 	+ 	11 28 26 +2 ° NO 
PA + 3-PG • 11 	+ 	11 41 	 40 	 +1 ° NO 
Abbreviations: PC = phosphocitrate , PNP = imidodiphosphate , 	3-PG = 3-phosphoglycerate, 	cit. = 	citrate, 
PA = phosphonoacetate 
Amounts used were : 3.3mg PC, 12mg PNP , 16mg 3-PG, 76mg cit. , 20mg PA 
-I- 1 t s were determined at pH 7.4 , 20 °C, as described in the text. 
Al t (expected) was calculated on the basis of an additive effect of inhibitors on HAP formation. 
°Differences are not significant. 
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of carboxylic groups required for inhibition is as yet 
unknown. Formic and oxalic acids do not inhibit, but 
citric acid is a very weak inhibitor. 	Notably, 	the 
dehydroxyl 	and 	dehydro 	derivatives 	of citric 	acid, 
namely tricarballylic acid and aconitic acid, 	fail to 
inhibit (Tew et al., 1980) so the hydroxyl group, perhaps 
due to its position in a tetrahedral environment, must be 
associated with the weak inhibitory ability of citrate. 
Certainly it has been implicated in the Ca-binding ability 
of citrate (Kieboom et al., 1978). However, as indicated by 
the ability of phosphonoacetate and phosphonoformate to potent-
ly inhibit HAP formation, hydroxyl groups in compounds with 
phosphate groups are not needed for potent inhibition . 
Further; :3-phosphoglycerate inhibits, ULAL in contra.s- t 
phosphoserine, in which the hydroxy group is replaced by 
an amino group, does not inhibit over the concentration range 
studied. Thus, although amino acids bind to HAP (Kresak, 
1977) the amino group must alter the binding characteristics 
sufficiently to abolish inhibition. 
The types of functional groups are of primary import-
ance in determining whether a compound inhibits or not, 
but secondary factors, including (i) the number of active 
groups, (ii) their proximity, (iii) stereochemical arrangement, 
(iv) steric factors, (v) lipophilicity, and (vi) lability 
of the molecule, also influence inhibitor potency. 
In general, as the number of anionic groups increases 
so does inhibitor power. Thus ATP is more powerful than 
ADP, tripolyphosphate is better than PP i , and PC is stronger 
than 2- and 3-phosphoglycerate. As mentioned above, 
sufficient carboxylic groups will confer inhibitory activity 
on a molecule but, as with all inhibitors, the potency of 
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inhibition is modified by the proximity of the active groups 
and their stereochemistry. 
The proximity of the groups is vital since the closer 
the anionic groups the more strongly a molecule inhibits 
HAP formation. Thus phosphonoformate is more potent than 
2-phosphoglycerate which is more powerful than 3-phospho-
glycerate. With macromolecular inhibitors this also holds 
since polyaspartate is more potent than polyglutamate of 
similar molecular weight (Hay et al., 1979). Further, it 
follows that a linear arrangement of active groups should 
be less potent than an irregular arrangement which allows 
for a closer 'packing' of active groups. This may explain 
in part why PC is so much more potent than tripolyphosphate. 
The results presented here also permit another 
important stereochemical factor to be elaborated: the hybrid-
ization of the atom 'radiating' chelating side arms. This 
appears to be important since it has been noted that EHDP 
is a disproportionately stronger inhibitor than nitrilotri 
(methylene phosphonic acid) when assessed on the number 
of anionic groups present (Meyer and Nancollas, 1973). Thus 
the stereochemical arrangement of chelating groups about 
the tetrahedral 'sp 3 ' carbon is more suitable to binding 
to active sites than about a trigonal nitrogen. Again, such 
stereochemical considerations may be another reason phospho-
citrate is such a potent inhibitor. If the anionic groups 
are bound to an 'sp 2 ' hybridized carbon (i.e. double bonded 
carbon), the molecule no longer inhibits as indicated by 
the fact that the inhibition is seen with phosphonoacetate 
but not with phosphoenol pyruvate. This may reflect that 
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the altered ' sp 2 , bond angle splays out the chelating groups 
so that they no longer bind sufficiently to the active sites. 
The effect of substitution of a sterically bulky group 
onto a parent inhibitor is demonstrated by PP i and ADP. 
The inhibitory capability of ADP in comparison is decreased, 
perhaps reflecting decreased ability to fully bind the active 
sites. This phenomenon has also been observed by Hay et 
al. (1979 ) ; digestion of macromolecular inhibitors yielded 
fragments showing more potent crystal-growth inhibition. 
In general then, molecular size opposes the effects of increas-
ing the number of groups and proximity by rendering binding 
to active sites less efficient. 
Compounds tested in this study were hydrophilic but 
it should be noted that certain anionic molecules may disrupt 
HAP formation by a unique mechanism. Wuthier and Eane s 
(1975 ) have shown that anionic phospholipids , phosphatidyl 
serine for example, will stabilise ACP if added after initial 
precipitation. However, if the amorphous precursor is formed 
in the presence of phosphatidyl serine then its inhibitory 
effect is not as •pronounced. It was suggested that this was 
due to phosphatidyl serine altering the structure of the 
amorphous phase by micelle formation, such that its surface 
area was increased, aiding the surface-dependent processes 
involved in HAP formation. According to the criteria outlined 
here, phosphatidyl serine should not be an inhibitor, and 
indeed the concentrations required by Wuthier and Eanes 
(1975 ) to produce inhibition are too high for it to be consider-
ed as a potent inhibitor. 
From the data presented here it is evident that as 
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inhibitors EHDP > imidodiphosphate > PP. . The order may be 
partly explained by increasing lability on calcium phosphate 
surfaces which are known to catalyse tra-nsphosphorylation 
reactions (Francis, 1969; Krane and Glimcher, 1962; Fleisch 
et al., 1968). Blumenthal et al. (1977) have proposed 
that ATP inhibits HAP formation until a sufficient amount 
is removed by hydrolysis, whereas Hay et al. (1979) have 
suggested that for stable peptide inhibitors precipitation 
occurs when the inhibitor concentration has been reduced 
by interaction with newly formed nuclei. For the phosphoric 
ester compounds studied in this work, it is probably a 
combination of these processes that eventually permits trans-
formation of ACP into HAP. 
All anionic inhibitory compounds are Ca ++ chelators, 
but inhibition is not due to chelation in itself since EGTA 
does not significantly inhibit HAP formation. Neither is activ-
ity due to the attachment of a sterically bulky group to 
a phosphate moiety since p-nitrophenyl phosphate (with a 
P-O-C linkage) and 1- and 2-aminoethyl phosphonic acid 
(with a P-C linkage) failed to inhibit the transformation. 
Inhibition might have been expected if it was difficult to 
incorporate sterically bulky molecules into the HAP lattice, 
thus making HAP formation energetically less favoured. 
What appears obligatory for inhibition to occur is 
adsorption onto calcium phosphate surfaces. This is a well-
known process, HAP adsorbing, for example, nucleotides 
(Kawasaki, 1978), pyrophosphate (Fleisch et al., 1968), 
phosphonates (Francis, 1969) , and, as shown here, PC and 
citrate. ACP also adsorbs compounds of similar types (Termine 
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and Conn, 1976). By measuring the surface area of HAP, 
Meyer and Nancollas (1973) showed that inhibitors do not 
cover the entire surface, leading to the proposal that inhibit-
ors act by binding to active growth sites which are defect 
sites in the crystal lattice, a phenomenon general to all 
crystal types. The results presented here concur with the 
proposal of adsorption being a universal feature of inhibition, 
but turbidimetric, base titrimetric and calcium-ion activity 
measurements have allowed recognition of two inhibitor types 
(see Figure 5.5 and 5.6). 
TEM evidence - indicates that prior to transformation 
ACP spherules in all cases are of similar appearance. After 
the transformation, however, aggregates of needle-like 
deposits are visible, although dimensions of the individual 
particles are too small for comparative measurements. Since 
the amount of post-transitional solid found in the presence 
of Type I inhibitors at the maximum change in turbidity, 
as indicated by calcium and base titrimetric measurements, 
is marginally less than with the control or with Type II 
inhibitors (see Figure 5.6), the magnitude of the turbidimetric 
changes is interpreted as due to the formation of many, 
very small particles during the conversion process. In 
contrast, Type II inhibitors do not alter the dimensions of 
the particles involved in the transition compared to the 
control, even though the onset of the conversion process 
is delayed, sometimes as long as with Type I inhibitors. 
Hence the grouping does not just reflect the inhibitor potency. 
Needles of HAP are usually formed after the conversion 
process; this does not happen when a sufficiently high 
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concentration of Type I inhibitor is present. No transformation 
occurs and ACP spherules are indefinitely stabilised. With 
concentrations of Type I inhibitors a little less than that 
shown to be required to completely block conversion, it is 
still possible to detect a small degree of transformation - 
for example 10% of the control value at 604M EHDP (see Figure 
5.6) - but not enough for TEM to reveal HAP needles. 
Although no direct evidence is presented here, it might be 
predicted that at some concentrations of Type I inhibitors, 
when ACP is only partly converted to HAP, ACP spherules 
co-exist with HAP needles after the incomplete transformation. 
Whatever the morphological subtleties that are respons- 
ible for the nature of the turbidity changes, the - fact remains 
that turbidimetric data ( AA 633)  clearly group inhibitors into 
two classes. It is suggested that the phenomenon underlying 
this observation is that Type I inhibitors are crystal growth 
inhibitors and in fact most of them are established as such. 
Potent inhibition is not due to calcium chelation - itself but 
is considered to be the result of adsorption onto ACP and 
HAP (Meyer and Nancollas, .1973; Fleisch et al., 1968). Type 
I inhibitors then, in a rationale based on the work of Posner 
and his co-workers (Posner and Betts, 1975; Posner et al. , 
1978), stabilize HAP embryos and inhibit subsequent growth 
by binding to active sites and poisoning heterogenous nucleat- 
ion. At high concentration of inhibitors, embryos fail to 
reach their critical size and re-dissolve which explains the 
decreasing turbidity change. The concomitant fall in base 
consumption and calcium-ion depletion confirms the decreasing 
extent of conversion of ACP to HAP occurring at these concent- 
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rations as do TEM data. Type II inhibitors, in comparison, 
are considered to act mainly by decreasing the lability of 
ACP . Both classes bind to ACP and HAP ( Termine and Conn, 
1976; Tew et al., 1980) and it therefore appears that Type 
I ( crystal-growth) inhibitors either bind with higher affinity 
to the defect sites on HAP from which crystal growth proceeds, 
or that these sites are different to those bound by Type 
II inhibitors, or both. There is ample evidence for both 
processes. For example, nucleotides elute off HAP chromato-
graphy columns in an order reflecting binding affinity 
(Kawasaki, 1978 ) . As to the nature of the binding sites on 
HAP, there is evidence indicating multiple binding sites exist 
even for closely related inhibitors. For example, Jung et 
al. (1973 ) have demonstrated that there are two classes of 
Ebinding sites for PP . , 	HDP and C1 2 MDP and furthermore, 
that at high concentrations of PP . 	HAP binds more inhibitor 
molecules than can be predicted by the Taves and Reedy 
(1969 ) model. 
Although inhibitors have been grouped into 
two types based on the manner by which their increasing 
concentration affects the parameters defining the transition, 
it does not necessarily indicate that only two mechanisms 
underlie this division. With Type I (crystal-growth) inhibitors 
it is likely that binding to active growth sites on HAP is 
the fundamental mechanism, although, as has been mentioned, 
it is possible that even closely related compounds, such 
as PP i and the diphosphonates , may bind to different sites 
on HAP and with varying affinities. With Type 11 inhibitors 
ACP is considered to be the main locus of action ; but diverse 
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mechanisms must be responsible for their inhibitory action 
since, for example, Mg ++ and citrate 3- will bind to different 
sites. 
Further, it has been suggested that ATP prevents 
HAP embryo formation until it is removed by surface-catalysed 
hydrolysis (Blumenthal et al., 1977) ; Type II inhibitors 
such as citrate and phosphonoformate, which are not hydro-
lysed, cannot inhibit by this mechanism. 
The recognition that inhibitors may or may not affect 
the extent of conversion is not new. Blumenthal et al. (1975 ) 
found that HAP formed in the presence of ATP was crystalline; 
with EHDP present HAP was only partly crystalline. This 
is consistent with the rationale presented here. The suggestion 
that some inhibitors do not alter the dimensions of the part-
icles involved, again, has been observed previously. Boskey 
and Posner (1974) demonstrated that Mg, a Type II inhibitor 
- 
from our data, did not alter the dimension of the crystallites 
formed relative to the control, and suggested that this was 
due to its locus - of action being ACP . This is exactly what 
is proposed here for all Type II inhibitors : the apparent 
primary site of action is at the ACP surface. Type I inhibit-
ors also possess the capacity to decrease ACP lability, but 
it is secondary to the crystal-growth poisoning ability. 
The synergism demonstrated to occur when a Type 
I and Type II inhibitor are added together can be understood 
on the basis of binding to different active sites on ACP and 
HAP. When this occurs such an efficient coverage of the 
surfaces is achieved that growth and nucleation are more 
effectively hindered than in the presence of just Type 
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or Type II inhibitors. It is in this context that the synergism 
between PC and citrate, described in the previous chapter, 
can be considered. The phenomenon of synergism emphasises 
that in physiological fluids complex interactions between 
ions may occur. 
The data reported here then, allows for the prediction 
of compounds that will inhibit HAP formation, and offer a 
preliminary estimate of potency. An explanation has been 
given of the mechanisms at the calcium phosphate surfaces 
which may underlie the separation of inhibitors into two 
classes, - but, as yet, no attempt has been made to elucidate 
any structural features of a molecule which will a priori  
indicate whether it is a Type •I or Type II inhibitor. Indeed, 
no obvious pattern readily emerges, but it is tempting to 
ascribe Type I inhibition to the presence of one phosphate 
group and, in close proximity, either another phosphate 
or multiple carboxyl groups. However, nucleotides need special 
consideration because whereas ti . ipolyphosphate and PP i are 
Type I inhibitors, ATP and ADP are Type II inhibitors. 
PP. is not completely hydrolysed before transformation 
(Fleisch et al., 1968), but it could be that nucleotides are 
hydrolysed before the conversion process can occur. Certainly 
this has been shown for ATP (Blumenthal et al., 1977) but 
evidence is lacking on the stability of ADP under these 
conditions. If ADP is not hydrolysed it may be that it binds 
poorly to those active sites on HAP that bind Type I inhibit-
ors, perhaps due to the sterically bulky adenosine group. 
Kawasaki(1978) has shown that the adenosine moiety sterically 
obstructs one C site per molecule and in our rationale this 
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decrease in coverage may be sufficient to permit HAP crystal 
growth to proceed unhindered, at least over the concentration 
range studied here. Alternatively, it may be that this inability 
of ADP, and indeed ATP, to bind as efficiently as PP and 
tripolyphosphate to HAP embryos, makes them more susceptible 
to the surface-catalysed hydrolysis. Whatever the active 
site ( s ) , the decrease in accessibility of ADP and ATP ( relative 
to pyrophosphate and tripolyphosphate) for these binding 
sites is likely to explain the profound difference in inhibitory . • 
types. This accessibility consideration consequent upon the 
molecular weight, together with the nature of groups outlined 
above, gives some criteria for predicting which group an 
inhibitor may be placed. 
The study described here has confined itself essential-
ly to low molecular weight compounds that potently inhibit 
HAP formation, that is increase I at low concentrations 
( 5-100 pM) and these inhibitors appear to fall into two groups, 
Type I or .Type II inhibitors. . However, this finding does 
not preclude the possibility that there may be other types 
of inhibitors which affect the ACP to HAP transition in a 
different manner. For example, it has been suggested that 
bulky anionic macromolecules can bind to ACP and HAP 
sufficiently to sterically interfere with the conversion process 
( Hay et al., 1979; Blumenthal et al., 1979) . This appears 
to result in proteoglycans not signficantly affecting It  but 
decreasing the rate and extent of the trans formation 
( Blumenthal et al., 1979 ) at concentrations too high for these 
polysulphonated macromolecules to be considered potent inhib-
itors in vitro. This is consistent with the data presented 
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here on the structure-activity relationship of low molecular 
weight inhibitors but does indicate that macromolecules open 
up new mechanistic possibilities for inhibition. 
The results presented in this chapter have led to 
the proposal of guidelines which allow prediction of the ability 
of a molecule to inhibit HAP formation. Secondary factors will 
influence the degree of potency exhibited and also determine 
if a molecule is an inhibitor of crystal-growth or not. 	This 
latter characteristic is the basic difference between the two 
groups or inhibitors that have been recognised in this study. 
5.5 	SUMMARY  
1. The transition of ACP into HAP can be monitored 
++ by not only base titration but also Ca 	-ion activity in 
solution, and turbidity. 
2. Inhibitors of the ACP-HAP transformation must 
possess at least one phosphate group and either a carboxylic 
moiety or preferably a phosphate group; otherwise they will 
not be potent inhibitors. 
3. Secondary factors influence inhibitory . ability: 
(i) the number of active groups, (ii) their proximity, (iii) 
stereochemical arrangement, (iv) steric factors, (v ) lipophil-
icity, and (vi) lability of the molecule. 
4. Low molecular weight inhibitors can be grouped 
into two classes depending on how they affect the parameters 
defining the transition of ACP into HAP: Type I (crystal 
growth) and Type II inhibitors. 
5. Type I inhibitors are crystal-growth inhibitors 
and at high concentrations indefinitely stabilise the ACP 
spherules. 	PC, 	EHDP , 	tripolyphosphate, 	imidodiphosphate 
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and PP. are Type I inhibitors. 
6. Type II inhibitors act by a variety of 
mechanisms but do not alter the dimensions of the HAP 
crystallites formed after the conversion of ACP. Type II 
inhibitors are: ATP, ADP, phosphoformate, 2-phosphoglycerate, 
3-phosphoglycerate, Mg ++ and citrate. 
7. A compound with a phosphate - _ group and, 
in close proximity, either another phosphate group or multiple 
carboxyl groups will be a Type I inhibitor provided no bulky 
side-groups are present. 
8. Pairs of Type I inhibitors, or pairs of Type 
II inhibitors have an additive effect on inhibition. Type 
I and Type Ii inhibitors added together have a synergistic 
effect. 
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CHAPTER 6 
THE NATURAL OCCURRENCE OF PHOSPHOCITRATE 
6.1 INTRODUCTION  
The potent inhibitory activity of PC in vitro emphasises 
the need to prove whether or not PC occurs in biological 
tissues, and if it does, whether it could exert an influence 
on biological calcification systems. Although the properties 
of the molecule strongly support the contention that its 
physiological role is in controlling calcification, there is 
no conclusive evidence to date that PC has ever been isolated 
and confirmed as a natural biological inhibitor. Indeed 
Lehninger (1977), in his reported studies, suggested that 
the inhibition seen might not be due to PC but to some 
impurity isolated in the fraction supposedly containing PC. 
On the other hand, Tew et al. (1978) concluded that since 
a fraction isolated from mitochondria by ion-exchange chromat- 
ography inhibited the transformation of ACP into HAP, it 
therefore contained PC. However, the agent responsible for 
inhibition cannot be unambiguously identified in this manner, 
since many compounds inhibit the transformation process. 
Howard (1976) made a tentative proposal that the 
biological inhibitor isolated by ion-exchange chromatography 
from urine and mitochondria was PC. However, the lability 
of the biological inhibitor recorded some years earlier by 
Howard et al. (1967) did not match the data published by 
Meyer et al. (1959) on the lability data for ?C. Further, 
Howard presented evidence suggesting that the biological 
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inhibitor could be formed artificially on the ion-exchange 
column merely by eluting citrate and phosphate under acid 
conditions. Therefore the question of whether PC did indeed 
occur biologically, or was only an artefact of the 
chromatographic procedure, remained unanswered. 
The problems encountered by these workers have now 
been overcome by the methodology developed here permitting 
isolation of material from biological sources and its 
subsequent comparison with synthetic PC. Further, although 
NMR spectral data together with mass spectroscopy provide 
information on the structural nature of a compound, unfortun-
ately it is not always possible to obtain sufficient amounts 
from biological material for analysis by these methods. 
Consequently a. more versatile approach has been adopted, 
whereby a range of techniques are used for characterising 
PC, more valuable than using any single' technique. One 
other possible criticism has already been eliminated, namely 
the demonstration that chromatography at neutral pH avoids 
• PC artefact formation. The data also indicate that acidific-
ation and neutralisation does not cause PC production, 
justifying the use of acid extraction techniques for tissue 
preparation. 
This chapter, therefore, reports on the use of ion-
exchange chromatography to isolate naturally-occurring PC 
from various sources and its subsequent detection 'and 
characterisation by a range of techniques, including enzymatic 
and chemical citrate assays, TLC, analytical isotachophoresis 
and high-voltage electrophoresis. Kidney, intestine and bone, 
which are the primary sites of Ca ++ metabolism, were 
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investigated because PC can influence calcifying systems. 
Liver was also included for comparison. In addition, normal 
urine was also investigated to determine if PC was present, 
since under pathological conditions calcifications may form 
in the urinary tract. 
6.2 	METHODS 
6.2.1 COLLECTION AND TREATMENT OF BIOLOGICAL SAMPLES 
6.2.1.1 Whole tissue  
The possibility that PC occurs in nature was initially 
exainined by subjecting biological extracts to chromatography 
and analysing relevant fractions. The biological extracts 
were prepared from kidneys, liver or intestine excised from 
animals (rats or rabbits) killed by cervical dislocation. 
Metabolic transformation (if any) of PC was minimised by 
freeze-clamping the tissue samples on excision. The frozen 
tissue was then pulverised in a stainless steel pestle and 
mortar, and the powder added to ice-cold perchloric acid 
(10m1/g tissue) for protein denaturation. 
6.2.1.2 Bone  
Bone was collected essentially as described by Perkins 
and Walker (1958). Tibias and fibias were dissected free 
from adherent tissue before the bones were split and the 
marrow removed using a jet of water. The bones were stored 
in liquid nitrogen before being pulverised. The bone. fragments 
were suspended in ice-cold 0.5M HC10 4 
(5m1/g), Dowex 50W-
X8 (lg/g bone) added and the mixture vigorously stirred 
for several hours. It was evident that not all of the bone 
fragments had been completely dissolved but a sample for 
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analytical purposes was obtained after filtering the mixture 
to separate the resin and bone particles from extracted 
compounds. 
6.2.1.3 Urine 
Mid-morning (9-11 a.m. ) urine samples were collected 
from male medical students in two 10L flasks containing a 
few crystals of thymol each. Urine, so collected was processed 
within 8h. Between 2 and 6L of urine was filtered through 
a Hollow Fibre Dialyser/Concentrator (Amicon Model DC2) 
giving a filtrate that was immediately loaded onto a column 
of AG 1-X8 (HCO - ). 3 
6.2.1.4 Mitochondria  
6.2.1.4.1 	Kidney and liver 
The • procedure used to isolate mitochondria 
from kidneys and liver was essentially that of Bustamante 
et al. (1977). Accordingly, excised tissue was cleansed of 
connective tissue, blood and fat before mincing with scissors 
to fragments smaller than 0.5 x 0.5cm. A suspension of 
fragments in ice-cold 0.25M sucrose, 0.15mM EDTA and 0.01M 
Tris-HC1, pH 7.4 (10m1/g tissue) was homogenised using a 
chilled Potter-Elvehjem glass homogeniser and a motor-driven 
Teflon pestle. Three strokes of the pestle were sufficient 
to prepare the homogenate which was then' layered over 0.34M 
sucrose (10m1/30m1 of homogenate). The tubes were centrifuged 
800g for 10 min at 2 ° C before 0.25M sucrose layer was 
removed by pipette. The 0.25M sucrose suspension was then 
centrifuged at 10,000g for 15 min to give a pellet containing 
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mitochondria. The supernatant was poured off and the 
mitochondrial pellet resuspended in 0.25M sucrose before 
centrifugation for 15 min at 10,000g. The supernatant was 
again poured off, the pellet suspended in 0.25M sucrose and 
the volume of the mitochondrial suspension recorded. An 
aliquot (0.5m1) was taken for subsequent analysis. To the 
bulk suspension an equal volume of ice-cold 1.0M HC10
4 
was 
added. This suspension was homogenised in a Potter-Elvehjem 
glass homogeniser by two strokes of the Teflon pestle before 
the protein and perchlorate were removed by centrifugation. 
6.2.1.4.2 	Intestine 
Rat intestinal mitochondria were prepared as 
outlined by de Jong et al. (1978). The small intestine from 
the ligament of Treitz to within ca. 10cm of the ileocaecal 
sphincter was excised and immersed in ice-cold isolation 
medium comprising 0.154M NaC1, 10mM Tris-HC1 and 5mM EDTA, 
pH 7.4. A glass canula was inserted in one end and held 
in place with cotton thread, whilst the luminal contents were 
flushed out using a 10m1 syringe filled with the isolation 
medium. The mucosal surface was exposed by cutting open 
the intestine with a pair of blunt-nosed scissors and then 
the intestinal epithelium was scraped off using a microscope 
slide and transferred to ca. 20m1 of homogenisation medium 
(0.25M sucrose, 5mM EDTA, pH 7.4 and 0.1M Tris-HC1). The 
suspension was poured into a stainless steel bomb (Yeda 
Press, Yeda Scientific Instruments, Rehorot, Israel) and 
equilibrated under a pressure of 150 lb/inch 2 of nitrogen 
for 30 min. The outlet valve was then opened to allow slow 
expulsion of the suspension and the volume was adjusted 
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to 40m1 and 1 drop of anti-foam (Dow Corning Corp., Midland, 
U.S.A.) was added before the suspension was homogenised 
in a Potter-Elvehjem glass homogeniser with three strokes 
of a Teflon pestle. The mitochondria were then prepared 
as described above. 
• 6.2.2 BIURET TEST FOR PROTEIN 
The biuret test for protein (Gornall et al., 1949) was 
used quantitate the amounts of mitochondrial protein 
isolated from different sources. Biuret reagent (2m1) and 
1N NaOH (1m1) was added to 100-200111 of the mitochondrial 
suspension. The mixture was stirred, then left for 15-30 
min before reading at 540nm. Controls included mitochondria 
suspended in 3m1 of NaOH and a solution of lml NaOH 
in , 2m1 biuret reagent. Standards of 1-10mg bovine serum 
albumin (Grade A) were routinely included. 
6.2.3 DEPROTEINISATION 
Whole tissue and/or mitochondria were deproteinised 
by either of two techniques. 
6.2.3.1 HC104,deproteinisation  
Whole tissues (10m1/g wet weight) or mitochondria 
(5m1/100mg) were homogenised for 30s in ice-cold 0.5M 
HC10 	with a top drive blender (SiIversen Top Drive, 4 
Waterside, 	Chesham, 	Buckinghamshire, 	England) 	before 
centrifugation at 8,000g for 10 min to remove denatured 
protein. The chilled supernatant was ,immediately neutralised 
with cold conc. KOH then kept on ice for 10-15 min before 
the while precipitate was removed by centrifugation. The 
supernatant contained the metabolites extracted from the 
biological samples. 
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6.2.3.2 Trichloroacetic acid (TCA) deproteinisation  
The TCA extraction procedure was essentially that 
'of Khym (1975). Either 2m1 of 6% TCA was added dropwise 
to blood (1m1) or lml of 12% TCA was added dropwise to 
ca. 800mg of frozen tissue powder. The suspensions were 
vigorously stirred and then centrifuged at 2,000g for 5 min. 
The supernatant was removed and 4m1 of a solution of tri-
n-octylamine in Freon (S'.8m1 in 50m1) was added. The 
stoppered tubes were shaken horizontally for 15-20 min to 
ensure thorough extraction before the upper layer was removed, 
leaving a deproteinised aqueous layer (pH 6.0-7.0) which 
was lyophilised: 
6.2.4 ION-EXCHANGE CHROMATOGRAPHY 
The chromatographic procedure used to isolate PC 
comprised two steps: (i) batch-wise elution to produce a 
crude PC fraction free from citrate and P 1 . and (ii) gradient 
elution to give a PC peak eluting off the column at a 
characteristic volume. 
6.2.4.1 Batch-wise purification 
6.2.4.1.1 	Whole tissue 
5-10 pl of [ 14 Li citrate was added to extracts 
from whole tissue (5-25g) and an aliquot (0.5m1) counted 
after the addition of scintillant [ 3g 2,5-diphenyloxazole 
(PPO) in ethanol, ethylene, glycol, xylene and triton X-100, 
106:37:600:257, v/v ]. The tissue extract was then loaded 
at room temperature onto a 3 x 10cm AG 1-X8 (HCO-) column 3 
at a flow rate of 1-2m1/min. An aliquot (0.5m1) from the 
eluant was taken, scintillant added and the sample counted. 
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From information on the number of counts present in the 
sample before and after passage through the ion-exchange 
column, the degree of binding of citrate was calculated. 
With a 3 x 10cm column, > 95% binding was achieved. 
The column was eluted with 1-1.5 L of 0.27M NaHCO 
before 1L of 0.45M NaHCO was passed through the column. 3 
This latter eluant was collected under refrigeration before 
decarbonation with AG 50W-X8. Sufficient AG 50W-X8 was added 
to the sodium bicarbonate eluant to alter the pH to 4-6. 
The mixture was filtered, the filtrate neutralised and 
lyophilised before being dissolved in 50-100ml of water. At 
this stage the solution was ready for the second chromato-
graphic procedure. 
6.2.4.1.2 	Mitochondria and bone samples 
Neutral extracts were loaded onto 1 x 10cm 
columns of AG 1-X8 ( HCO
3
) after the addition of 5-10l of 
[ 14 citrate. Aliquots ( 0.5ml ) of the extracts were taken 
before and after passage through the column enabling the 
binding of citrate to be estimated. Under these conditions, 
>95% binding was achieved and the column was eluted with 
500-600m1 of NaHCO
3 
buffer which was collected in a chilled 
container. This fraction was decarbonated and subsequently 
treated to give a neutral crude PC fraction, as described 
above. 
6.2.4.1-3 	Urine samples 
The high salt content , of urine required the 
use of a large amount of resin in an attempt to fully find 
anions present. Accordingly, 2L of urine was passed through 
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a 5 x 50cm column of AG 1-X8 (HCO 3 ) . Samples (0.5m1) of 
urine were taken before and after passage through the ion-
exchange column and analysed for phosphate. Binding was 
>70% under these conditions. The column was eluted with 
with 2L of 0.27M NaHCO 3 
before 1.5L of 0.45M buffer was 
used to batch-elute PC. This fraction was collected in a 
chilled container, decarbonated and lyophilised as described 
above. ' 
6.2.4.2 Gradient elution of PC  
Lyophilised samples from the treated 0.45M fractions 
of the batch-wise eluted columns were taken up in 50-100m1 
of water and 5 ill of [ 14  CI-citrate added. These solutions 
were each loaded onto a 1 x 10cm column of AG 1-X8 (HCO- ) 3 
and the radioactivity present before and after passage 
through the column determined. In all cases > 95% binding 
was obtained. The columns were eluted either individually 
or simultaneously as follows : 
	
6.2.4.2.1 	Treatment of individual columns 
Five hundred ml of 0.27M NaHCO 3 
was passed 
through the column to remove any traces of citrate before 
a linear gradient from 0.27 to 0.5M NaHCO 3 
was applied 
to elute PC. Five hundred ml each of 0.27M and 0.5M 
NaHCO 
3 
was used to provide the linear gradient and 300 
x 4m1 fractions were collected and subsequently analysed. 
6.2.4.2.2 	Simultaneous elution of columns 
When columns were treated simultaneously, one 
1 x 10cm column of AG 1-X8 (HCO ) was loaded with 50- 3
• 100 g of PC for comparative purposes. The columns were 
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connected to a Durrum 12 channel peristaltic pump (Model 
11000, Palo Alto, California, U.S.A. ) and the flow rate 
carefully equalised to lml/min. Then 500m1 of 0.27M 
NaHCO
3 was passed through each column before applying a 
linear gradient to elute PC. For 'n' columns, 'n' x 500m1 
of both 0.27M and 0.5M NaHCO
3 were used to provide the 
gradient. One hundred and fifty ml of the gradient was 
collected from each column before 20 x 15m1 fractions were 
simultaneously collected from each column for subsequent 
analysis. 
6.2.5 CITRATE ANALYSES 
Acidic conditions for the hydrolysis of PC prior 
citrate analysis were achieved by adding 0.8m1 of 5N 
H 2 SO 4 into every fifth tube. Tube contents were then heated 
at 100 o C • for 4h before chemical citrate analysis as described 
in 	Section 3.2.1.1.1 using either 4,4' -methylene-dianiline 
or benzidene as the chromophore. 
In some instances the fluorimetric coupled enzyme 
test for PC was used (Section 3.2.1.1.2) . 
6.2.6 SEPARATION TECHNIQUES 
Citrate analyses indicated where PC eluted, so relevant 
tubes were pooled, decarbonated and lyophilised to give 
samples that were further analysed by TLC (Section 3.2.3.2) , 
high-voltage electrophoresis (Section 3.2.3.3) and analytical 
isotachophoresis (Section 3.2.3.4) . Where necessary the 
biological material was stained for Other P 	or citrate 
(Section 2.3.3 ) . 
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6.2.7 NMR SPECTROSCOPIC EXAMINATION 
Rat kidneys were extracted with perchloric acid to 
give neutral extracts that were analysed by 31 P NMR spectro-
scopy (courtesy of Dr. Se eley, Oxford University) . An external 
standard of PC in 200mM NaC1 and at an identical pH to 
the sample was used for comparative purposes. 
6.3 	RESULTS 
6.3.1 RECOVERY OF PC FROM HC10 4 
AND TCA EXTRACTS 
When [ 32 El-PC was added to lg of tissue, homogenised 
and then deproteinised using either HC10 4 
or TCA (Section 
6.2.1) , a quantitative recovery of > 98% was obtained for 
each technique in at least 3 separate trials. Acidification 
and neutralisation of a solution of , citrate and phosphate 
was shown, in Chapter 3, not to cause artefactual PC 
production. This observation, together with the fact that 
the HC10 
4 
extraction technique is more readily applicable 
to a larger scale operation, led to the use of this method 
as a routine. 
6.3.2 ION-EXCHANGE CHROMATOGRAPHY OF BIOLOGICAL EXTRACTS 
Ion-exchange chromatography was used to isolate PC 
from biological extracts. Some of these purified fractions 
were subsequently analysed by TLC, electrophoresis, isotacho-
phoresis and enzymatic assay in order to confirm the identity 
of the compound eluting from the column. 
6.3.2.1 Whole tissue  
• Extracts of rat and rabbit liver and kidneys when 
subjected to ion-exchange chromatography with linear gradient 
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elution, always gave a peak that eluted at a volume charact-
eristic of PC and which contained citrate after hydrolysis. 
•Figure 6.1 gives typical results obtained with whole tissues. 
Liver extracts from two rats, or kidneys from six rats were 
used, the data being confirmed on at least four separate 
occasions. For rabbit extracts, liver and kidneys were 
obtained on separate occasions from four different animals, 
with consistent results. Significantly, in all cases a compound 
which contained hydrolysable citrate eluted from the ion-
exchange column at a volume characteristic of PC. In fact, 
when [ 32 P1-PC was added to one rat kidney extract the radio-
activity eluted at exactly the same position as the peak 
containing the hydrolysable citrate. Further, quantitative 
recovery of [ 3213 ]-PC was obtained. 
6.3.2.2 Mitochondria  
When mitochondria from rat or rabbit liver or kidney 
were isolated and fractionated, a peak containing hydrolys-
able citrate was observed and again this peak corresponded 
to PC, eluting at a characteristic volume. Typical results 
are shown in Figure 6.2 and each experiment was confirmed 
three times. 
In a single experiment mitochondria from the intestine 
of three rats was subjected to ion-exchange purification and, 
once more, a peak eluting at the characteristic volume of 
PC and containing hydrolysable citrate was observed (Figure 
6.2). Furthermore, [ 32 13 ]-PC eluted with this peak when added 
to a rat kidney mitochondrial preparation. 
From the area under the curve for hydrolysable citrate, 
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Figure 6.1 Resolution of PC from kidney and liver extracts 
of rats and rabbits by ion exchange chromatography. 
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Figure 6.2 Separation of PC from extracts of 
sofot-tissue 	mitochondria 	by 
chromatography. 
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an indication of the initial amount of PC present in the 
biological extract may be calculated since mitochondrial 
protein was routinely analysed. A quantitative comparison 
(expressed as nmol PC/mg mitochondrial protein) is given 
in Table 6.1, indicating that kidney mitochondria from either 
species contained more PC than liver mitochondria. The richest 
source was rat intestinal mitochondria. It should be 
emphasised that in some experiments PC was not detected, 
perhaps due to some biological variation as yet 
undefined. Therefore these results can only be preliminary 
estimates of PC levels in mitochondria. 
6.3.2.3 Bone 
Treated bone samples from rabbit hind-legs were 
subject to ion-exchange chromatographic techniques and a 
qualitative indication of the presence of PC was obtained 
after citrate analysis. Although the amount of hydrolysable 
citrate detected in eluted fractions was very small, the 
consistent appearance of material in the eluant corresponding 
to the volume at which PC eluted nevertheless suggested 
that PC was indeed present (Figure 6.3). 
6.3.2.4 Urine  
Quantitation with human urine was not possible since 
the high salt content of urine prevented full binding to ion-
exchange columns. Nevertheless, chemical citrate analysis 
indicated hydrolysable citrate was present, eluting at the 
same volume as PC. As with the analysis of bone, the amount 
of citrate present in the eluant was very small, but detected 
Table 6.1 Preliminary estimation of the amount of 
PC present in mitochondria from various 
sources. 
[PC] 
TYPE OF MITOCHONDRIA (jig/mg. mito.protein) 
rat, rabbit liver 	 0.41-0.2* 
rat, rabbit kidney 	0.81'0.2* 
rat intestine 	 1.2+ 
*Data from at least 3 trials; mean ±1 S.D. 
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consistently over a range of tubes corresponding to the 
position PC is expected to elute off the column (Figure 6.3). 
6.3.3 FURTHER ANALYSIS OF ISOLATED FRACTIONS 
Having detected PC in the eluant of chromatographic 
columns, fractions containing PC from whole tissue and 
mitochondrial extracts were pooled, decarbonated and lyophil-
ised so that further characterisation could be attempted. 
All the analytical procedures were used on rabbit liver and 
rat kidney mitochondrial extracts in order to ensure that 
the identity of the peaks eluting off the columns were PC. 
Once this was assured other samples were not subjected to 
the full range of analytical techniques. 
6.3.3.1 Enzymatic analysis  
Enzymatic analysis, which can determine both free 
citrate and PC, was used to examine rabbit liver and rat 
kidney extracts and all the mitochondrial extracts. Initial 
experiments involving the addition of PC into the biological 
fractions indicated that an incubation with alkaline phosphat-
ase for 10 mm a t 37 ° C and pH 10 was insufficient to 
completely hydrolyse PC. However, it was established that 
PC was hydrolysed completely after lh under these conditions. 
Unhydrolysed and hydrolysed samples from each sample 
were analysed for citrate fluorimetrically (Section 3.2.1.1.2). 
After the reaction was complete 1.0 ug of citrate was added 
as an internal standard to check the kinetics of citrate lyase 
and to enable calculation of the amount of hydrolysable 
citrate present in the biological sample. Typically no free 
citrate ( <1% total citrate) was detectable (see Figure 6.4). 
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Figure 6.4 Fluorimetric 	determination 	of 	phosphocitrate 
in a rat kidney extract using a coupled enzyme 
assay. 
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Since phosphatase digestion is necessary before citrate can 
be detected, then clearly the compound must be a conjugate 
of citrate and phosphate. Phosphocitrate is the only realistic 
candidate since citryl phosphates ( phosphate esterified to 
carboxyl groups ) are too unstable to occur naturally (Section 
2.5). 
The values for citrate were identical for the enzymatic 
and the chemical methods of assay; this constitutes an 
important validation for the estimates of mitochondrial PC 
concentration. 
6.3.3.2 Separation techniques  
Although the elution characteristics from ion-exchange 
columns and chemical and especially enzymatic analyses 
indicate that PC was present in biological samples, further 
proof was sought by comparing the material with synthetic 
PC using thin-layer chromatography, high-voltage electro-
phoresis and analytical isotachophoresis. 
6.3.3.2.1 	Thin-layer chromatography (TLC) 
Biological samples applied to cellulose coated 
plates developed in an isobutyric acid based solvent (Section 
3.2.2.2) gave a compound running at the same R F to PC 
and which stained for phosphate after either chemical or 
enzymatic hydrolysis. This spot had an R F quite different 
to that for either citrate or P. . However, insufficient material 
was present for a citrate stain , to be successful so an 
alternative approach was adopted to investi gate whether 
the material running with the same R 
F 
as PC did indeed 
contain citrate. 
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Accordingly, a PC standard and biological sample 
were applied separately and subjected to the chromatographic 
procedure. The plate was marked into 2 x 2cm strips and 
bands of cellulose were scraped off the plate and material 
recovered by treating the cellulose with three lots of 4m1 
of Me0H/H 2 0/1N H SO4 (10:10:2) . Cellulose was vigorously 
shaken with the eluting solvent then centrifuged. The super-
natants for each band were pooled and lyophilised before 
hydrolysis at 100 o C for 4h in 5m1 H 2 0. The samples were 
then analysed chemically for citrate and the results are 
given in Figure 6.5. Notably hydrolysable citrate was detected 
at the same R F as authentic. PC. In this system citrate runs 
6-7cm from the origin and no free citrate was detected. Thus 
TLC indicated that the peak eluting from ion-exchange columns 
containing hydrolysable citrate was a phosphate and citrate 
containing compound with an R F identical to PC. 
	
6.3.3.2.2 	High-voltage electrophoresis 
High-voltage electrophoresis indicated that a 
compound staining for phosphate and with the same mobility 
as PC was present in the biological samples. Again, insuffic-
ient material was present to allow specific citrate stains 
to be used. In contrast to TLC, citrate and PC are not 
resolved by electrophoresis, so the paper was not sectioned 
for subsequent elution and citrate analysis since this could 
not be a definitive test for PC. 
6.3.3.2.3 	Analytical isotachophoresis 
Extracts from rabbit liver and rat kidney 
mitochondria were subjected to isotachophoresis with a view 
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Figure 6.5 Presence of PC in a rat liver mitochondrial 
extract determined by TLC. 
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to reinforcing the identification of the compound eluting from 
the ion-exchange column as PC. The conductimetric trace 
obtained after isotachophoresis is given in Figure 6.6. A 
component with a step height characteristic of PC was observ-
able and when an internal PC standard was included it 
migrated with this •zone. 
In an extension of this approach the biological samples 
were incubated with alkaline phosphatase at a pH of 7. 
Incubating at a pH of 7 rather than 10 was necessary since 
adjusting the pH from 10 to 7 increased the salt content 
of the sample enough to interfere with subsequent analysis. 
Analytical isotachophoresis indicated that the PC zone had 
indeed decreased in length but had not been entirely elimin-
ated because the pH is not optimal for complete hydrolysis. 
Nevertheless, the citrate zone in contrast had increased in 
- width at the expense of PC and this behaviour is consistent 
with the component being PC. 
6.3.3.3 31 P NMR Spectroscopy 
Figures 6.7a and 6.8a give the 	31 P NNIR spectra 
of rat kidney and liver perchloric acid extracts respectively. 
An external standard of PC (2 prnol) at the same pH as 'the 
biological samples was routinely included (Figures 6.7h and 
6.8b). Peaks in the spectra are tentatively identified based 
on the work of Ogawa et al. (1978). The presence of a peak 
due to PC is difficult to detect due to proximity of resonances 
resulting from the phospholipids phosphatidyl choline (GPC) . 
and phosphatidyl ethanolamine (GPE). Thus, unless PC is 
purified and concentrated before 31 P NMR spectroscopy, its 
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Figure 6.6 Isotachophoretic identification of PC from biological 
sources: detection of citrate after incubation wit h 
alkaline phosphatase 
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Figure 6.7 	31P NMR spectra of rat kidney extracts in the 
presence or absence of added PC. 
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presence will be masked by other, more abundant, phosphoric 
esters. 
Sargeant and Stinson (1979 ) have demonstrated that vanadate 
is a potent phosphatase inhibitor. Therefore in one experiment 
1mM vanadate was added in an attempt to minimise any 
hydrolysis of PC. The homogenate was deproteinised and 
analysed in an identical way to a sample without added 
vanadate. However, no peak due to PC was observable, again 
emphasising the need to concentrate PC before spectroscopic 
analysis. 
6.4 	DISCUSSION  
The 	data 	presented demonstrate that PC occurs 
naturally. Previous work by Lehninger (1977) and Howard 
(1976) had failed to identify definitively the compound(s) s ) 
responsible for the potent anti-calcifying ability they observed 
in biological fractions. In contrast, all of the analytical 
techniques employed here confirmed the identity of the 
isolated material as PC. Such a finding was possible only 
after preparation of authenticated PC and demonstration that 
separation by an ion-exchange chromatography at neutral 
pH does not lead to artefact formation of PC. 
Further studies indicated that a quantitative recovery 
of PC after deproteinisation of biological samples was possible 
allowing investigation of biological extracts. Perchloric acid 
extracts from various tissues, selected due to their importance 
in Ca ++ metabolism, and mitochondria from soft tissues, were 
subjected to ion-exchange chromatography giving a peak 
containing hydrolysable citrate. Significantly the peak eluted 
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at a volume characteristic of PC. In order to ensure that 
this compound was indeed PC, biological fractions were 
subjected to further analysis. 
The coupled enzymatic assay indicated that citrate 
could only be detected in the biological samples after pre-
incubation with alkaline phosphatase. Although citryl 
phosphate ( i.e . phosphate esterified to a carboxyl group ) 
might meet enzyme requirements, stability data eliminate 
this possibility as the compound relative to PC is short-lived 
( see Section 2.5 for details ) . In additional tests PC from 
biological extracts co-electrophoresed and co-chromatographed 
with a reference standard of PC. A phosphate staining spot 
with the same R F as authentic PC was eluted under the 
conditions and shown to contain citrate. Analytical isotacho-
phoresis indicated that not only did the biological samples 
contain a component with the same mobility as PC, but when 
incubated with alkaline phosphatase the zone decreased in 
width and citrate was released. Thus the approach adopted 
using a variety of techniques to characterise PC has enabled 
unambiguous demonstration that PC occurs naturally in whole 
tissue ( kidney , intestine and liver ) and mitochondria ( liver 
- O. 4, kidney - O. 8, intestine - 1. 2nmol PC/mg mitochondrial 
protein ) . 
Whereas the identification of PC in whole tissue and 
mitochondria is assured, PC has only been tentatively 
identified in bone and urine based on its eluting volume 
from ion-exchange columns and chemical citrate analysis. 
With bone the avid binding of PC to hydroxyapatite has 
hampered studies and it may even be that , like the nucleotides 
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( Krane and Glimcher, 1969 ) , PC is decomposed by the HAP 
catalytic surface. Despite these problems a qualitative 
indication that PC occurs in bone was obtained. 
In urine, the high concentration of salts made invest-
igation difficult since a large amount- of resin was required 
to bind only a relatively small amount of urine. Such an 
approach was adopted because the usual method used to 
separate salts from urinary metabolites was inapplicable. 
In this method barium was used to precipitate the unwanted 
anions, but , it was found that PC co-precipitated or was 
adsorbed onto the precipitated material. Nevertheless, even 
omitting the barium precipitation step from the procedure, 
PC, albeit at a very low concentration, was observed in 
urine. As another consideration, urine does contain phosphat-
ase activity so the possibility arises that PC may be present 
initially at high concentration in the , kidney tubules. However, 
due to the time of passage of urine, and collection, storage 
and filtration of the samples, it is possible that only a 
low concentration is then present after hydrolysis in vivo  
and during the work-up of the samples. 
Although PC has been identified in biological extracts 
using a range of techniques, a further test using 31 P NMR 
spectroscopy was unable to confirm its presence for two 
reasons: ( i) the PC resonance was obscured by the resonances 
from phospholipids, and (ii) the PC concentration was 
probably too low for detection without prior purification. 
Thus ion-exchange chromatography is indicated but even 
after this it may be necessary to adjust the pH to shift 
the PC resonance away from phospholipid resonances ( see 
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Section 2.4.3.1.3) which are independent of pH (Seeley, pers. 
comm. ) . However, due to the unique features of the 13 C NMR 
spectrum of PC, it may be that 13C NMR spectroscopy could 
be the most useful of the spectroscopic techniques for charact-
erising PC in vivo. The low natural abundance of 13 C 
indicates that it would be necessary to process at least 100 
pairs of rabbit kidneys to obtain 1-5mg of material sufficient 
for spectroscopic purposes. If, however, rabbit chow was 
supplemented with 'a [ '3C]-labelled  compound, less rabbits 
would have to be used since PC might be isotopically-labelled 
allowing 13 C NMR on smaller amounts of extracted material. 
For mitochondrial investigations into the biosynthesis of PC, 
13 C NMR of mitochondria incubated in the presence of a 
13 C-labelled substrate could prove useful because of the 
unique 	13 C NMR spectrum of PC. In order to transfer a 
suitable PC substrate 	( e. g . 	acetate ) 	into mitochondria 
[ 13 C]-acetyl carnitine added to the incubation may be useful. 
Even without these spectroscopic data, analysis 
indicates that PC does indeed occur naturally ; this, together 
with its recognised physico-chemical properties, establishes 
it as a new factor for consideration in the control of biolog-
ical calcification. It is consequently valuable to discuss 
how its presence at various sites relates to possible roles 
it might have physiologically. 
W hen calcium phosphate granules are deposited in 
mitochondria they form as the amorphous rather than crystall-
ine state. This amorphous phase is more labile (Termine 
and Eanes , 1972) and soluble (Meyer and Eanes, 1978a ) than 
HAP so that Ca ++ stores are more readily mobilised by 
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mitochondria, a factor crucial to the intracellular handling 
of Ca ++ . Because of its mitochondrial occurrence and physico-
chemical properties, PC could have a role in stabilising 
this amorphous form. 
The possible presence of PC in bone suggests it may 
be involved in the mineralisation process. However, what 
must be determined is whether PC is bound to HAP before 
it is deposited in bone or whether its presence merely reflects 
a high affinity of PC for HAP, so that PC in the extracellular 
fluid is removed from the circulation by HAP. In the former 
.case, it may be that PC stabilises the mitochondrial micro-
packets of ACP proposed by Lehninger (1970) to be the source 
for the HAP of bone. 
The proposed roles of PC all centre on its ability 
to inhibit calcification. It is possible then that its amounts 
in mitochondria from soft tissue (intestine > kidney >> liyer) 
reflect the amount of Ca ++ flux in that tissue and a need 
to maintain a labile store of calcium phosphate in the 
mitochondria of those tissues. Further, its presence in kidney 
indicates it may be secreted into urine and, in fact, PC 
has been tentatively identified there. At this site PC could 
play a role in inhibiting lithiasis since it inhibits both 
calcium oxalate and calcium phosphate formation and exerts 
a potentiating effect on the inhibitory ability of artificial 
urine. 
The possible role of PC in urine to inhibit lithiasis 
indicates that a valuable study could be to determine the 
levels of PC in the urine of stone-formers and to compare 
this with the levels found in the urine of healthy individuals. 
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Such a study could be facilitated by employing one of the 
unique characteristics of PC, namely its adsorption onto 
HAP, to afford preliminary separation of PC from interefering 
- salts (e.g. SO 42- 	P 2-  ) which are only slightly adsorbed. 
Before this approach could be adopted, however, it would 
be necessary to devise a method to recover PC from HAP. 
Although data in this chapter have demonstrated that 
PC is found at three key sites of Ca ++ homeostasis - kidney, 
intestine and bone - and have allowed a preliminary estim-
ation of its concentration in mitochondria from soft tissue, 
many more avenues of research have been opened up. The 
questions posed could be answered by studies along two lines. 
First, investigation of (a) the distribution of naturally-
occurring (endogenous) PC, and (b) the fate of administered 
(exogenous) PC, at the subcellular level which could aid 
definition of the biological role(s) s ) of PC, its potential for 
clinical use, and its likely site( s) of biosynthesis. Second, 
detection of PC from diverse biological sources, including 
biological calcifying systems might allow discussion 
of its physiological role( s) and interspecies comparisons. 
Biological calcifying systems worth investigating include 
tendon calcification, worm calciferous gland, hen egg shell 
gland, molluscan vel iger development, and slime moulds 
(Althoff et al., 1978; Yamada, 1976). As an extension of 
these types of study, the effect of added PC on calcification 
could also be studied. 
6.5 	SUMMARY  
1. 	TCA and HC10 4 extraction techniques quarititat- 
ively recovered PC. 
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2. PC was detected by TLC, electrophoresis, 
isotachophoresis, and enzymatic and chemical citrate assays 
in purified fractions of biological extracts. 
3. PC was found in rat and rabbit kidney and 
liver, rat intestine. Preliminary experiments indicated PC 
might occur in rabbit bone and human urine. 
4. Soft tissue mitochondria contain PC at a level 
of ca. lnmol/mg mitochondrial protein depending on the source 
of the mitochondria: 
5. Intestinal mitochondria > 	renal mitochondria 
> liver mitochondria as sources of PC. 
6. 31 P NMR failed to detect PC in impurified 
biological extracts. Phospholipids may have obscured the 
PC signal. 
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CHAPTER 7  
IN VIVO LABILITY OF PHOSPHOCITRATE 
7.1 	INTRODUCTION  
The natural occurrence of PC raises many interesting 
questions. , for example, ( i) is it involved in controlling 
mitochondrial calcification, ( ii) is it a metabolic substrate, 
( iii) does it act as a phospho-donor in intermediary 
metabolism, ( iv ) does it have a role in urolithiasis, and 
(v ) can its physico-chemical properties be exerted in vivo 
as a controlling influence on calcification? The last question 
has important clinical ramifications , since if PC is stable 
in vivo, advantage could be taken of its anti-calcifying 
properties. PC could be of potential use when it is desirable 
to inhibit Ca ++ salt deposition ( or dissolution) as in the 
treatment of, for example, Paget ' s disease, osteolytic sarcoma 
or urolithiasis. 
An attempt has been made to obtain data that might 
answer some of these questions by taking advantage of the 
availability of [ 13 1-PC (Chapter 2) . This present chapter 
then reports on the fate of intravenously injected [ 3213 ]-PC, 
in particular its tissue distribution and lability. Comparative 
experiments using an injection of [ 32 P 1-P i •- the labelled 
[ 3 2 hydrolysis product of 	P] -PC 	are also reported since 
enzymatic cleavage of PC is expected in vivo. 
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7.2 	METHODS 
7TO RATS: 
COLLECTION AND TREATMENT OF SAMPLES 
The fate of administered radioisotopes was studied 
in male 170-180g Wistar 	rats. A solution of lmg (0.5p C 1 ) 
32 of 	 meither sodium [ 	In-PC (specific activity 200 p C / ol; 
prepared as described in Section 2.4.2) or [ 32 13 ]-1D i (specific 
activity 70 p C /mmol; obtained from Radiochemical Center, 
Buckinghamshire, Amersham, England) wa_s administered intra-
venously through a tail vein to a rat lightly anaesthetized 
with ether. At designated times rats• were exsanguinated, 
the blood collected in heparinized tubes and immediately 
frozen in liquid nitrogen. Simultaneously the body cavity 
was opened; kidneys, intestine and liver were excised, freeze-
clamped and stored in liquid nitrogen. Bone from fore and 
hind limbs was taken as quickly as poss ible;the cartilagenous 
ends were removed and the marrow blown. out. The demarrowed 
bone samples were stored in liquid nitrogen. 
In one set of experiments, ureters were ligated prior 
to the injection of the radioisotope and, at the conclusion 
of the experiment, the bladder and its contents were retained 
and kept frozen.. 
7.2.2 MEASUREMENT OF TOTAL COUNTS 
Total [ 32N-radioactivity present in tis.sues was assess-
ed by the method of Mahin and Lc:dberg (1966). Blood 
(200 p 1 ) , urine (200 pl) or powdered soft tissue (200mg) or 
bone (150mg) samples were treated with 200 p 1 of 60% 
NCI° 4 and 4001-11 of 30% 1-120 2, before se aling the tubes with 
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tops resistant to digestion conditions. The tubes were heated 
either at 30-60 ° C for blood and urine samples, or 70-80 ° C 
for tissue samples. The samples were digested for 1-72h until 
dissolved and the liquid was colourless or only faintly dis-
coloured. 
Scintillation fluid [18ml of a mixture of 0.6% 2,5- 
diphenyloxazole (FPO) in toluene, and cellusolve (10:6) v/v)] 
was added to each of the samples and the vials counted. 
7.2.3 TCA EXTRACTION OF SAMPLES 
The recovery of radiolabelled metabolites from tissue 
samples for subsequent analysis involved the dropwise 
addition of ice-cold trichloro acetic acid (TCA) to vigorously 
stirred samples. One ml of 12% TCA was added to blood 
samples (1m1), whereas 2m1 of 6% TCA was added to tissue 
samples ( <800mg). The denatured protein was removed by 
centrifugation and the supernatant was retained and shaken 
horizontally for 10-15 min, with •4m1 of a solution of tri-n-
octylamine in Freon (Refrigerant R11; '8):8m1 to 50m1). The 
tubes were centrifuged at 100g for 5 min to clarify the 
neutral aqueous layer which was then removed and lyophilised 
before analysing for inorganic phosphate and running electro- 
• phoretograms. 
7.2.4 ANALYSIS OF INORGANIC PHOSPHATE 
Organic phosphoric esters were separated from inorganic 
phosphate essentially by the method of Ohnishi (1978) using 
a stationary support of polyvinyl pyrrolidene (PVPP) to adsorb 
the phosphate-molybdate complex , allowing unbound. phosphoric 
esters to pass' through. 
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7.2.4.1 Preparation of PVPP columns  
• 	 PVPP (10g) was washed twice with 500m1 volumes 
of 0.5M HC1 then twice with water. The suspension was 
filtered and the PVPP air-dried overnight. Powdered PVPP 
(1g) was then suspended in 10m1 of water and, as it was 
being vigorously stirred, 0.5ml portions were taken and 
transferred into cotton-wool plugged, 2m1 tuberculin syringes. 
The syringes were supported in test tubes enabling collection 
of the eluant. The tubes were centrifuged at 200g for 5 min 
before the addition of lml of water and another centrifugation 
at 200g for 5 min. 
7.2.4.2 Solutions required for column operation  
Solutions required included: 5% ammonium molybdate 
(w/v ) filtered before use ( AMB reagent) , 250mM formate 
adjusted to a pH of 3.0 with HC1 ( formate buffer ) , 0.5M 
NH 4 0H (eluting solution) , 3M Tris solution, 0.5M Tris-HC1 
buffer, pH 7.4, and scintillant (that described above, 7.2.2) . 
7.2.4.3 Column operations  
Washing solution (0.75m1 of 1:3:1 H 2 0/AMB reagent/ 
formate buffer, v/v,  , prepared daily) was added to the tops 
of the columns and these were centrifuged at low speed (8g ) 
for 5 min. The lyophilised TCA extracts were each dissolved 
in 0.3-0.5m1 water. From this 0.25m1 was taken and added 
to 0.75m1 of AMB reagent and 0.25m1 of formate buffer before 
thorough mixing. A lml sample of this solution was taken 
and transferred carefully to the top of a PVPP column in 
tuberculin 	syringe, 	ensuring 	no 	air-locks 	formed. 
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Low speed (8g ) centrifugation for 5 min left [ 3 2 13 ]- 
P. adsorbed as a yellow band on the PVPP column. Residual 
organic phosphoric esters were recovered with 0.5ml of the 
washing solution. Combined eluant and washing were added 
to a counting vial and 18ml of scintillant added. Also counted 
was an aliquot of the untreated sample allowing calculation 
of the percentage of the total count due to organic phosphoric 
esters. 
Elution of adsorbed [ 32 	 from the column was 
effected by transferring the columns into new test tubes and 
adding 0.75m1 of the eluting solution before centrifugation 
at 200g for 10 min. The eluant was transferred into a count-
ing vial and 0.85m1 of 0.5M Tris-HC1 buffer (pH 7.0) was 
added, followed by scintillant. The process was repeated 
and the sum of the radioactivity in the two vials gave the 
counts due to [ 32 13 1-P i . 
Appropriate blanks were included enabling the back-
ground to be counted. In this way the proportion of the 
total counts due to inorganic phosphate or phosphoric esters 
could be determined. 
7.2.5 DETERMINATION OF [ 3213 ]--PC 
The proportion of the total counts due to [ 32 F, 1-pc. 
was determined by high-voltage electrophoresis . • Accordingly, 
lyophilised TCA extracts were dissolved in a minimum amount 
of water (ca. 100 pl). An aliquot (10-20 pl) was taken and 
counted. One half of the remainder (40 pl) was applied to 
Whatman 3MM paper and to the other half [ 32 13 1-P i and 
[ 32  P1-PC  standards were added; the standards contained 
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the same amount of radioactivity as the biological extracts. 
A mixture of the extract and internal standards was then 
also applied. This procedure ensures that the reference 
standards are present in a quantity that does not obscure 
the counts in the biological standard nor is insufficient 
for observation. 
Separation of radiolabelled components was effected 
by electrophoresis (Section 3.3.2.3) . After 2h the 
paper was cut into two sections (origin to 17cm mark, 17cm 
to 37cm mark) and each section then placed in a Birkoff 
spark chamber for visualisation of the radioactive areas. 
The level of radioactivity in each spot was subsequent- - 
ly quantitated in the following manner: the paper was marked 
in a grid fashion and cut into sections (approximately 2 
x 3cm), each section was coiled to allow it to be placed 
in a vial supported by a thoroughly washed (0.5N HC1) fine 
mesh (nylon material) as shown in Figure 7.1. The paper 
was completely moistened with lml of 0.5N HCI and the lid 
was screwed on so that the supported coil of paper was fixed 
in place (see Figure 7.1). The vial was centrifuged at 100g 
for 5 min before another 1.0m.1 of 0.5N HC1 was added and 
the process repeated. 
Scintillant (18.0m1) was added to the 2m1 of acid 
extract and the radioactivity determined. Appropriate blanks 
were also included. 
7-3 	RESULTS 
7.3.1 TOTAL COUNTS IN SAMPLE 
Initial experiments involved excision of liver, kidney 
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* Figure 7.1 Apparatus used to elute radio-active components 
from electrophoretog rams. 
   
SCREW CAP 
PAPER GRID 
NYLON MESH 
COUNTING VIAL 
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and bone and the collection of blood at 5, 15 and 30 min 
 1 L iver and kidney 
weights were recorded and since the total skeletal weight 
and blood volume may be calculated knowing the sex and 
body weight of the rats used (Donaldson, 1920; Altman and 
Dittmar, 1974) the counts in the samples could be expressed 
as a proportion of the total count found in each organ. 
Figures 7.2 and 7.3 give the results obtained after 
an injection of 32 P ;-Pi (Figure 7.2) or 32 13 1-PC ( Figure 
7.3). After 30 min, uptake by the tissues appeared to be 
almost complete in both experiments. When 32 P 1-P i was 
injected, 20% of the total injected count resided in bone 
after 30 min, 10% in liver and <5% in kidney. However, after 
an injection of [ 32 P] -PC more than 40% of the total count 
was taken up into bone followed by 15% in kidney and only 
5% in liver. 
To compare a wider range of biological samples, rats 
were killed after 30 min and samples collected as before, 
but in addition urine •and intestine were also retained. 
Results are given in Figure 7.4 and indicate that intestine 
and urine only contain a small amount of the initial radio-
activity administered ( <5%). 
7.3.2 PROPORTION OF [ 32In-P IN BIOLOGICAL SAMPLES 
From the data presented above, it is tempting to 
identify bone and kidney as the major sites of PC uptake. 
However, what is unknown is the proportions of counts due 
, to unreacted 	32 P J-PC and the proportion due to one of its 
[ 32p I hydrolysis products 	 PC is totally recovered 
o
 
O %
 IN
IT
IA
L 
RA
D
IO
-A
C
TI
V
IT
Y
 
NJ
 
0
 
CO
 
o
 
X-
- o
 
Eulmouoj anssp  
1:
17' CD
  .. .
 aDupapaddvsip jo  AlIA1.13P-OlpP1 0 
%
 IN
IT
IA
L 
R
A
D
IO
-A
C
TI
V
IT
Y
 
208 
Figure 7.3 Rate of disappearance of radio-activity in blood 
and its appearance in tissue following adminis-
tration of [32 P]-PC. 
Time (min) 
• skeleton 
o- - - - - -o liver 
• blood 
6 kidney 
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Figure 7.4 Distribution of radio-activity 30 	min after 
administration of [ 32 13 ]-PC to rats. 
60 
50 
1 0 
KIDNEY 
BLOOD 
INTESTINE 
L_1 
BONE LIVER 	_ URINE 
Means ± 1 S.E. 
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under conditions used to adsorb [ 32 PI-13 . onto PVPP columns 
so that this treatment is applicable to biological extracts. 
Table 7.1 gives the proportion of total counts due to organic 
phosphoric esters in liver, kidney and blood at designated 
times after an injection of [ 32 P ]-PC. The data indicates 
that with the exception of blood, [ 32 P 1-P i was prominent 
in the tissues. 
7.3.3 PROPORTION OF [ 32P11-PC  IN BIOLOGICAL SAMPLES 
High voltage electrophoresis was used to resolve 
the [ 32 P 1-labelled components as an initial step in determin-
ing the proportion of initial [ 32P]-PC  present. Results from 
these analyses are given in Figures 7.5 and 7.6 for experi- 
ments with [ 32 P}-PC and [ 32 P ]-P respectively. [32 P1-PC 
and [ 32  P1-It  in the samples are easily identifiable because 
internal standards were included. 
Clearly [ 32 P ]-PC remains essentially unchanged in 
blood even after 30 min but in contrast, only 15% of the 
radioactivity present in the kidney was due to PC after only 
5 min ; and after 30 min only a trace ( < 5%) of [ 32 P ]-PC 
remained in kidney. Electrophoretic patterns obtained from 
liver extracts indicated that [ 32 P]-PC had been hydrolysed 
and a large number of phosphoric esters produced. 
The comparative experiments with [ 3 2 P ]-P . indicated 
that, at least in kidney and blood, no phosphoric ester was 
produced which migrates with the same mobility as PC, ensur-
ing that spots identified as [ 32 P 1-PC were probably not 
contaminated with some compound co-electrophoresing with 
i t. 
TIME AFTER 
INJECTION (min) 
% RADIOACTIVITY DUE TO ORGANIC PHOSPHATES* 
BLOOD 
	
KIDNEY 	 LIVER 
Table 7.1 Proportion of radiolabelled compounds present as organic compounds after 
administration of [ 32M-PC. 
5 95±4 40±3 53±4 
15 87-13 47±6 58±6 
30 781-2 38±3 45±5 
*At least 3 trials; means 1 S.E. 
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Figure 7.5 Radio -active components resolved by electro-
phoresis after administration of [ 32 P]-PC. 
Distance from origin (cm) ) 
radio-activity associated with the separated compounds 
reference standards of PC and P. 1 
0 
A 
12 24 36 
C14 
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Figure 7.6 Radio-active components resolved by electro-
phoresis after administration of [ 	. 
2_ 
BLOOD 
30 min 
PC 	Pi 
UIffl ffll  
PC 	P. 
Mil 
12 	24 
	36 
Distance from origin (cm) 
radio-activity associated with separated compounds 
IJIffI reference standards of PC and P. 
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Detailed analysis of the electrophoretograms made 
it possible to distinguish whether PC was being metabolised 
to organic esters or whether PC was being hydrolysed to 
P . which was then incorporated into organic phosphoric esters. 
With blood and kidney two major organic components (A and 
B in Figure 7.6) were prominent after an injection of 
both apparent in kidney even after 5 min. Peaks 
A and B were also observed in the electrophoretic patterns 
from kidney extracts after an injection of [ 32 P1-PC ( see 
Figure 7.5) supporting the contention that PC was being 
hydrolysed to citrate and P before P 1  . became incorporated 
into the phosphoric esters responsible for the characteristic 
electrophoretic patterns observed. 
In urine ( Figure 7.7) no PC was detectable after 30 
min . Figure 7.8 shows the electrophoretic pattern obtained 
after a 30 min incubation of [ 32 13 ]C with urine in vitro  
at 37 °C. In the latter instance very little hydrolysis occurred. 
These observations are consistent with the rapid hydrolysis 
of PC occurring at the kidney site before passage into urine. 
7.4 	DISCUSSION 
An understanding of the metabolism of administered 
PC could provide an insight into the physiological roles 
of this compound. It is clear ' from the data presented that 
radioactivity from an intravenous injection of [ 32  P1-PC  was 
widely distributed throughout an animal after 30 min. Time 
course studies indicated uptake by the tissues was essentially 
complete after 30 min , blood being almost completely depleted 
of ,[ 32 P 1--PC, whereas the radioactivity was concentrated 
12 24 36 
1 
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Figure 7.7 Radio-active components resolved by high-voltage 
electrophoresis after administration of [ 32P ] -PC. 
Distance from origin (cm) 
radio-activity associated with separated compounds 
11111111 reference standards of PC and P. 
URINE 
30 min 
( in vitro) 
PC 	P. 
El [MI 
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Figure 7.8 Radio-active components resolved by high-voltage 
[ electrophoresis: 	32 N-PC incubated with urine 
in vitro. 
12 	24 	3 
Distance from origin ( cm) 
1111 radio-activity associated with separated compounds 
1111111 reference standards of PC P 1 
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mostly in bone (ca. 40%) or the kidney (ca. 15%). 
The rapid uptake of [ 32 P}-PC into bone is consistent 
with the demonstration in vitro that PC was avidly bound 
by HAP (Chapter 5). However, direct evidence that it is • 
PC bound to bone is lacking due to difficulty in eluting 
PC from HAP. Nevertheless, the uptake of counts into bone 
is likely to be a true reflection of PC uptake since (1) only 
ca. 20% of the hydrolysis product of [ 32 P]-PC, namely 
[32 p]p 
i  ' is adsorbed onto bone, and (2) [ 321]-PC remains 
essentially unchanged in blood. 
Another important site fcir the uptake of [ 32 P1-PC 
is the kidney where PC is rapidly hydrolysed. This contrasts 
to its behaviour in blood where it remains essentially 
unchanged even though blood is rich in phosphatase activity. 
In the kidney, the lability of PC suggests that special 
conditions may prevail there for phosphatase action, or that 
phosphatases there have a special propensity to hydrolyse 
PC, or even that a specific PC cleavage enzyme exists which 
rapidly inactivates the molecule. The degradative process 
for PC at the kidney site therefore warrants further study. 
The lability of administered (exogeneous ) PC in kidney 
is relevant to understanding the role of endogeneous 
(naturally occurring) PC. Despite the lytic activity demon- 
strated by the kidney, PC is detectable in kidney mitochon- 
dria. PC should be completely hydrolysed in the time it takes 
to prepare mitochondria so these observations suggest that 
mitochondrial compartmentalisation must act to shield endogen- 
eous PC from the lytic activity in the extramitochondrial 
compartment. Perhaps inactivation of the molecule is necessary 
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should it leak out of the mitochondria where its potent anti-
calcifying properties ensure HAP needles do not form. It 
is important then to gain further information on the intra-
cellular distribution of PC and to elucidate the biological 
site ( s ) of synthesis and degradation. 
The lability of PC in kidney explains why, when 
[ 3P]-PC is injected, only [
32  is observed in urine 
after 30 min, in contrast to the stability that [ 32 P1 -PC 
exhibits when incubated in urine in vitro. In fact analysis 
of the electrophoretograms indicated that the hydrolysis of 
[ 32  P]-PC into [ 32P1-  and citrate was the major in vivo 
reaction. This fact militates against a role for PC as a 
phospho-donor in intermediary metabolism. 
The data also allow consideration of the possible 
therapeutic usefulness of PC apart from discussion on the 
physiological properties of PC. PC is stable in blood which 
may be a property making PC useful in the prevention of 
calcium deposition associated with arterial calcification. 
Analogously, the diphosphonates , less potent inhibitors of 
calcification than PC, are known to inhibit arterial calcific-
ation ( Fleisch et al. ,1965 ) , indicating the likely applicability 
of PC. 
In some instances, it is necessary to have a compound 
that will bind to bone decreasing bone turnover, for example 
in the treatment of Paget ' s disease or osteolytic sarcoma. 
Studies have indicated that although diphosphonates , inert 
analogues of pyrophosphate, will inhibit urolithiasis (Ohata 
and Pak,  1973,  1974 ) and decrease bone turnover ( Russell 
et al., 19 80-, Khairi et al . , 1977 ) prolonged treatment leads 
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to 	many 	undesirable 	side-effects 	(Russell 	et 	al., 
1981). Certainly they are not recommended for treating 
urolithiasis (Bone et al., 1979). Therefore, moderate 
lability of a therapeutic agent appears desirable, and PC 
may be useful in decreasing bone turnover without long-term 
side-effects. 
The lability of PC in the kidney makes it doubtful 
whether it could be of therapeutic usefulness in the prevention 
of lithiasis. It may be, however, that an analogue of PC 
stable to enzymatic hydrolysis but possessing its physico-
chemical properties is more desirable. The analogues of PC 
that may be of potential and are predicted to be inhibitors 
of HAP formation based on their structures, are given in 
Figure 7.9. Based on knowledge of the behaviour of pyrophos-
phate, ATP and ADP and their analogues (Yount et al., 1971; 
Yount, 1974; Wilkes et al., 1973; Meyers et al., 1963), the 
expected order of lability of PC and its analogues is: 
P-O-C > P-N-C >> P-C-C = 0. Consequently the "P-C-C" analogue 
may not be therapeutically useful due to its inertness. In 
the treatment of urolithiasis and perhaps skeletal disorders, 
the "P-N-C" analogue is indicated as a potentially useful 
therapeutic agent. 
The synthesis of the "P-N-C" analogues could be 
achieved using either of the two phosphorylating techniques 
described in this thesis - o-phenylene chlorophosphate or 
2-cyanoethyl phosphate once "amino-citrate" is prepared. 
In fact the extra reactivity that amino groups have in these 
coupling reactions (Bodanszky and du Vigneud, 1959) should 
increase the yield available using the methods. However, 
Figure 7.9 Structures of phosphocitrate and its analogues 
CH,- CO, H 
R- 0 - C - CO, H 
C H2 '..". 0O2H 
Phosphocitrate 
CHf." CO2 H 
R- NH- C- CO2 H 
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N-analogue of phosphocitrate 
CH 2-CO,H 
R- CH,- C - CO 2 H 
CH 2 - CO2 H 
C-analogue of phosphocitrate 
0 
II 
R= HO -P - 
HO 
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no such coupling reactions are possible with "methyl citrate" 
due to the inertness of methyl groups in such reactions. 
The information presented in this chapter is not only 
of use in elucidating the possible biological roles of PC 
and indicating potential clinical utility, but also for indicat-
ing future research directions. These include: (1) the use 
of [ 32  P]-PC or 99m Tc-PC as a bone-imaging agent (Rohlin, 
1976; Rohlin and Hammarstrom, 1976), (2) elucidation of the 
factor( s) responsible for the difference in the lability of 
PC in blood and kidney, (3) evaluation of the use of PC 
in the prevention of arterial calcification and to decrease 
bone turnover, and (4) synthesis •of PC analogues and assess-
ment of their (a) anti-calcifying ability, (b) lability in 
vivo, and (c) uses in therapy. 
7.5 	SUMMARY  
1. Intravenously administered PC is taken up 
specifically by bone (40%) and kidney (15%). 
2. PC is rapidly hydrolysed in kidney but is 
stable in blood and, in vitro, Urine. 
3. PC is degraded in vivo to P . and citrate and 
does not appear to act as a phospho-donor, or to be metabol-
ised directly to other phosphoric esters. 
4. Endogeneous PC is not hydrolysed because its 
location in mitochondria protects it from the lytic activity 
in the cytosol. 
5. In therapy, if advantage of the physico-chemical 
properties of PC is to be taken, then analogues stable to 
enzymatic degradation must be synthesised. 
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CHAPTER 8 
THE SUBCELLULAR DISTRIBUTION AND BIOSYNTHESIS OF 
PHOSPHOCITRATE  
8.1 	INTRODUCTION  
Fundamental roles for PC in vivo can certainly be 
envisaged based on its physico-chemical properties and its 
demonstrated natural occurrence in association with mito-
chondria. One role involves stabilising the calcium phosphate 
granules that form in mitochondria as the amorphous rather 
than crystalline form. The proposed action of PC consequently 
affects the intracellular handling of Ca  conceivably, 
could be modified and extended in specific tissues. Alteration 
could be associated with the degree of Ca  in a tissue 
(for example, intestine) or a further need to closely regulate 
Ca  (i.e. bone). 
Mitochondria appear to be a likely site for the biosyn-
thesis of PC since it has been found in this subcellular 
organelle. If, however, PC were present in other cellular 
compartments then other roles, and indeed other sites for 
its biosynthesis, require consideration. Clearly information 
is needed on the subcellular distribution of PC so that some 
of the questions posed can be investigated more thoroughly. 
This chapter describes approaches taken to gain such data 
• 
and also reports experiments concerning the biosynthesis 
of PC. 
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8.2 	METHODS 
8.2.1 STUDIES ON THE LABILITY OF PC IN TISSUE HOMOGENATES 
AND METHODS OF INHIBIT PHOSPHATASE ACTIVITY 
Tissue homogenates (10m1 of 250mM sucrose at pH 7.4/g 
tissue wet weight) were prepared in a Potter-Elvehjem 
homogeniser using three strokes of a Teflon pestle. For 
lability studies [ 32 P]-PC was added into the homogenate 
and at designated times aliquots were removed and de-
proteinised with HC10
4 
(Section 6.2.3.1) and the protein-free 
solution ele ctrophoresed to determine unreacted { 32 pi _pc 
as described previously ( Section 7.3.3).. 
In one group of experiments the possibility of inhibit-
ing the in vivo hydrolysis of PC was investigated by adding 
vanadate to a solution of PC in the presence or absence 
of tissue homogenate. • Deproteinisation and electrophoresis 
of the protein-free samples was then undertaken. 
In another approach, phosphatase activity in tissue 
homogenates was determined in the presence or absence of 
an inhibitor selected from a range of known inhibitors of 
the enzyme. Phosphatase activity was determined at pH 7.4 
using p-:nitrophenyl phosphate (p-NPP) as the substrate 
(Section 2.4.3.2.2). 
8.2.2 SUCCINATE DEHYDROGENASE ACTIVITY 
Succinate 	dehydrogenase 	activity is 	restricted 	to 
mitochondria so that this enzyme can be used to determine 
the mitochondrial content of biological preparations. Accord-
ingly , either 50p1 of homogenate or 100p1 of a mitochondrial 
suspension was added to 400 pl of sodium phosphate buffer 
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(0.2M, pH 7.4), 300 ill of sodium succinate (0.2M, pH 7.4) 
and 100 pl of 1% MTT [3,(4,5-dimethyl thiazole),2,5-diphenyl 
tetrazolium bromide]. The mixture was incubated at 37 0  C 
for 10-20 min before the reaction was terminated by the 
addition of 0.5ml of 1% trichloroacetic acid and then 4m1 
of tetrahydrofuran was added. 
Tube contents were vigorously mixed before reading 
absorbance at 550nm. Tubes were read against control tubes 
prepared identically with the exception that water was 
substituted for succinate. 
8.2.3 DETERMINATION OF THE SUBCELLULAR DISTRIBUTION 
OF PC 
The subcellular distribution of PC was initially 
investigated by analysing mitochondria and whole tissue 
for PC so that the degree of PC localisation in mitochondria 
could be determined. Information so gained indicated whether 
or not mitochondria were the major source of PC. 
Three rabbits were killed and one kidney from each 
excised, freeze-clamped and weighed. The- remaining kidneys 
were rapidly excised, weighed and homogenised in buffered 
250mM sucrose (pH 7.4). The volume of the homogenate was 
recorded and a sample taken and analysed for succinate 
dehydrogenase activity. The remaining homogenate was 
subjected 	to 	a 	differential 	centrifugation 	to 	prepare 
mitochondria. 
8.2.3.1Whole tissue extract 
Frozen kidney samples were deproteinised with 200m1 
of ice-cold 0.5N HC10 	and homogenised using a top drive 4 
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homogeniser 	( Silversen 	Top 	Drive, 	Waterside, 	Chesham , 
Buckinghamshire ) for 1 min . Denatured protein was removed 
by centrifugation at 800g for 10 min, the supernatant neutral- 
ised with concentrated KOH, and then left to stand at 
°C for 10-15 min before the KC10 4 was removed by centrifug-
ation. In order to determine the degree of b inding,  10 111 
of [ 14 citrate was added to the extract and lml aliquots 
were taken before and after passage through a 15 x 3cm 
Dowex 1-X8 ( HCO -) column. Measurement of the radioactivity 
3 
present in the two aliquots enabled calculation of the percent-
age binding. Typically >99% binding was obtained. 
8.2.3.2 Mitochondrial extract  
The mitochondria, once isolated, were suspended 
ind 250mM sucrose, the volume recorded, an d an aliquot 
of lml taken for subsequent analysis of protein and succinate 
dehhydrogenase activity. An equal volume of ice-cold 1N 
HCIO was added to the mitochondrial suspension- and a 
4 
neutral extract prepared in the usual way (Sec tion 6.2.3.4 ) . 
The extract was loaded onto a 10 x lcm colu.mn of Dowex 
1-X8 (HCO ) after the addition of 5 pl of [ 14 ---,- Li citrate to 
3 
enable calculation of the percentage binding. 	Under these 
conditions > 99% was achieved. 
8.2.3.3 Analysis of PC in biological extracts  
The larger ( 3 x 15cm ) column was eluted with 700- 
800m1 of 0.27M NaHCO 3 (pH 7.0-7.4) : the smaller (1 x 10cm) 
column was eluted with 400-500ml of the buffer. The columns 
were then eluted with 800m1 and 600m1 of 0 . 45M N a HCO
3 
buffer 
these 	fractions 	were 	collected 	in 	chilled respectively ; 
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containers. The two fractions were decarbonated with AG 
50W-X8 (H + ), and sufficient resin was added to lower the 
pH to 5-6. The mixture was filtered, the filtrate neutralised 
with dilute NaOH and lyophilised. The freeze-dried residues 
were dissolved in 50-100m1 of water and then applied to 
two 1 x 10cm Dowex 1-X8 (HCO ) columns. A third column 
was loaded with 50 pg of synthetic PC and column outlets 
were connected to a single channel of a peristaltic pump 
(Durrum 12 channel, Model 11000, Palo Alto, California). 
This procedure enabled the characteristic eluting volume 
for PC to be determined each run. 
Initially the three columns were eluted with 400m1 
of 0.27M NaHCO
3 
each, and then subjected to gradient elution 
as described before (Section 6.2.4.2.2). The 15m1 fractions 
that were obtained were then decarbonated and acidified 
with 1.8m1 of 5N H 2 SO 4 
before hydrolysis at 100 ° C for 5hr 
followed by lyophilisation. The dried material was dissolved 
in 2.5m1 of warm water and transferred into a test tube. 
An additional amount of 2.5m1 water was used to rinse out 
the freeze-drying flasks. The combined contents were then 
chemically analysed for citrate (Section 3.2.2.1.1). 
8.2. 4 BIOSYNTHETIC EXPERIMENTS 
Three approaches were adopted in attempts to elucidate 
aspects of the biosynthesis of PC. 
8.2.4.1 In vivo 
The effect of ingestion of Ca 	the PC content of 
intestinal mitochondria 	was 	studied since 	the evidence 
presented in this thesis so far supports a role for PC in 
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the Ca ++ 	handling of cells, in particular mitochondria. 
The reasoning was that perhaps Ca +-I--loading of this organelle 
triggered PC production enabling storage of Ca  
as ACP rather than as HAP. Accordingly, four male rats 
(150-250g) were fasted overnight before giving 200mg calcium 
gluconate in lml of 10% sucrose orally. The rats were killed 
30 min later, blood collected and intestines excised. Serum 
was prepared and its Ca  determined by Atomic 
Absorption Spectroscopy (Section4.3.2.2). Intestinal 
mitochondria were prepared (Section 6.2.1.4.2) and 0.2ml 
samples taken for protein and Ca  The 
remaining mitoichondrial suspension was deproteinised with 
HC10a neutral extract prepared and column chromatography 4 ' 
undertaken •as described previously (Section 6.2.4.2) for 
the analysis of PC content. 
In control experiments rats were treated in an identical 
manner except that calcium gluconate was omitted from the 
10% sucrose solution. 
8.2.4.2 In vitro - Mitochondrial incubations  
Using the same rationale as with the whole animal 
experiments, namely that Ca ++ -loading might initiate PC 
production in mitochondria, rabbit kidney mitochondria were 
prepared and incubated in a medium known to cause C a ++ 
loading and the deposition of calcium phosphate granules 
(Greenawalt et al., 1964). Rabbit kidney mitochondria were 
prepared in the usual way (Section 6.2.1.4.3) , before 200- 
400mg mitochondria protein was suspended in Medium I (Table 
8.1) (1m1/mg protein) and incubated at 37 ° C. At designated 
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Table 8.1 	The 	composition of 	Medium 	I 	for 	calcium-loading 
mitochondria. incubated 
SUBSTANCE CONCENTRATION (mM) 
ATP 3.0 
sodium succinate 10.0 
P i 4.0 
Mg Cl 2 10.0 
Tris-HC1 	(pH 7.0) 10.0 
CaC1 2 4.0 
Taken from Greenawalt etal. (1964). 
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times (0, 15, 30 min) one-third of the incubating suspension 
was removed, the mitochondria sedimented, deproteinised 
and subjected to column chromatography before analysis of 
PC as previously described (Section 6.2.4 ) . 
	
In other experiments, Ca 	omitted from Medium 
I and 4mM citrate substituted. This experiment was designed 
to investigate whether the presence of the likely PC 
precursors - P i and citrate - together with an energy source, 
ATP, could promote mitochondrial PC production. Apart from 
the substitution of citrate for Ca ++ , the experiment was 
conducted in an identical manner to the in vivo Ca "-loading 
experiments. 
8.2.4.3 Incubation with alkaline phosphatase  
If 	high 	concentrations 	of 	a 	phospho-accepting 
compound ( for example, glycerol, serine) , P i and a phospho-
donor ( for example, phosphocreatine, ATP) are incubated 
with alkaline phosphatase, then the enzyme catalyses the 
reverse reaction: the phosphorylation of the phospho-
acceptor ( Kay , 1928; Morton, 1958 ) . The possibility that 
"reverse" phosphatase activity could produce phosphocitrate 
'therefore was studied. Typically trisodium citrate (2.94g) 
and 126mg of NaH 2 P0 4 were dissolved in 5m1 water and the 
pH adjusted to 9.8-9.9. The tube contents were incubated 
at 37 ° C for 20 min , in the presence or absence of either 
100U of alkaline phosphatase and/or 30mg phosphocreatine. 
After this period 5m1 of 1N HC10 4 
was added, the solution 
diluted to 50m1 with distilled water and the pH adjusted 
to 7-8 with KOH. Following centrifugation at 1,000g for 15 
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min to remove the precipitate, the solutions were loaded 
onto 1 x 10cm columns of Dowex 1-X8 (HCO
3
) and subsequently 
eluted and analysed (Section 6.2.4.2) . 
8.3 	RESULTS 
8.3.1 STUDIES ON THE LABILITY OF PC AND METHODS TO 
INHIBIT PHOSPHATASE ACTIVITY 
[ 32 I3 1-PC added to rabbit kidney homogenates was 
rapidly hydrolysed within 5 min based on the disappearance 
32 	 32 of [ 	I3 1-PC and the appearance of other [ 	13 1-labelled 
compounds as shown in Figure 8.1. This result indicated 
that if PC was to be detected in purified subcellular 
fractions a method had to be developed to inhibit the hydro-
lytic reactions, since procedures to separate cellular 
organelles from cytosol take longer than 5 min. Consequently 
the use of inhibitors to minimise phosphatase activity was 
studied. 
In view of the known inhibition of alkaline phosphatase 
by vanadate the ability of this inhibitor to decrease the 
phosphohydrolytic activity in kidney homogenates was 
investigated. However, the addition of 5mM of vanadate into 
an homogenate at 0 ° C did not apparently significantly 
decrease the hydrolysis of [ 32 13 1-PC ( Figure 8.2) . When a 
solution of PC was treated with vanadate (i.e. no homogenate 
was present) , electrophoresis indicated that [ 32 P1 -PC had 
been largely destroyed ( Figure 8.3). In fact, vanadate is 
known to oxidise organic compounds not only under acidic 
conditions but also at neutral pH; this may have been the 
reason for the depletion of [ 32 13 1-PC observed here. 
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Figure 8.1 Radio-active components resolved by electro-
phoresis: [ 32  P 1-PC added into rabbit kidney 
homogenates and a 5 min incubation period. 
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32 Figure 8.2 Electrophoretic resolution of [ 	P 1-labelled 
compounds following incubation of rabbit kidney 
homogenate with [ 32 P ]-PC in the presence of 
vanadate. 
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Figure 8.3 Effect of vanadate on [ 32 P]-PC  as indicated 
by electrophoretic resolution of labelled compounds 
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In other experiments, a range of inhibitors reported 
to inhibit alkaline phosphatase activity were tested for their 
inhibitory ability in kidney and intestinal homogenates. 
Activity at pH 7.4 and room temperature was measured using 
E-NPP as substrate, before and after the addition of an 
inhibitor. Results are given in Table 8.2 for diluted tissue 
homogenates. The most potent inhibitor was clearly vanadate 
and, significantly, some inhibitors displayed specificity. 
L-cysteine and L-phenylalanine were more effective in intest-
inal homogenates whereas tetramisole and E-bromolevamisole 
were particularly potent inhibitors of diluted kidney homogen-
ates. Two -inhibitors vanadate and tetramisole - were 
therefore selected to investigate whether they were effective 
when 10% homogenates were routinely prepared. Tetramisole 
was selected in preference to p-bromolevamisole since its 
relative purchasing cost (1980: $9.90/10g) enabled a large 
amount to be added into homogenates, more than compensating 
for its lower potency compared to its derivative, p-bromo-
levamisole (1980: $42/100mg). Table 8.3 indicates that only 
5mM vanadate caused > 90% inhibition. Further, at 00C activity 
was 51 ±6% that at room temperature. Unfortunately under 
such conditions, vanadate causes hydrolysis of PC. 
Thus data indicated that hydrolytic activity in 
homogenates could not be inhibited sufficiently to prevent 
PC hydrolysis. Therefore a quantitative determination of 
the subcellular distribution of PC using this type of 
compound was not possible. 
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Table 8.2 Inhibition of p-NPPase activity in diluted tissue 
homogenates. 
(mM) INHIBITOR 
% INHIBITION* 
KIDNEY INTESTINE 
EDTA 	(3) 67±8 68±2 
1-cysteine 	(3) 52 1-5 93±1 
(±)-tetramisole 	(3) 95 -±1 11±4 
p-bromolevamisole 	(1) 96±2 14±1 
thiophylline 	(3) 57 ±6 84±3 
thioglycollate 	(3) 7±2 13±3 
L-phenylalanine 	(3) 2±1 36±3 
vanadate 	(1) 95±2 97±1 
*3 trials; mean :1:1 S.E. 
1.3g kidney was homogenised in 20m1 sucrose and 50p 1 taken 
to determine the extent of inhibition by added test substances. 
236 
Table 8.3 Inhibition of p-NPPase activity in undiluted 10% 
tissue homogenates. 
% 
INHIBITOR (mM) 
INHIBITION* 
KIDNEY 
Vanadate 	(2.5) 88-±1 
Vanadate 	(5) 95±1 
Tetramisole 	(5) 61±2 
Tetramisole 	(10) 69±2 
*3 trials; mean ±1 S.E. 
1.3g kidney was homogenised in 15m1 sucrose and 2m1 taken 
for assay purposes. 
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8.3.2 SUBCELLULAR DISTRIBUTION OF PC 
The question of whether PC was primarily associated 
with mitochondria or not was investigated by determining 
the PC content of mitochondria and of whole tissue. By 
knowing the yield of mitochondria the contribution of 
mitochondrial PC to the total PC content of whole tissues 
could be estimated. The yield was determined by monitoring 
succinate dehydrogenase activity. 
Results are given in Figure 8.4 for a typical 
experiment illustrating the amount of PC initially present 
in the kidney and that found in mitochondria isolated from 
that tissue. Data show that 12 pg of PC was present in 40mg 
mitochondrial protein and that 48 pg of PC was present in 
whole kidney. The yield of mitochondria was found to be 
26%, giving a corrected figure of 45 pg of PC present in the 
mitochondria of a whole kidney. This corresponds to 98% 
of the PC in whole tissue being located in mitochondria. 
The experiment was repeated on four separate occasions and 
the complete results indicate that kidney mitochondria 
contain 0.68nmol PC/mg mitochondrial protein and 
that this organelle contained 95±5% of the total PC in 
whole kidney. 
8.3. 3 ' BIOSYNTHESIS OF PC 
8.3.3.1 In vivo 
Table 8.4 . summarises data from a study in which 
rats were given an oral dose of calcium gluconate and were 
killed 30 min later. Intestinal mitochondria were isolated 
and analysed for PC. Notably, serum and mitochondrial 
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Table 8.4 Effect of an oral dosage of calcium gluconate 
on calcium concentrations in serum and on PC 
and calcium levels in intestinal mitochondria. 
Levels of 
C 2+ a or PC 
 
Treatment 
 
C ++ a 	loading 
 
None 
[Ca] mitochondria 	8.6 	 3.9 pg/mg protein 
[PC] mitochondria 	0.4 	0.65nmol/mg protein 
[Ca] serum 	 20 	 11 mg % 
8 	10 12 14 	16 18 20 
( 48 ug ) 
\/\ 	
KIDNEY 
I 	I 	I 	. 
8 	10 	12 14 	16 18 20 
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Figure 8.4 Ion-exchange chromatographic separation of 
PC from biological extracts. 
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Ca 	Were raised indicating the successful Ca ++ - 
loading of the biological system. However, there was no 
evidence that PC had been synthesised under these conditions. 
8.3. 3.2 In vitro - Mitochondrial incubations  
Rabbit kidney mitochondria were incubated in either 
a medium known to cause Ca  of the organelle, 
or a medium rich in citrate. Figure 8.5 summarises the results 
from such experiments. Mitochondria appeared to synthesize 
PC in response to incubation in a Ca  medium over 
30 min; but, in these experiments, the degree of PC synthesis 
varied ccinsiderably. In contrast, incubation in • a citrate-
rich medium did not cause any PC production by mitochondria. 
8.3.3.3 In vitro - Transphosphorylation 
Attempts to prove a role for PC in transphosphoryl-
ation systems were not successful. When citrate was used 
in this type of reaction, no PC production was detected. 
8.4 	DISCUSSION  
PC has been demonstrated to occur naturally, in 
particular associated with mitochondria. The question then 
arises as to whether mitochondria are the sole or major sub-
cellular source of PC. One way of answering this question 
is to isolate cytosol and other subcellular components and 
to analyse them for PC. However, the in vivo lability of 
PC suggested that any attempt to quantitatively isolate PC 
from homogenates without first inhibiting the hydrolytic 
activity could only succeed if components were rapidly 
fractiohated. This may explain why when cytosol from a 
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perfused liver was isolated by the usual differential 
centrifugation techniques, results ( not shown here ) indicated 
that no PC could be detected. 
• 
Although most methods for fractionating organelles 
involve lengthy differential centrifugation, another method 
for preparing cytosol is available, whereby the tissue homo-
genate is _passed through an Affi-gel 731 column ( Bio-Rad 
•Laboratories, 	Richmond, California, 	U. S. A. ) 	which binds 
membraneous components ( Jacobson and Branton, 1977 ) . Even 
so, this method requires at least lh by which time endogenous 
cytosolic PC, if present, would be destroyed. 
One 	recently 	developed 	differential 	centrifugation . 
technique for fractionating subcellular components uses 
organic solvents thus apparently inactivating many enzymes, 
enabling metabolite concentrations in the various cellular 
compartments to be measured ( Elbers et al., 1974)- . However, 
at present this technique can only process small amounts 
of sample, insufficient to yield detectable amounts of PC. 
Consequently, the use of inhibitors was investigated 
with a view to isolating cytosol by centrifugation after the 
addition of suitable inhibitors. A range of inhibitors was 
tested in rabbit kidney and intestine homogenates. Although 
vanadate potently inhibited tissue homogenates from both 
kidney and liver, tetramisole and E-bromolevamisole exhibited 
a tissue-specific effect, inhibiting only in kidney. No 
inhibitor was found that could entirely inhibit hydrolytic 
activity in tissue homogenates although 5mM vanadate 
approached this. However, vanadate was found to modify 
PC under the conditions used. 
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This inability then, of inhibitors to decrease markedly 
phosphatase activity in homogenates led to the adoption of 
another method to investigate the subcellular distribution 
of PC. In this approach, the yield of mitochondria was 
measured by monitoring succinate dehydrogenase activity. 
This enabled the mitochondrial contribution to the total PC 
content of whole kidney to be calculated as 95± 5%. This 
important result indicates that PC is exclusively located 
in mitochondria. 
The finding that PC is almost completely recovered 
from mitochondria despite the length of time required for 
organelle isolation, suggests mitochondrial compartmental-
isation acts to protect PC from the lytic activity in the extra-
mitochondrial compartment, substantiating the suggestion 
made in Chapter 7. 
Recognition that PC is a mitochondrial metabolite 
suggests that this organelle- is the site for the biosynthesis 
of PC. The proposed role of PC in stabilising calcium 
phosphate deposits as an amorphous rather than crystalline 
deposit suggests that the level of mitochondrial Ca  
be a stimulus for PC production. These ideas are partly 
substantiated by the data presented here, but could not 
be supported by oral Ca 	experiments. In these 
experiments, although [Ca ++] 	rose in serum and in 
mitochondria, no increase in the intestinal mitochondrial 
PC levels were observed over a 30 min time period. However, 
when rabbit kidney mitochondria were incubated in a medium 
containing Ca ÷ -1- -loading, there was a tendency to increase 
PC levels after 30 min, albeit erratic in the magnitude of 
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the increase. Substitution of 5mM citrate for Ca ++ abolished 
PC production. These preliminary results, although suggesting 
that mitochondria do in fact synthesize PC and perhaps in 
response to Ca ++ -loading, also emphasize the need for further 
investigations. Investigations should aim to elucidate the 
effect of length of incubation, source and age of mitochondria, 
and incubation media on mitochondrial PC production in vitro. 
Additional experiments could establish the way in which 
the nutritional status of rats might affect the PC content 
of mitochondria in different tissues. The high and low calcium 
diets used by Omdahl and DeLuca (1973 ) might be particularly 
useful in this regard. 
Elucidation of the optimal conditions for PC biosyn-
thesis could prove useful for preparing [ 32 13 1-PC biologically 
as an alternative to its chemical synthesis. In fact the use 
of [ 313]-P  in biological experiments will be desirable since 
ion-exchange chromatography followed by high-voltage electro-
phoresis, as described in the last" chapter, should allow 
for an accurate determination of the types of phosphoric 
esters present . and the extent of their biosynthesis. The 
investigation of the transphosphorylation of phosphatases 
would also be aided by the• use of [ 32 P ]-P i . Preliminary 
results presented here indicate PC cannot be produced by 
transphosphorylation , but other enzymes and conditions need 
to be tested to reinforce this conclusion. This requirement 
is emphasized by the following observations : 
1. 	Glycerol has been phosphorylated by intestinal 
alkaline phosphatase ( Kay , 1928) , albeit in a reaction medium 
with 	high 	concentrations 	of 	glycerol 	and phosphate. 
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At the bone site there is a high concentration of both 
phosphate and citrate (up to 2% the dry weight of bone 
[Dickens, 19411) so that conditions here are favourable for 
PC production by reverse phosphatase activity. There this 
apparently artificial reaction could have physiological 
significance. 
2. 	Different phosphatases show different substrate 
preferences. For example, intestinal alkaline 	phosphatase 
phosphorylates compounds in order of preference: ethanolamine 
> tris > glycerol >> lactose, L-serine = 0 (Linden and Alais, 
1976), whereas a glycoprotein from pre-osseous cartilage 
phosphorylates in the order L-serine >> tris > diethanolamine 
(Stagni et al., 1979). 
k Preliminary data suggests Ca +4-  -loading may stimulate 
mitochondrial PC production, at least in vitro; the PC content 
in tissue (i.e. liver << .kidney < intestine) may therefore 
be related to levels of Ca  in these tissues and 
to the flux Of Ca ++ at these sites. In this model the presence 
of PC in periods of Ca ++ -loading is needed to ensure 
amorphous rather than crystalline calcium phosphate is 
deposited in the mitochondrial matrix. The solubility and 
lability of ACP relative to HAP ensures Ca 4-+ ca n be readily 
mobilised from the mitochondrial Ca ++ 'sink ' . This reasoning 
highlights the need to investigate whether or not chondrocyte 
mitochondria contain PC and, in particular, the potential 
role of PC in biomineralisation since it has been shown that 
prior to mineralisation, mitochondrial calcium phosphate 
granules disappear and simultaneous extracellular calcium 
phosphate deposits occur. 
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The data presented in this chapter indicate PC in 
a mitochondrial metabolite and tentatively suggests it is 
++ synthesized by this organelle in response to Ca 	-loading. 
The information also indicates future avenues of research 
worth investigating. 
8.5 	SUMMARY  
1. PC was found to be rapidly hydrolysed in rabbit 
kidney homogenates. 
2. Kidney and 	intestine phosphatase activity 
was inhibited by a range of inhibitors: vanadate, tetramisole, 
L-cysteine and L-phenylalanine. Only vanadate approached 
complete inhibition; but vanadate caused breakdown of PC. 
3. Mitochondria from rabbit kidney were found 
to contain 95 ± 5% of the total PC found in that tissue. 
4. Ca 	orally did not cause mitochon- 
drial PC production after 30 min. 
5. Rabbit kidney mitochondria incubated in a 
Ca 	medium produced PC. Substitution of citrate 
for Ca ++ in the medium prevented PC production. 
6. PC was not produced by transphosphorylation 
of citrate with phosphocreatine mediated by calf intestine 
alkaline phosphatase. 
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CHAPTER 9 
GENERAL DISCUSSION  
Calcium homeostasis involves control at many levels 
including the subcellular level (for example,- Ca ++ flux in 
mitochondria), the cellular level (for example, ATP energised 
uptake and release of Ca ++), and at the organ level mediated 
by hormones (for example, parathyroid hormone and vitamin 
D). However, the useful operation of these regulatory 
mechanisms demands that the formation and resorption of 
Ca++ salts from both intracellular (for example, mitochondrial) 
and extracellular deposits (for example, bone) must be tightly 
controlled. Although investigations into the role of Ca++ 
and P. concentrations, and nucleating agents on Ca  
precipitation have been published, much interest has recently 
been focussed on the role that inhibitors of this process 
might play in regulating Ca ++ salt formation. Many compounds 
have been considered as inhibitory factors influencing biolog-
ical calcification. For example, pyrophosphate has been 
suggested as a compound preventing lithiasis in normal 
individuals (Fleisch and Bisaz, 1964; Fleisch and Russell, 
1970), and/or causing bone mineralisation through its removal 
by matrix vesicles (Felix and Fleisch,1976). Another compound 
suggested in this latter role is ATP but as with pyrophosphate 
many factors such as the ubiquity of these organic 
phosphate esters - have led to these inhibitors not being 
generally accepted as controlling calcification (Posner, 1969; 
Posner et al., 1978 ) . Nevertheless, the role that inhibitors 
*Some of the work presented here has been published by the candidate and his super-
visors — copies are enclosed in the thesis. See statement in Acknowledgements. 
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could play in influencing biological calcification is considered 
so important that much current research aims at finding 
new inhibitory factors that might control Ca  deposition 
in biological systems. 
At the commencement of this present investigation, 
current reports indicated that a fraction potently inhibiting 
HAP formation could be isolated from such diverse sources 
as milk, mitochondria and urine (Howard, 1976; Tew and Mahle, 
1977; Lehninger, 1977; Lehninger et al., 1978) . However, the 
identity of the agent( s) responsible for inhibition was unclear 
because little evidence existed enabling the elucidation of its 
structure. From unpublished 1 H NMR data, Howard (1976 ) report-
ed that the material contained a citrate molecule and, in an- 
other approach, found that by acidifying and neutralising 
solutions of P and citrate in vitro, a potent inhibitor was 
formed. Because this artificial compound appeared to be 
chromatographically similar to the natural inhibitor, it 
was proposed that the inhibitor might be phosphocitrate (PC ) 
The natural occurrence of this inhibitory compound 
was thrown into doubt by the observation that ion-exchange 
chromatography under acidic conditions - the method used 
to purify biological fractions - caused the production of 
the inhibitory agent from P i and citrate ( Howard, 1976 ) . 
Another limitation of these studies was the fact that no 
authenticated PC was available to enable a detailed 
comparison with biological components, nor could be ability 
of pure PC to inhibit HAP be unambiguously determined. 
Hence Lehninger (1977) cautioned that the active component 
in the biological fraction might not be PC but some other 
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compound isolated with it and added that "rigorous identific-
ation will require an unambiguous high-yield organic 
synthesis of PC and comparison with the highly purified 
naturally-occurring inhibitor". 
Consequently the studies reported in this thesis 
initially aimed at preparing and unambiguously characterising 
PC. A further requirement was that the organic synthesis 
should allow isotopic labelling of PC, since such a compound 
would be of great value in biological experiments. The 
availability of PC was also seen as allowing the development 
of methods for isolating and analysing PC which could 
ultimately be applied to biological samples to prove 
definitively the presence or absence of PC in nature. 
Meyer et al. (1959 ) had, in fact, originally reported 
a synthesis of PC but it was a low-yield method, used 
specialised equipment, and required reagents that did not 
facilitate isotopic labelling of PC. A more powerful phosphor-
ylating reagent was indicated and later Tener (1961 ) 
described the use of cyanoethylphosphate (CEP) to phosphor-
ylate nucleosides. This reagent not only was more powerful 
than the reagent employed by Meyer et al. (1959) - dibenzyl 
chlorophosphate - but also permitted [ 32 P 1-labelling because 
of the easy preparation of [ 32P]-CEP  from [
32 F] -P . 
Recently a new potent phosphorylating reagent - o-
phenylene chlorophosphate - has been reported ( Khwaja et 
al., 1970 ) that reacts even with tertiary, steric ally hindered 
hydroxyl groups which is the type that must be phosphor yl-
ated to prepare PC. However, using o-phenylene chloro-
phosphate , isotopic labelling of PC is difficult since either 
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32 [ 	P 1-PC1 5 
must be used to prepare the phosphorylating 
reagent by a lengthy synthetic method, or [ 14 C1-citrate must 
be esterified to give triethyl citrate, one of the required 
starting materials. Nevertheless, because of the potential 
high yields available using o-phenylene chlorophosphate , 
its use in preparing PC was investigated along with CEP, 
the reagent foreseen as enabling ready isotopic labelling 
of PC. 
Condensation of CEP with triethylcitrate ( TEC) mediated 
by dicyclohexyl carbodi-imide ( DCC) followed by alkaline 
hydrolysis gave crude PC. The development of an ion-exchange 
system using bicarbonate buffers and operating at neutral 
pH enabled the purification of PC. With nitrate as the eluting 
ion even better resolution of P citrate and PC was obtained; 
but with bicarbonate buffer all that is needed to recover 
PC is to decarbonate the buffer with AG 50W [ H , whereas 
with nitrate, insoluble salts must be formed. Consequently, 
ion-exchange chromatography using sodium bicarbonate buffers 
was used to give sodium PC which was characterised by 
a range of techniques. NMR spectroscopic data was used 
to provide unambiguous proof of the structure of the prepared 
compound. Not only 1 H NMR spectroscopy was used for this 
purpose, but also 31  P and 13 C NMR spectroscopy, the latter 
giving a unique spectrum characterising PC completely. 
Further characterisation was obtained using thin-layer 
chromatographic, chemical and enzymatic systems, especially 
developed for separating and analysing PC (Chapter 2; 
Williams and Sallis, 1980 ; Williams and Sallis, 1981a). 
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The overall yield obtained using CEP was generally 
poor (ca. 10%) ; but using o-phenylene chlorophosphate a 
higher yield appeared possible since the initial phosphoryl-
ation of triethyl citrate was almost quantitative. The removal 
of a protecting group, however, by either oxidative or 
reductive cleavage, proved troublesome. Oxidative cleavage 
was found to produce a dye which not only formed a polymeric 
material but bound non-specifically to ion-exchange resins 
disrupting binding and resolution. The selective removal 
of the dye was not successful using a range of adsorbents 
including activated charcoal, Florisil and Celite. 
The other alternative, reductive cleavage, requires 
platinum oxide (an expensive reagent) resulting in the 
formation of 1,2-cyclohexyldiol in contrast to a quinone 
produced if oxidation is used. This diol should not interfere 
with ion-exchange techniques. The use of reductive cleavage 
was not investigated because it was found that complete 
hydrogenation of the intermediate was difficult to achieve, 
yet was necessary to avoid the formation of dye. In any 
case isotopic labelling was easier and produced a higher 
specific activity product if [ 32 P}-CEP was used. Although 
[C] - citrate itr te could have been used to prepare [ 14 C]-triethyl 
citrate for reaction with o-phenylene chlorophosphate, the 
low specific activity of commercially available [ 14 C1-citrate 
compared with [ 32 P] -P which is also significantly less 
expensive, led to the use of P-32 as the isotopic label for 
PC. Despite the shorter half-life of P-32 compared with C-
14, the higher specific activity product obtainable was 
adjudged to be of particular advantage for experiments where 
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the fate of labelled PC administered to rats was to be 
determined. Therefore the CEP method is the method-of-choice 
for preparing isotopically labelled PC. 
Tew et al. (1980 ) reported a synthesis of PC using 
o-phenylene chlorophosphate just after its preparation from 
CEP had been published (Williams and Sallis , 1980 ) , which 
confirmed some of the data reported here. A yield of 30-80% 
was reported by Tew et al. (1980 ) , which is higher than 
that available using CEP (ca. 10%) . Consequently, as expected 
due to the reactivity of o-phenylene chlorophosphate , this 
reagent is superior for the preparation of unlabelled PC. 
Nevertheless, several improvements to the method reported 
by Tew et al. (1980 ) can now be suggested based on the 
findings using CEP. 
For example, hydrolysis in the presence of Ca ++ could 
be improved since Meyer et al. (1959 ) noted that the mono-
ethyl ester of PC was quite soluble - even in the presence 
of Ca This may explain the variable yield obtained by 
Tew et al. (1980) who used a short hydrolysis time and 
insufficient excess of Ca 	-PC is quite stable at 0° C and 
is precipitated using excess Ca 	a useful modification 
would be to extend the hydrolysis time from 4h to 16h and 
to use excess Ca ++, in amounts described here ( see Chapter 
2) . The more efficient removal of ethyl ester groups combined 
with the precipitation of PC should optimise the yield of 
this method. 
An additional improvement would appear to be the 
substitution of the AG 1-X8 ( HCO 
3 
) system developed here 
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for the cellulose-based system used by Tew et al. (1980) 
which necessitates formation of the undesirable Ca  
In contrast, the ion-exchange system enables clear resolution 
of P. citrate and PC, has a higher binding capacity and, 
further, allows the sodium rather than the Ca ++ salt to be 
routinely prepared. Clearly for studies of calcification it 
is desirable to have more soluble sodium salt, uncontaminated 
with divalent metal ions. 
The method of Tew et al. (1980), using o-phenylene 
chlorophosphate, improved by altering the hydrolysis 
conditions and substituting the ion-exchange method developed 
for the CEP synthesis should provide an optimal synthesis 
of PC. The CEP method, however, appears better for producing 
isotopically labelled PC since [ 32 P1-PC yielded with a high 
specific activity. 
Both syntheses satisfy the criterion reported by 
Lehninger (1977) noted above, but even with the availability 
of authentic material, resolution of biological components 
and methods for identifying PC in biological extracts 
required the development of methods for the separation and 
analysis of PC which did not previously exist. Although 
NMR and mass spectroscopy provide information on the 
structural nature of a compound, with biological samples 
it is not always possible to obtain sufficient amounts of 
pure material for analysis by these spectroscopic methods. 
Instead, a range of techniques for characterising PC were 
established - chemical and enzymatic assay, TLC, high-voltage 
electrophoresis and analytic isotachophoresis - more valuable 
than any single method since each method has some limitations 
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(Chapter 3; Williams and Sallis , 1981a ) . 
Chemically, 	citric 	acid 	can 	be 	colorimetrically 
determined after degradation to pentabromoacetone ( P BA ) 
and reaction with benzidine ( Jones ', 1967 ) . PC can be 
estimated by this method if prior hydrolysis is carried out. 
An alternative to benzidi ne is 4,4 ' -dimethylaniline ; it was 
found that, although it did not give as intense a colour 
reaction as benzid ine , it did give a linear response to citrate 
over a wider concentration range. The use of both reagents•
therefore constitutes a flexible citrate assay. Unfortunately 
PC itself gives some reaction in the assay system, presumably 
due to partial hydrolysis, so this method can only be used 
to measure total citrate. 
A method to determine free citrate and PC, however, 
was developed based on the sensitive and selective enzymatic 
citrate assay of P assonneau and Brown (1974). One portion 
of 'a sample was analysed for citrate, and another was treated 
with alkaline phosphatase to cleave PC. Free citrate was 
measurable since it was found that citrate lyase did not 
degrade PC to citrate. Total citrate (citrate + PC) was 
determined after phosphatase activity had selectively cleaved 
PC into phosphate and citrate. This fluorimetric assay system 
is particularly valuable because of its sensitivity ( 0.05- 
10 tig ) and ability to selectively analyse citrate and PC. 
A thin-layer chromatographic system - was also developed 
that separated citrate and P i from PC, although citrate and 
P . were themselves not clearly separated from one another. 
Citrate and 13 . however, could be selectively visualised 
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due to the range of staining techniques available (Chapters 
2, 3). PC was detectable after either chemical or enzymatic 
hydrolysis. 
Another separation technique for use in resolving 
PC from other compounds was high-voltage electrophoresis. 
The procedure of Khwaja et al. (1970) was applied success-
fully to the resolution of PC and P. although citrate and 
PC were not so definitively separated. Consequently this 
method was foreseen as of potential advantage in separating 
[ 32 131-labelled components. 
Analytical 	isotachophoresis 	was 	another technique 
applied to the resolution of PC from other anions. Anions 
separate into discrete zones using this method, each with 
a unique conductivity which serves to characterise them when 
conductimetric methods are used to detect resolved components. 
Although this method is of great potential use, one major 
disadvantage is that if salts are present in sufficient 
concentration then clear-cut resolution is lost. 
A preliminary purification is required before any 
of these separation or analytical techniques can be used 
because (1) of the high concentration of citrate relative 
to PC present in most of the biological extracts, (2) a need 
to separate salts from material to be analysed, and (3) a 
necessity to remove fluorometric species interfering with 
enzymatic analyses. Ion-exchange chromatography was found 
to be suited to this purpose since it has a high-binding 
capacity and it was not found to cause PC production from 
P i and citrate as an artefact of chromatography. Furthermore, 
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if chromatography was omitted and a solution of citrate and 
P. (in concentrations ca. 100 times that present in biological 
extracts ) subjected to the acidification and neutralisation 
methods used to prepare biological extracts, again PC was 
not produced. Therefore biological extracts were prepared 
and purified by ion-exchange chromatography with the know-
ledge that if PC was detected it was derived from the sample 
and not artefactually. The "PC-rich" fraction was then 
analysed by a range of techniques. 
Whereas a range of separation systems - TLC, electro-
phoresis and analytical isotachophoresis - was found to be 
useful in characterising PC, GLC could not be applied. 
Derivatisation by methylation with thionyl chloride failed, 
as did trimethylsilylation using a wide variety of reagents 
and conditions. However, only in one instance were P i and 
citrate detected after trimethylsilylation of PC suggesting 
that either no derivatisation of PC was occurring or complex 
fragmentation resulted from the required conditions. 
Diazomethane is the only other reagent which is powerful 
enough yet could react under relatively mild conditions that 
might esterify PC enabling GLC. In fact, Tew et al. (1980) 
have used diazomethane to derivatise PC but reported that 
only the trimethyl-ester rather than the necessary penta-
methyl ester, was obtainable. A wide, range of derivatisation 
reagents and reaction conditions are therefore apparently 
not applicable to PC. 
It is not surprising then that Sutor et al. (1979a) 
reported there was no evidence for the existence of PC in 
urine, using GLC techniques. This finding, together with 
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the observations that artificial urine inhibited the transform-
ation, of ACP into HAP to the same degree as natural urine, 
led Sutor et al. (1979b) to propose that all inhibitors in 
urine are known. This conclusion, however , is questionable, 
since the artificial urine used was oversimplified; it did 
not contain components found in urine 	known to promote 
Ca" 	salt precipitation (Hallson and Rose, 1979; Fleisch, 
1978) which would lead to an underestimation of the inhibitory 
capacity of urine. Consequently, it is argued here that a 
role of PC in the prevention of urolithiasis is still an open 
question. 
If future experiments confirm the preliminary results 
here that indicate PC is found in urine, then several 
interesting questions arise, including : (1) does PC concentrat-
ion fall in patients predisposed to • form stones? (2) is its 
concentration higher in tubules than when voided? (3) does 
it possess the physico-chemical properties enabling it to 
inhibit lithiasis? Although the first question cannot be 
answered at present, speculation can be made on the other 
points. The stability of PC in urine (Chapter 7) suggests 
its concentration at the time of voiding is the same as at 
its time of secretion. However, it' may be that the epithelial 
lining at the proposed site of secretiori. may possess some 
hydrolytic activity so that PC after acting to inhibit stone 
nucleation in the kidney tubules is rapidly degraded. 
Clearly further work is necessary to clarify these points. 
If PC is to play a role in urolithiasis, or indeed 
any calcifying system, it must have the ability to inhibit 
calcification. Synthetic PC has been tested in vitro for its 
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ability to inhibit calcium oxalate and hydroxyapatite (HAP) 
precipitation. The results presented in this thesis show PC 
to be the most potent of a range of powerful inhibitors of 
HAP formation including ATP, EHDP, PNP and PP i (Chapter 4; 
Williams and Sallis, 1979, 1981b; Williams et al., 1980). Although 
Tew et al. (1978) reported that the "purified factor" 
presumably PC - could not inhibit without the presence of 
citrate, these workers have recently published reports which 
confirm the firidings presented in this thesis (Tew et al., 
1980; Reddi et al., 1980). These observations strengthen 
the possibility that it is indeed PC which is responsible 
for the inhibitory ability of certain biological fractions. 
With regard to calcium oxalate formation, PC is , weight-
for-weight, more potent than chondroitin sulphate C (Chapter 
4; Williams and Sallis, 1981a) one of the most potent inhibit-
ors of calcium oxalate formation. Although on a molar basis 
chondroitin sulphate C is more potent than PC, PC is more 
potent on this basis than pyrophosphate, a moderately power-
ful inhibitor. Recently Tew and Malis (1981) havedemonstrated 
that PC inhibits the epitaxial growth of calcium oxalate 
upon HAP. These observations indicate that if PC is found 
in sufficient quantity in urine, then it has the physico-
chemical properties to make it an important factor influencing 
urolithiasis. 
The unique structure of PC has led to an understanding 
of how the structure of a molecule influences its ability 
to inhibit HAP formation (Chapter 5; Williams and Sallis, 
1979). It is proposed here that for potent inhibition to occur 
a molecule should possess at least one phosphate group and 
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- at some other position - either a phosphate group preferably 
or a carboxylic moiety. A wide range of inhibitors has been 
tested, and this has led to an extension of this basic rule 
to include the effect of secondary factors on inhibitor strength 
(Chapter 5; Williams and Sallis, 1981b). These are (i) the 
number of active groups, (ii) their proximity, (iii) stereo-
chemical arrangement, (iv) steric factors, (v) lipophilicity, 
and (vi) lability of the molecule. It was also noted that 
primary amino groups abolish inhibitor potential presumably 
by altering binding characteristics. 
This information should not only enable the recognition 
of biological compounds previously overlooked as inhibitors, 
but should also permit the development of potent anticalcifying 
compounds potentially useful in the therapy of Ca  
disorders. Three compounds of interest optimally satisfying 
the structural criteria mentioned are shown in Figure 9.1. 
All have four phosphate groups radiating from a central 
carbon. However, the bridge between phosphorous and carbon 
is different in these compounds: P-O-C, P-N-C, P-C-C. 
Results presented . in this thesis on the lability of PC in 
vivo, and published data on the in vivo stability of 
pyrophosphate indicates compound 1 is to be expected to 
be rapidly degraded by enzymatic hydrolysis. Therefore 
compounds II and III with stabler P-X-C (X may be C or 
N) bonds are predicted to be of more clinical value. Further-
more, since these compounds are predicted to be more potent 
inhibitors than PC they may ultimately prove to be more 
useful , in therapy than PC or its analogues. Synthesis of 
compounds I and II from pentaerythritol is envisaged. 
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Figure 9.1 Derivatives of pentaerythritol predicted to be 
potent inhibitors of HAP formation. 
O-P 
CH 2 
0-CH 2- C-CHTO 
CH 2 
\ 0:-P 
COMPOUND 1 = 'tetraphosphopentaerythritol 
/ NH- P 
CH 2 
NH- CH,- C-CH,- NH 
CH 2 
NH- P 
COMPOUND 11 = N-analogue of compound 1 
,CHF P 
C CH2 	H2 
CH 2- C- CH,- CH, 
• 	
I 
CH 2 	P 
N CHF-13 
COMPOUND 11 = C-analogue of compound • 1 
0 
II 
P= -P-OH 
OH 
261 
•Another application of this structure-activity relation-
ship is to the elucidation of the mechanisms of inhibition 
at the calcium phosphate surfaces. Such an application has 
been facilitated by the recognition that inhibitors group 
into two classes depending on how their increasing concentrat-
ion affects parameters defining the transition of ACP into 
HAP' (Chapter 5; Williams and Sdllis, 1981b). One group - 
Type I inhibitors - that includes PC, are crystal-growth 
inhibitors which act by binding to active growth sites on 
HAP. The other group - Type II inhibitors - apparently act 
at the ACP surface to decrease its lability, and do so by 
a variety of mechanisms. Type II inhibitors are a diverse 
range of inhibitors including Mg citrate and ATP. Type 
I inhibitors, in contrast, appear to share some common 
structural features. They are low molecular weight compounds 
.containing one phosphate group and in close proximity, either 
another phosphate group or multiple carboxyl groups, but 
no bulky inert groups (for example, an adenosine moiety). 
Another interesting observation to arise from the 
recognition of these two classes of inhibitors is the syner-
gistic effect two inhibitors, comprising one inhibitor from 
each group, has on HAP formation. This probably arises 
from an efficient binding to different active sites on HAP. 
In particular, PC acts synergistically with phosphoglycerate 
and citrate. Mg
++ g requires special consideration since its 
action is probably to protect phosphoric esters from hydrolysis 
on calcium phosphate surfaces, through its chelating ability 
(Blumenthal et al., 1977). PC also acts synergistically 
with Mg++ , so the physiological situation can be visualised 
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where PC acts as a potentiating agent, a small amount 
sufficient to .dramatically increase the inhibitory ability 
of a physiological fluid. No such synergism was found between 
ions in the inhibition of calcium oxalate formation. 
The recognition of these two groups of inhibitors and 
mechanisms of inhibition does not preclude the possibility 
that other mechanisms and types of inhibitor exist. For 
example, proteoglycans do not significantly affect the 
induction time but alter the rate and extent of transformation 
(Blumenthal et al., 1979). One explanation might be that 
the molecule binds to the ACP spherules and sterically 
hinders the surface-dependent processes necessary to transform 
ACP into HAP. Whatever the exact cause this finding 
emphasises that high molecular weight inhibitors may inhibit 
by mechanisms other than those discussed here. 
The wide range of compounds that can inhibit the 
formation of HAP casts doubt on the claim by Tew et al. 
(1978) that "using assays which measure the rate and extent 
of transformation of ACP into HAP and the rate of HAP crystal 
growth, we have found mitochondria contain phosphocitrate". 
Nevertheless, this fortuitous insight has now been proved 
to be correct by the more rigorous approach used in this 
study. The subsequent examination of biological fractions 
was made possible through the establishment of systems for 
the isolation, detection and analysis of PC (Chapter 6; 
Williams and Sallis, 1981a). 
Rat and rabbit liver and kidney homogenates examined 
for PC content were found to 'give, after ion-exchange 
chromatography, a fraction which, when hydrolysed, contained 
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P. 	and citrate. Furthermore, the compound eluted with the 
same elution volume as authentic PC. Enzymatic analysis 
provided additional evidence that the compound isolated was 
PC for only when the compound was incubated with a 
phosphatase was it possible to obtain a reaction with citrate 
lyase. Comparison of the biological fraction with authentic 
PC by thin-layer chromatography, high-voltage electrophoresis 
and analytical isotachophoresis confirmed its identity. 
However, results with bone and urine are not unequivocal 
since their high concentrations of citrate, P i and other anions 
made purification difficult and only small amounts of PC 
were detectable. Hence, although a qualitative indication 
of the presence of PC was obtained in both cases, a more 
detailed examination is indicated. 
This demonstration that PC exists in nature led to 
an examination of the suggestion that mitochondria might 
be an important source of PC (Howard, 1976; Lehninger, 
1977). Mitochondria from rabbit liver, kidney and intestine 
were found to contain PC and on preliminary estimates 
contained 0.4, 0.8 and 1.2mmol PC/mg mitochondrial protein, 
respectively, although the intestinal source requires further 
study before the exact PC level can be confidently ascertained 
(Chapter 6, Williams and Sallis, 1981a, c). It is likely that 
PC levels are influenced by the status of the mitochondria, 
or indeed the whole animal, with respect to Ca  P. 
levels. 
The increasing order of PC levels in these mitochondria 
correlates with an increasing Ca ++ flux through the tissue, 
perhaps reflecting a need to maintain calcium phosphate 
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depOsiis in the amorphous phase which is relatively labile 
(Termine and Eanes, 1972) , enabling rapid mobilisation of 
Ca This reasoning emphasises the desirability of a study 
to analyse chondrocyte mitochondria for PC, since large 
Ca++ fluxes occur at the mineralisation site. 
In order to gain data that, might assist in the 
definition of the biological roles of PC, [ 32 P1-PC was given 
intravenously to rats and the tissue distribution and lability 
of [ 32P I-PC determined. Comparative experiments with 
[ 32, 13 1-P1  aided interpretation of results, and specific points 
arising from such a study (Chapter 7; Williams and Sallis, 
1981a. , d) include the following; (1 ) major sites of , PC uptake 
were bone, Consistent with its in vitro properties, and kidney; 
(2) PC is not metabolised directly but first hydrolysed to 
citrate and P (3) in contrast to the stability of PC in 
• blood, the compound is very labile at the kidney site. This 
latter finding suggests : ( a ) special conditions prevail at 
the kidney site for the hydrolysis of PC; (b ) compartmental-
isation must act to protect PC from the lytic activity in 
the extramitochondrial compartment since PC is detectable 
in kidney mitochondria ; (c) PC may be of use itself in 
preventing arterial calcification since it is stable in blood. 
However, for the treatment of nephro- and urolithiasis PC 
is not likely to be very suitable. Although PC is stable 
in urine, passage from blood into kidney then urine results 
in extensive hydrolysis of the compound emphasising the 
need for stable analogues. 
At the time these results on the in vivo lability of 
PC were published (Williams and Sallis , 1981a) , Tew et al. 
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(1981) reported work in which an injection of PC prior to 
administration of parathyroid hormone led to an 'inhibition 
of subsequent nephrolithiasis. Significantly, however, this total 
effect is not likely to be due to PC alone since it is rapidly 
hydrolysed at the kidney site. Tew et al. (1981), who 
concluded PC might have some clinical usefulness in the 
treatment of lithiasis, were unaware of the degree of 
lability of PC in vivo. 
A possible explanation for the apparent inhibitory 
action of PC is that PC is selectively taken up by the kidney 
the second most important site for PC uptake - where it 
is rapidly hydrolysed to P . and citrate which by virtue 
of its weak anti-calcifying ability inhibits nephrolithiasis. 
In this model PC acts to concentrate citrate - a weak 
inhibitor - in sufficient amounts in the kidney to cause 
inhibition. If indeed this is the mechanism, then administrat-
ion of citrate should be as effective as PC, provided kidney 
uptake is similar. 
After the presentation 	of results indicating the in vivo 
lability of PC (Williams and Sallis, 1981a), in which it was 
suggested that an analogue of PC could be of more therapeutic 
use than PC, Reddi et al. (1980) reported an experiment 
where PC was found to be unable to inhibit ectopic calcificat-
ion. In this study, demineralised bone matrix implants were 
used to induce calcification and the inability of PC to inhibit 
was suggested to be due to in vivo hydrolysis, although 
no direct evidence substantiating this claim was presented. 
This explanation would be in keeping with the now known 
lability of PC, , especially when the phosphatase activity, 
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which is rich in mineralising bone, is taken into account. 
Reddi et al. (1980 ) also concluded that an analogue of PC 
stable to in vivo enzymatic hydrolysis is necessary for 
biological 	experiments, 	confirming 	previous 	suggestions 
(Williams and Sallis , 1981a ) . 
With concensus on the desirability of an analogue 
of PC for use in biological systems, the question arises 
as to .which of the compounds would be of most potential 
use. The analogues of PC with a P-C-C bond would be 
predicted to be most inert in biological systems and therein 
lies its potential disadvantage. Diphosphonates , inert analogues 
of pyrophbsphate , have undesirable long-term effects because 
they bind to the skeleton causing an irreversible decrease 
in bone turnover ( Bone et al., 1979; Fast et al., 1977,   
1978 ) and adversely affect vitamin D metabolism ( Parry and 
Avioli , 1981 ) . For , this reason, PC itself and its analogue 
with a P-N-C bond may be more useful because of their in 
vivo lability. PC, which is stable in blood, is of potential 
use in preventing arterial calcification and as an agent 
decreasing bone turnover which could eventually be destroyed. 
Reduction in bone turnover is necessary for treating Paget ' s 
disease for example, and also bone lysis due to sarcoma. 
The P-N-C analogue may also prove useful for reducing bone 
turnover, but its particular advantage is due to its potential 
stability in the kidney. If, in contrast to PC, the P-N-C 
analogue is stable in the 'kidney, and if throughput into 
the urine is sufficient, then the possibility arises of prevent-
ing ' lithiasis. A list of some of the potential clinical applic-
ations of phosphocitrate and its analogues is given in Table 
9.1. 
Table 9.1 Some potential clinical uses of phosphocitrate 
or its analogues* 
Ecotopic calcification 
Myositis ossificans progressiva. 
Myositis ossificans of other types 
e. g. paraplegia, hip surgery 	 
Calcinosis of various types 
e.g. scleroderma , tumeral calcinosis 	 
Vascular calcification 
Dental calculus and caries 
Excess bone turnover 
• Paget disease 
Bone dysplasias 
Excess bone loss 
Acute osteoporosis 
e.g. immobilization, . paraplegia 	 
Post menopausal and senile osteoporosis 
Chronic renal failure 
Inoperable parathyroid adenoma and parathyroid carcinoma 
Bone metastases, myeloma 
Rheumatoid arthritis 
Ankylosing spondylitis 
Calcium-containing renal stones 
Bone-scanning agents 
99 nr, e.g. 	c-Sn-EHDP. 
*Based on the possible clinical applications of diphosphonates 
given by Russell et al. (1981). 
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The lability of PC at the kidney site indicates that 
since endogenous PC is detectable in kidney mitochondria, 
then compartmentalisation within this organelle protects PC 
from hydrolysis. In an attempt to confirm this conclusion 
and to study the subcellular distribution of PC, the contrib-
ution of mitochondrial PC to the total PC content of whole 
kidney was measured. It was found that rabbit kidney 
mitochondria contain 95 ± 5% of the total PC found in this 
organ. This result indicates that PC is a mitochondrial 
metabolite and suggests that its biological role ( s ) is/are 
based on its action in mitochondria. The information supports 
the speculative claim that PC acts to stabilise the calcium 
phosphate granules that form in mitochondria in the amorphous 
form. 
With PC established as a uniquely mitochondrial 
metabolite, the problem of its biosynthesis was studied, 
especially with -regard to this organelle being the likely 
site of PC production. Rats given an oral load of Ca ++ , 
however, failed to show an increase in PC levels in intestinal 
mitochondria, despite the demonstration that the Ca  
in mitochondria rose. This approach - Ca + + -loading - was 
++ 	 ++ continued since Ca 	flux, or more explicitly Ca -loading, 
and deposition of its phosphate salt in mitochondria, is the 
process in which PC is considered to act. In fact, kidney 
mitochondria incubated in a medium which is known to cause 
massive Ca ++ -loading, did show an increase in PC levels, 
albeit an irregular one. The substitution of citrate for 
Ca not cause an increase in PC levels. 
These data support the proposed biological role for 
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PC, but further experimentation to determine the exact stimuli 
for PC production is required. The enzyme( s) responsible 
for PC biosynthesis in mitochondria is/are unknown at this 
stage. Attempts to phosphorylate citrate by a transphosphoryl-
ation using calf intestine alkaline phosphatase failed, but 
a more thorough investigation of this possible method for 
PC biosynthesis is indicated. Different phosphate donors, 
incubation medium and alkaline phosphatases need consideration. 
The mitochondrial location of PC and its biosynthesis 
under Ca ++ -loading conditions is the, closest that evidence 
has come to proving absolutely that PC acts in mitochondria 
to ensure HAP does not crystallise. Although such a general-
ised role can be envisaged to occur in all mitochondria, 
this basic role must be modified in specific tissues. Already 
it has been shown that PC levels are different in mitochondria 
from various tissue sources correlating with levels of Ca++ 
flux expected at those sites. 
At the bone site possible roles for PC need special 
consideration. It has been suggested that mitochondria are 
intimately involved in the mineralisation process. Recent 
EM evidence (Matthews et al., 1970; Brighton and Hunt, 
1978a, b) indicates that the calcium phosphate amorphous 
granules form in the mithchondria prior to calcification of 
the epiphyseal plate. Such deposits disappear simultaneously 
with the appearance of HAP needles in matrix vesicles 
small, phosphatase-rich bodies found at the mineralisation 
front. The detailed molecular mechanism responsible for this 
transformation into HAP is unknown' but PC can be envisaged 
to play a role in this process since it is labile to 
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phosphatase activity. Consequently, PC could act to. stabilise 
mitochondrial deposits in the amorphous phase ; but once 
deposits are transferred to matrix vesicles, phosphatases 
inactivate PC allowing the transformation of ACP into HAP 
needles to proceed. 
There is, however, another important action PC may 
have at the bone site. The Robison hypothesis of bone 
formation ( Robison , 1923 ) states that phosphatase activity 
at the calcifying site hydrolyses organic phosphoric esters 
elevating local P i concentrations and providing the impetus 
for calcification. This idea has been the focus of much 
research interest since its initial proposal in 1923,  but 
because of (1 ) the ubiquity of alkaline phosphatase , and 
( 2) the lack of an organic phosphate unique to the calcify-
ing site, the hypothesis has been unable to explain satisfact-
orily why calcification only occurs at certain well-defined 
sites (Posner, 1969 ) . Examples of phosphoric esters whose 
• ubiquity has made models of bone formation involving their 
hydrolysis contentious, are ATP ( Leonard and Scullin, 1969) 
and pyrophosphate ( Fleisch and Russell, 1970). 
In contrast to models based on ATP or pyrophosphate,•
any proposed model involving PC as the agent responsible 
for increasing phosphate concentrations can account for the 
specificity of mineralisation. It is possible that PC could 
be delivered to the calcifying site in a controlled fashion 
since it is associated with mitochondria. Once at the site 
of mineralisation, its hydrolysis would boost the local 
P . concentration. Thus PC could have a duel role : unhydro- 
lysed it acts to inhibit HAP precipitation, whereas after 
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hydrolysis, one of its cleavage products promotes hydroxy-
apatite. formation. 
Evidence that phosphatase activity influences mineral-
isation is, in fact, available. Alkaline phosphatase levels 
are known to rise markedly just before calcification (Bernard, 
1978; Firschein and Urist, 1971; Althoff et al., 1978). Further, 
a recent report has indicated that if phosphatase activity 
is inhibited by L-tetramisole (levamisole) then mineralisation 
does not proceed (Fallon et al., 1979). Notably the dextro 
isomer of tetramisole does not inhibit alkaline phosphatase 
and was found not to interfere with the normal calcification 
process. Thus phosphatase activity appears essential for 
normal mineral deposition. 
•There As, however, no direct evidence, as yet, that 
PC is a causative factor in mineralisation. Over eight years 
ago, before the existence of PC in nature was known, Reddi 
and Huggins (1972) published a report describing the 
induction of bone cells and bone after bone matrix or bone 
ash implantation. Alkaline phosphatase and citrate levels 
were monitored and re-appraisal of this work, in the light 
of the data presented in this thesis, provides indirect 
evidence that it may be influential in controlling calcification. 
Reddi and Huggins(1972) reported that the subcutaneous 
transplantation of bone ash resulted in the production of 
multinucleated cells and, eleven ,days after implantation, 
a small rise in citrate levels which eventually fell back to 
its original level after another fourteen days. Alkaline 
phosphatase levels remained unchanged and no bone formation 
was observed. 
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In contrast, when demineralised bone matrix was 
implanted then a very large increase in citrate levels was 
noticeable at day 11, accompanying the histological appear-
ance of bone. Significantly, a considerable elevation of 
alkaline phosphatase preceded the increase in citrate 
concentration. 
The timing of events after the implantation of demineral-
ised bone matrix induction of alkaline phosphatase , 
followed by citrate production and mineralisation - together 
with the fact that PC is now knoWn to occur naturally, 
suggests another explanation for these observations. The 
large rise in citrate concentrations might be due to a prior 
increase in PC levels at the mineralising site. The phosphat-
ase activity induced prior to calcification ensures that PC 
is rapidly cleaved removing this inhibitor of HAP formation 
and supplying one of its precursors - P. This proposed 
appearance of PC at the calcifying site may even correlate 
with the disappearance of calcium phosphate deposits from 
the mitochondrial matrix, where it acts to stabilise ACP 
granules. This model is consistent with the idea that 
mitochondria is the primary source of PC. 
The inability of bone ash implantation to induce 
calcification can also be explained by this • new model. The 
lack Of induction of alkaline phosphatase results in PC 
remaining essentially unhydrolysed so that inhibition of HAP . 
formation results and P levels fail to rise sufficiently to 
cause mineralisation. The small increase in citrate levels 
may be due to a limited amount of PC hydrolysis or may 
even be due solely to PC itself, gives a partial reaction 
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in the colorimetric (PBA) assay used by Reddi and Huggins 
(1972) to determine citrate. 
Whatever the exact explanation for the failure of bone 
ash implantation to induce mineralisation, the possibility 
arises that, after implanting demineralised bone matrix, 
a sudden increase in PC levels at the calcifying site is 
a causative factor in mineralisation. This indicates that 
the Robison hypothesis of bone formation deserves reconsider-
ation, especially in view of the unique properties of PC: 
its specific location, enzymatic lability and physico-chemical 
properties. 
Clearly investigation of bone is warranted to examine 
whether or not PC has a special role in this tissue. However, 
as noted before, PC appears to have a general role in all 
mitochondria to stabilise calcium phosphate deposits. In this 
regard another important question arises. Is soft tissue 
calcification the result of a lack of PC in mitochondria? 
Such a lack could enable HAP needles to form in mitochondria; 
once formed this nidus could cause precipitation of Ca++ 
and P . from physiological fluids due to the insolubility of 
HAP relative to ACP. 
The results presented in this thesis have established 
PC as a new metabolite and provide stimulus for further 
research in this interesting area of Ca  Although 
many important aspects of the role of inhibitors of biological 
calcification, especially concerning PC, have been investigated 
and valuable results obtained, other interesting and important 
questions have arisen from the studies reported. Basically, 
two broad areas are indicated for further study - biochemical 
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and therapeutic. The results presented suggest PC is located 
in the mitochondria and preliminary data indicate it may 
be synthesised in this organelle perhaps under the impetus 
of Ca ++ -loading. This area of research needs further 
investigation as does bone and urine, to confirm whether 
PC is in fact found in these sources. 
The physico-chemical properties of PC indicate PC 
has therapeutic values where it is stable - blood,for example. 
However, studies into its in vivo lability indicate analogues 
of PC, stable to enzymatic degradation, are another new 
field of research. Information so gained may prove of great 
importance in the treatment and control of lithiasis as well 
as many metabolic bone diseases. 
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THE SOURCES OF PHOSPHOCITRATE AND ITS ROLE AS AN INHIBITOR OF 
CALCIUM PHOSPHATE AND CALCIUM OXALATE CRYSTALLIZATION 
G. Williams and J. D. Sallis 
Department of Biochemistry, University of Tasmania, 
Hobart, Tasmania, Australia 
Earlier studies reported by Howard l and Lehninger 2 suggested 
that a substance containing Pi and citrate, and tentatively assigned 
the structure of phosphocitrate, existed in nature and was a potent 
inhibitor of hydroxyapatite (HAP) formation. These observations led 
us to attempt to isolate and characterize phosphocitrate from 
biological sources with a view to defining a physiological role for 
this compound in calcification systems. 
As an initial step toward achieving this goal, we have recently 
synthesized and characterized labelled and unlabelled phospho-
citrate 3 . During the developmental period, systems for monitoring 
reactions and identifying phosphocitrate in biological studies were 
established. Whilst NMR data ( 1H-NMR, 13C-NMR, 3IP-NMR) together 
with mass spectrometry provide information on the structural nature 
of a compound, with biological samples it is not always possible to 
obtain sufficient amounts of pure material for analysis by these 
methods. Instead, we have found that a range of techniques is more 
valuable for characterizing phosphocitrate than any single method, 
and .a summary of systems that we are now using is presented iii 
Table 1. 
Ion exchange chromatography at neutral pH enables preliminary 
seliaration of biological samples with minimal hydrolysis and elimi-
nates phosphocitrate artefact formation. Thin layer chromatography, 
high voltage electrophoresis, enzymatic and chemical analyses pro-
vide versatility for identification. Currently, we are investigating 
the application of analytical isotachophoresis for identification and 
quantitation of phosphocitrate as analysis is rapid, and separation 
of phosphocitrate from interfering ions or compounds appears com-
plete. 
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Synthetic phosphocitrate has been tested in vitro for its 
ability to inhibit HAP and calcium oxalate crystal formation. By 
simultaneous measurement of alkali addition, calcium ion concentra-
tion and laser beam light scattering, information on the relative 
ability of compounds to inhibit the transformation of amorphous 
calcium phosphate (ACP) into HAP can be assessed. Comparative 
studies have shown that phosphocitrate is the most potent of many 
inhibitors tested including ethane-l-hydroxy-1, 1-diphosphonate 
(EHDP), ATP and pyrophosphate 4,5 . Data derived from this system 
have proved useful in defining the structural requirements of a 
compound for inhibition. 
More recently, our studies with the system have been extended 
and light scattering data (Figure 1) used to demonstrate that 
inhibitors may be classified into two groups, Type I and Type II. 
Type I are all crystal growth inhibitors and, at lower concentrations 
result in the formation of highly dispersed HAP suspensions, as 
indicated by an increase in the turbidity change. At higher 
concentrations the extent of conversion into HAP is inhibited. In 
contrast, Type II compounds do not inhibit crystal growth nor alter 
the turbidity measurements or extent of conversion. Electron 
microscopic observations have substantiated these conclusions. As 
examples, Type I (in order of potency) includes phosphocitrate, 
EHDP, tripolyphosphate, imidodiphosphate and pyrophosphate whereas 
Type II includes ATP, ADP, phosphonoformate, 2-phosphoglyceric acid, 
3-phosphoglyceric acid and citrate. Although such physicochemical 
studies are well defined in vitro, it is of questionable validity 
to extrapolate the results to the physiological situation. For 
example, inhibitors can, under certain conditions, interact 
synergistically to inhibit HAP formation. 
If phosphocitrate is to play an influential role in urolithia-
sis, it should inhibit calcium oxalate crystallization. We have 
studied the influence of phosphocitrate on calcium oxalate crystal 
growth, using both calcium ion monitoring systems and growth of 
calcium oxalate crystals on glass fibers. With the latter system, 
300 UM phosphocitrate inhibits growth of the crystals to an extent of 
66 ± 3% (relative to buffer); 1 mM pyrophosphate 49 ± 4%, and 100 VM 
chondroitin sulphate C 55 ± 7%. As with other inhibitors, crystal 
morphology changes noticeably in their presence. 
With phosphocitrate established as a potent inhibitor of 
calcification and with the availability of systems for the isolation 
and detection of the compound, we next turned our attention to 
possible tissue sources. Rabbit liver and kidney homogenates were 
acid extracted and, after neutralization, subjected to ion exchange 
chromatography. Following batch elution of P i and citrate, a gradient 
was applied, and fractions revealing the presence of citrate after 
hydrolysis were found to elute with the same elution volume as 
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1-0 
Figure 1. Effect of inhibitor concentration on the magnitude of 
the turbidity change associated with the transformation 
of amorphous calcium phosphate to hydroxyapatite. 
Figure 2. Separation of phosphocitrate from a kidney extract by ion 
exchange chromatography. Column 10 x 1.5 cm; AG1-X8, 
HCO3- . Batch elution with 0.27M NaHCO3 pH 7.4, then 
gradient elution as shown above (----). *Radioactivity 
profile has been superimposed. 
3l../U Ill...Ca lir rrivarrtykou r1/A I C 
synthetic phosphocitrate (Figure 2). We have no evidence that citrate 
and P. together lead to phosphocitrate production under these 
conditions. Enzymatic analysis provided additional evidence that the 
compound isolated was phosphocitrate for only when the compound was 
preincubated with a phosphatase was it possible to obtain a reaction 
with citrate lyase. Although citryl-l-phosphate (i.e. phosphate 
esterified to a carboxyl group) might meet the enzyme requirements, 
stability data eliminate the possibility, as this compound, relative 
to phosphocitrate, is short-lived 3 . In additional experiments, 
isolated phosphocitrate subjected to thin layer chromatography 
showed only a single band which co-chromatographed with the reference 
standard and, when hydrolyzed, gave citrate and P. 
This demonstration that,phosphocitrate does exist in tissues, led 
us to examine the suggestion` that the mitochondria might be an 
important source of this compound. Mitochondria from rabbit liver, 
kidney and intestine were found to contain phosphocitrate and, on 
preliminary estimates, have 05, 0.8 andlla;nmol phosphocitrate/mg 
mitochondrial protein respectively. More recent experiments, how-
ever, have led us to doubt the validity of the quantitative data as 
it is now clear that enzymatic hydrolysis is very active in tissues. 
If a similar situation occurs during isolation of the mitochondria, 
it might lead to an under-estimation of the true concentration. 
Further, the status of the mitochondria or indeed the whole animal 
with regard to calcium and phosphate levels could influence the value 
obtained. Phosphocitrate has been detected but not yet quantitated 
in the skeleton and, at present, we have no evidence for its exist-
ence in urine. Techniques are being investigated which will allow 
quantitation of phosphocitrate in bone, where presently, hydroxy-
apatite avidly binds the compound. In urine, metabolites and salts 
have so far made investigation of this possible source more difficult. 
In order to help define sites of action of phosphocitrate, 
[ 32P]-phosphocitrate was injected intravenously into rats and the 
time course of the accumulation of radioactivity in selected tissues 
was followed. The results are shown in Figure 3a. After 30 minutes, 
the majority of the radioactivity was associated with the skeleton 
(40%) and kidney (15%) whereas liver had only 5% of the initial 
radioactivity. These results alone, however, do not allow inter-
pretation of the distribution of phosphocitrate in tissue or of its 
specific binding. To have meaning, the radioactivity must be 
associated with phosphocitrate and not its hydrolyzed product, P. 
Two approaches have been made to resolve this problem. 
In the first instance, [ 3211-P1 was injected into rats , to 
determine rates of tissue labelling over the same time period, and to 
assess the affinity of the label for the skeleton (Figure 3b). 
Results indicate that only 20% radioactivity from [ 32P]-Pi was taken 
up by the skeleton in comparison to 40% when [ 32P]-phosphocitrate was 
injected. Kidney shows a similar pattern whereas for liver, the 
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relationship was reversed with minimal radioactivity accumulating 
after [ 32P]-phosphocitrate was given. 
In the second approach, acid extracts of soft tissue were 
prepared, the radioactivity associated with the organic and inorganic 
phosphate determined 7 , and the labelled metabolites further resolved 
and quantitated using high voltage electrophoresis. The organic 
phosphate to P i ratio shows that after 30 minutes, 80% of the radio-
activity in blood was in the organic phosphate fraction. Electro-
phoretic patterns (Figures 4 and 5) indicate that this radioactivity 
was associated with phosphocitrate. By contrast, the kidney has 40% 
represented as organic phosphates after 5 minutes, and electrophore-
sis indicates that only 15% of the radioactivity was due to 
Figure 3. Rate of disappearance of radioactivity in blood and its 
appearance in tissues following administration of [ 32 P]-
P1 or [ 341-phosphocitrate in rats. Female rats (170 g) 
were injected intravenously with 1 mg of the sodium salts 
of the labelled compounds. At designated times, samples 
of blood, bone and soft tissues were taken, oxidized and 
counted. Values shown are means ± 1 S.E. Total weights 
were obtained for liver and kidney; skeletal mass was 
calculated 8 and the total blood volume assessed at 
64 ml/kg. 
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Figures .4 and 5. Radioactive patterns for electrophoresis. Rats 
were injected intravenously with 1 mg (0.5 pCi) of either [ 3213 )- 
phosphocitrate (specific activity = 200 pCi/mmol or ( 32P]-P i 
(specific activity = 70 pCi/mmol) and at time intervals, 
relevant samples were c011ected, frozen and then extracted with 
trichloracetic acid. Following neutralization, aliquots were 
taken for high voltage electrophoresis as described in the text. 
The dried paper was marked in a grid pattern, then cut, and 
after acid extraction, radioactivity (slam) associated with 
the separated compounds was determined. Phosphocitrate and Pi 
were identified from reference standards 014100 treated in an 
identical manner. 
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phosphocitrate. Even less (about 5% of phosphocitrate) was found 
in kidney after 30 minutes, as shown in Figure 4. Because of the 
contrast in lability of phosphocitrate between blood and kidney, it 
is possible that special conditions prevail in the kidney for phos-
phatase action, or that there exists a specific phosphocitrate 
cleavage enzyme which rapidly inactivates the molecule. It should 
be noted that no other labelled compounds were detected of the same 
electrophoretic mobility as authentic phosphocitrate in tissue 
extracts from rats injected with [ 32P]-Pi (Figure 5). 
In order to determine whether (a)' phosphocitrate was being 
metabolized to organic phosphate esters or (b) phosphocitrate was 
being hydrolyzed into Pi which was then incorporated into organic 
phosphate esters, samples from the [ 321]-P i experiment were subjected 
to an identical electrophoretic analysis (Figure 5). Liver (not 
shown here) rapidly metabolized [ 32P]-P1 into several organic phos-
phates whereas blood and kidney formed two major organic compounds, 
shown as A and B in Fipre 5. In experiments using [ 321]-phospho-
citrate in place of [ 321]-Pi, both components A and B were 
discernable in kidney after 30 minutes (Figure 4). 
The data, we believe, support the contention that phosphocitrate 
is hydrolyzed to P i and citrate before any further metabolism occurs. 
Due to the avid binding of phosphocitrate in bone, as yet we have 
been unable to identify the radioactive compound(s) in bone. 
However, based on the electrophoretic analysis of blood and the 
relatively low uptake (20%) of [ 321:1-Pi itself, we believe that the 
radioactivity found in bone is a true indication of phosphocitrate 
uptake. Once adsorbed onto HAP, the further fate of phosphocitrate 
is difficult to determine experimentally. 
Exogenous phosphocitrate, then, is localized in at least two 
tissues - bone and kidney, but its physiological potency at least two 
sites must be dependent upon its stability in the microenvironment. 
Our in vivo data suggest that at the kidney site, phosphocitrate is 
rapidly inactivated. If however, endogenous phosphocitrate is 
strictly compartmentalized within the mitochondria, the lability 
data from whole tissue may be of limited meaning. Clearly it is 
important to gain further information regarding the intracellular 
distribution of phosphocitrate and to elucidate its biological 
site(s) of synthesis and degradation. The availability of a stable 
analogue of phosphocitrate capable of resisting enzyme attack would 
also be valuable. We are currently investigating the synthesis of 
two such compounds since their biological inertness should permit 
advantage to be taken, at the kidney site, of the physicochemical 
properties associated with the parent molecule, phosphocitrate. 
Because of the possible lability of phosphocitrate in bone, this 
compound may be more desirable in the treatment of skeletal dis-
orders than an inert analogue. 
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• 	Whilst, from the data presented here, a physiological role for 
phosphocitrate in the maintenance of mitochondrial calcium phosphate 
deposits in the amorphous state is easily envisaged, a much broader 
role for this molecule in the control of stone formation and other 
calcifying systems is forseen but has yet to be elucidated. 
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